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SUMMARY 
Protein aggregation into amyloid fibrils is the hallmark of many human pathologies, 
including Alzheimer's disease and Parkinson's disease. The aberrant assembly of 
peptides and proteins into fibrillar aggregates proceeds through oligomeric 
intermediates thought to be the primary pathogenic species in many of these protein 
deposition diseases. Since the first year of my PhD, I have been studying protein 
aggregation, focusing on misfolded protein oligomers formed by the N-terminal domain 
of the bacterial HypF protein from E. coli (HypF-N). These oligomers are a useful 
model system in the context of disease-associated protein aggregation because they 
have the same properties as the disease-related ones and are highly stable, allowing a 
detailed structural and functional investigation. Moreover, under two different 
conditions, HypF-N aggregates into two types of oligomers characterized by an 
opposite biological activity, since only one is toxic whereas the other is benign to 
cultured cells, facilitating the utilization of appropriate control nontoxic oligomers in 
our experiments. 
In Chapter 2, the first one describing results in my thesis, the toxicity of HypF-N 
oligomers, as well as the aggregates formed by the amyloid-β peptide and the islet 
amyloid polypeptide, was tested in the presence of molecular chaperones, namely αB-
crystallin, Hsp70, clusterin, α2-macroglobulin and haptoglobin. Molecular chaperones 
play a pivotal role in the regulation of the proteome homeostasis, as they facilitate 
protein folding, inhibit protein aggregation, disaggregate pre-formed assemblies and 
promote clearance of misfolded aggregates. In this chapter we show that molecular 
chaperones also affect the structure and toxicity of protein misfolded oligomers. Indeed, 
measures of the cell viability showed that all the five chaperones are effective in 
suppressing the toxicity of oligomers formed by all three proteins. Infrared spectroscopy 
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and site-directed labeling experiments using pyrene ruled out a structural reorganization 
within the discrete HypF-N oligomers, even at the amino acid residue level. By contrast, 
analysis performed using confocal microscopy, SDS-PAGE and intrinsic fluorescence 
measurements revealed binding between the oligomers and the chaperones; atomic force 
microscopy (AFM) imaging indicated that large assemblies of oligomers are formed in 
the presence of the chaperones. This suggests that the chaperones bind to the oligomers 
and promote their assembly into larger species, with consequent decrease in their 
diffusional mobility and burial of hydrophobic surface. 
In Chapter 3, with the aim of identifying the structural determinants responsible for 
the toxicity of misfolded oligomers, we created a set of HypF-N oligomeric variants by 
replacing one or more charged aminoacids with apolar aminoacids into the sequence of 
the wt protein, and allowing the mutated proteins to aggregate under different 
conditions. The resulting oligomeric species were characterized by different levels of 
cytotoxicity, as assessed by measurements of MTT reduction, tests with the apoptotic 
marker Hoechst and measurements of Ca
2+
 influx. The structural properties of the 
oligomeric variants was performed by evaluating the exposure of their hydrophobic 
surfaces to the solvent with ANS binding and by measuring their size by means of 
turbidimetry and light scattering measurements. A significant correlation was found 
between ANS binding and size of the oligomers, indicating that an increase of surface 
hydrophobicity causes an increase of the size of the oligomers. Moreover, both 
superficial hydrophobicity and size were found to influence the oligomer biological 
activity, cooperating in determining the levels of toxicity of the aggregates. 
In Chapter 4, we used HypF-N toxic misfolded oligomers to investigate their 
interactions with transthyretin (TTR). This protein is a homotetrameric protein which 
can disassemble into its monomers, misfold and aggregate into fibrils whose growth is 
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considered the cause of TTR amyloidoses. Nevertheless, an anti-amyloidogenic effect 
that prevents Aβ aggregation in vitro has recently been proposed for TTR. We have 
therefore explored the ability of three different types of TTR, human TTR (hTTR), 
mouse TTR (mTTR) and an engineered monomer of human TTR (M-TTR), to suppress 
the toxicity of HypF-N oligomers. Cell viability tests showed that hTTR, and to a 
greater extent M-TTR, can avoid the cell damage induced by protein oligomers, 
whereas mTTR does not show any protective effect. To shed light on the different 
behavior of the TTRs and on the molecular mechanism by which they can exert their 
potential protective ability, we have investigated the molecular structure of HypF-N 
oligomers after the incubation with TTRs. Thioflavin T assay and pyrene site-directed 
labeling showed that all the three types of TTR cannot structurally re-arrange toxic 
HypF-N oligomers into a nontoxic form. Intrinsic fluorescence measurements and SDS-
PAGE indicated that TTRs are able to bind to the oligomers. Following this binding, 
hTTR, and to a greater extent M-TTR, induced the formation of larger species, as 
shown by AFM and turbidimetry measurements. By contrast, the interaction with 
mTTR does not induce such formation of clusters. These data indicate that TTR 
suppresses the toxicity of HypF-N oligomers similarly to well established chaperones 
with an efficacy that correlates with its ability to disassemble into monomers. 
Finally, in Chapter 5, we tested the ability of HypF-N oligomers to induce the 
inflammatory response. In fact, increasing evidence suggests that neurodegeneration 
associated to aggregation of proteins is the result of many causes. The uncontrolled 
immune response in the brain has recently been established to play a central role in the 
onset and progression of diseases, such as Alzheimer’s disease and Parkinson’s disease. 
For this reason we explored the inflammatory response to the injury caused by HypF-N 
toxic and not toxic misfolded oligomers, with particular attention to the role of Hsps, 
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Hsp70 and αB-crystallin, as immune signals and potential suppressors of HypF-N 
oligomer-mediated inflammation. The results, obtained by the evaluation of microglia 
activation in terms of cytokine-release, showed that both the toxic and the nontoxic 
oligomers triggered a pro-inflammatory response, as assessed through ELISA 
measurements of a set of cytokines. Interestingly, at concentrations in which the two 
types of oligomers share the ability of leaving unaltered the cellular viability evaluated 
by MTT tests, the nontoxic species were found to be stronger inducers of inflammation 
with respect to the toxic oligomers. Such immune property of the nontoxic aggregates 
could be linked to their lower level of internalization in microglia cells and to the 
consequent maintenance of their stimulus from outside the cells. In addition, the 
nontoxic oligomers and the assemblies of toxic oligomers neutralized by chaperones 
were found to have the ability to induce inflammation without affecting cellular 
viability. 
In conclusion, the data presented in this thesis and collected entirely using 
misfolded protein oligomers by the model protein domain HypF-N have revealed (i) 
new structural determinants of protein oligomer toxicity, such as oligomer size and 
hydrophobic exposure and their interplay to determine toxicity, (ii) have revealed novel 
mechanisms by which molecular chaperones, including the emerging TTR, contribute to 
the maintenance of protein homeostasis and (iii) have shown how misfolded protein 
oligomers can be highly inflammatory, even in the absence of explicit toxicity. 
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Chapter 1 
INTRODUCTION  
1.1 Protein aggregation 
1.1.1 Folding, misfolding and aggregation of proteins 
Proteins are the fundamental constituents of living organisms, since they exert essential 
functions, participating in all the different processes that take place in the cells. These 
biological macromolecules are synthetized on cellular ribosomes as unstructured 
polypeptide chains that are able, in general, to spontaneously self-assemble into a 
compact three-dimensional structure, called “native state”. The native structure of a 
protein is necessary to allow the fulfilment of its specific function and generally 
corresponds to the conformation that is most thermodynamically stable under 
physiological conditions [Dobson et al., 1998]. The process through which proteins 
reach the native structure is the folding process and consists in a stochastic search of the 
most energetically favourable conformation, passing through many conformations 
accessible to a polypeptide chain [Levinthal, 1968; Dobson et al., 1998; Fersht, 2000].  
The importance of reaching and remaining in the folded state for a protein is 
underlined by the fact that cells have evolved mechanisms of control and regulation of 
the folding process [Dobson, 2003], such as molecular chaperones [Bukau and 
Horwich, 1998; Hartl and Hayer-Hartl, 2002], the heat shock response [Voellmy and 
Boellmann, 2007], the unfolded protein response [Kapoor and Sanyal, 2009], the 
endoplasmic reticulum associated degradation [Hoseki et al., 2010], the ubiquitin-
proteasome system [Claessen et al., 2012], the autophagy [ Bejarano and Cuervo, 2010] 
and enzymes that catalyse the restructuring of proteins [Schiene and Fischer, 2000].  
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A failure in the folding process, termed misfolding, can lead to relevant 
pathological conditions afflicting the mankind and generally referred to as “protein 
misfolding diseases”. Misfolding episodes take place when a protein adopts an 
alternative conformation to the native one (Figure 1.1) and, as a consequence, it can 
appear no longer able to perform its normal function, such as in cystic fibrosis [Amaral, 
2004], or unable to be translocated in its correct functional site, as in the early 
pulmonary emphysema [Lomas and Carrel, 2002]. In other cases, protein misfolding 
can induce the aggregation of proteins into highly organized fibrillar aggregates that 
deposit into the cells or, most commonly, in the extracellular space (Figure 1.1) [Chiti 
and Dobson, 2006]. These aggregates are called “amyloid fibrils” when they accumulate 
in the extracellular space, or “intracellular inclusions” when they form inside the cell 
[Westermark et al., 2005] and are associated with a broad range of human pathologies.  
Figure 1.1. Schematic 
representation of some of the 
many conformational states that 
can be adopted by a polypeptide 
chain and of the means by which 
they can be interconverted. 
Amyloid fibrils are one of the 
possible aggregate forms. All of 
these different conformational 
states and their interconversions 
are carefully regulated in the 
biological environment, by using 
machineries such as molecular 
chaperones, degradation 
systems, and other quality 
control processes. 
Conformational diseases will 
occur when such regulatory 
systems fail. Figure taken from 
Chiti and Dobson, 2006. 
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The aggregation process leading to amyloid formation has many features of a 
“nucleated growth” mechanism. The time course of the conversion of a monomeric 
peptide or protein into its fibrillar form typically consists of a lag phase followed by a 
rapid exponential growth phase [Naiki et al., 1997; Serio et al., 2000; Pedersen et al., 
2004]. The lag phase is considered to be the time required to allow the formation of 
“nuclei” and represents the rate-limiting step [Morris et al., 2009; Orte et al., 2008]. 
Once a nucleus is formed, fibril growth is thought to proceed rapidly by further 
association of either monomers or oligomers with the nucleus [Chiti and Dobson, 2006].  
The formation of aggregates can start from any of the conformational states adopted 
by a monomeric protein (Figure 1.1), including the fully unfolded state, the folded state 
and the partially folded state, although this latter have the highest propensity to self-
assemble [Bemporad et al., 2006; Chiti and Dobson, 2006]. The partially folded 
monomeric state can be found to be in rapid equilibrium with small soluble, 
unstructured oligomeric forms (Figure 1.1), interacting through hydrophobic surfaces 
exposed to the solvent that are normally buried in the native globular state. These 
oligomers, constituted by a few molecules and typically 2-5 nm in diameter, are 
transient, unstable and with heterogeneous conformations [Chiti and Dobson, 2006; 
Stefani, 2010]. The disordered oligomers undergo a structural reorganization into a β-
sheet structure and a further association with each other to form amyloid protofibrils, 
which appear to be either isolated beads or beaded chains with the individual beads 
again having a diameter of 2-5 nm. Protofibrils can associate and act as precursor of 
longer protofilaments and mature fibrils, which represent the end product of the 
aggregation process (Figure 1.1) and are thermodynamically stable [Jahn and Radford, 
2008]. 
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It is well recognised that proteins unrelated to any amyloid disease aggregate in vitro 
into structures indistinguishable from the amyloid fibrils produced by disease-associated 
peptides and proteins [Gujiarro et al., 1998; Litvinovich et al., 1998; Chiti et al., 1999; 
Chiti et al., 2001; Fändrich et al., 2001; Gast et al., 2003; Pedersen et al., 2006]. Hence, 
the formation of highly organized amyloid aggregates appears to be a generic property 
of polypeptide chains, rather than a characteristic of a few proteins linked to 
pathological conditions [Dobson, 1999; Chiti et al., 1999].  
 
1.1.2 Structural characteristics of amyloid fibrils 
Amyloid fibrils share morphological, structural and tinctorial properties, despite they 
originate from different peptides and proteins [Dobson, 2003; Chiti and Dobson, 2006; 
Nelson and Eisenberg, 2006]. Images acquired through transmission electron 
microscopy (TEM) or atomic force microscopy (AFM) have shown that amyloid fibrils 
are rigid, long, unbranched and usually composed by 2-6 thinner filaments, called 
“protofilaments”, each about 2-5 nm in diameter [Serpell et al., 2000]. These 
protofilaments twist together forming super-coiled fibrils generally 7-13 nm wide 
[Sunde and Blake, 1997; Serpell et al., 2000] or associate laterally to give origin to 
ribbons with a diameter ranging from 2-5 nm to 30 nm [Bauer et al., 1995; Saiki et al., 
2005; Pedersen et al., 2006]. 
From a structural point of view, amyloid fibrils are characterized by a common X-
ray diffraction pattern, typical of the cross-β structure consisting of parallel β-sheets 
whose strands are arranged perpendicularly to the long axis of the fibril [Eanes and 
Glenner, 1968; Sunde and Blake, 1997; Nelson and Eisenberg, 2006]. The β-sheet 
structure is confirmed by techniques such as circular dichroism, Fourier transform infra-
red spectroscopy, solid-state NMR spectroscopy, X-ray microcrystallography and site-
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directed spin labeling coupled to EPR [Bouchard et al., 2000; Balbach et al., 2002; 
Tycko, 2003; Jaroniec et al., 2004; Kajava et al., 2005; Ritter et al., 2005; Luca et al., 
2007; Vilar et al., 2008; Nelson et al., 2005; Sawaya et al., 2007; Török et al., 2002] 
allowing to obtain information on the cross-β architecture of amyloid fibrils at 
molecular or even atomic level (Figure 1.2). 
Amyloid fibrils also display the ability to bind specific dyes such as thioflavin T 
(ThT) and Congo red (CR) [Klunk et al., 1989; LeVine III, 1995; Nilsson, 2004]. Upon 
binding of ThT to amyloid fibrils, it is possible to observe in the ThT excitation 
spectrum a red-shift from 336 nm to 450 nm and the appearance of a new peak in its 
emission spectrum centred at around 485 nm, whose intensity is proportional to the 
extent of binding to the aggregates [LeVine III, 1995]. Fibrils stained with CR are 
characterized by a green birefringence under cross-polarized light [Missmahl and 
Hartwig, 1953].  
Figure 1.2. Molecular model of an amyloid fibril. (a) The protofilament of Aβ viewed down the 
long axis of the fibril. The segments 12-24 (red) and 30-40 (blue) are shown (Tycko, 2002). (b) 
The fibril from the C-terminal domain 218-289 of the fungal prion protein HET-s. The ribbon 
diagram shows the four β-strands (orange) (residues 226-234, 237-245, 262-270 and 273-282) 
and the long loop between β2 and β3 from one molecule. Flanking molecules along the fibril 
axis (gray) are shown (Ritter et al., 2005). 
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1.1.3 Amyloid fibrils and their relevance to human diseases 
Amyloid fibrils are the hallmark of a wide range of human diseases (Table 1.1), which 
can be divided into (i) neurodegenerative disordes, characterized by protein aggregation 
in the brain, (ii) nonneuropathic localised amyloidoses, in which aggregation involves a 
single type of tissue other than the brain, and (iii) nonneuropathic systemic 
amyloidoses, in which protein deposits are found in multiple tissues [Chiti and Dobson, 
2006]. Most of these pathologies can be either sporadic or hereditary. When they have a 
sporadic etiology, they are generally due to the age-related decline of the cellular 
machinery in charge of the maintenance of the proteome homeostasis. The familial 
forms are related to mutations that dramatically increase aggregation rates of proteins 
and are usually characterized by early onset and aggressive symptomatology [Chiti and 
Dobson, 2006]. Prion diseases can also be transmissible, since an infectious etiology has 
been found [Prusiner, 1982]. Other diseases, such as hemodialysis related amyloidosis, 
originate from medical treatment [Chiti and Dobson, 2006]. 
The peptides and proteins forming amyloid fibrils have very different structural 
properties but are usually small in size [Ramshini et al., 2011]. Some of them are 
proteins, such as lysozyme; others are peptides, such as the islet amyloid polypeptide 
(IAPP), fragments of larger proteins produced by a specific cleavage, such as the 
amyloid β peptide (Aβ), or by degradation, such as polyQ stretches [Stefani and 
Dobson, 2003; Chiti and Dobson, 2006].  
The causative relation between formation of amyloid fibrils or their precursor 
oligomers and the disease symptoms is widely accepted on the basis of numerous 
studies and of the post-mortem observation of amyloid aggregates in patients. 
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Table 1.1. Diseases associated with the formation of extracellular amyloid fibrils or intracellular 
inclusions with amyloid-like properties. 
Disease 
Aggregating protein 
or peptide 
Disease 
Aggregating protein 
or peptide 
Neurodegenerative diseases Nonneuropathic systemic amyloidoses 
  Alzheimer’s diseasea amyloid  peptide AL amyloidosisa 
immunoglobulin light 
chains or fragments 
Spongiform 
encephalopatiesa,c 
prion protein and 
fragments thereof 
AA amyloidosisa 
fragments of serum 
amyloid A protein 
Parkinson’s diseasea α-synuclein Familial Mediterranean fevera 
fragments of serum 
amyloid A protein 
Dementia with Lewy bodiesa α-synuclein Senile systemic amyloidosisa 
wild-type 
transthyretin 
Frontotemporal dementia 
with Parkinsonisma 
tau 
Familial amyloidotic 
polyneuropathyb 
mutants of 
transthyretin 
Amyotrophic lateral 
sclerosisa 
superoxide dismutase 
I 
Hemodialysis-related 
amyloidosisa 
β2-microglobulin 
Hungtington’s diseaseb 
hungtingtin with 
polyQ expansion 
ApoAI amyloidosisb 
N-terminal fragment 
of apolipoprotein AI 
Spinocerebral ataxiasb 
ataxins with polyQ 
expansion 
ApoAII amyloidosisb 
N-terminal fragment 
of apolipoprotein AII 
Spinocerebral ataxia 17b 
TATA box binding 
protein with polyQ 
expansion 
ApoAIV amyloidosisa 
N-terminal fragment 
of apolipoprotein AIV 
Spinal and bulbal muscular 
atrophyb 
androgen receptor 
with polyQ expansion 
Finnish hereditary 
amyloidosisb 
fragments of gelsolin 
mutants 
Hereditary dentatorubral-
pallidoluysian atrophyb 
athrophin-1 with 
polyQ expansion 
Lysozyme amyloidosisb mutants of lysozyme 
Familial British dementiab ABri Fibrinogen amyloidosisb 
variants of fibrinogen 
α-chain 
Familial Danish dementiab ADan 
Icelandic hereditary cerebral 
amyloid angiopathyb 
mutant of cystatin C 
Nonneuropathic localised diseases 
 
Type II diabetesa 
islet amyloid 
polypeptide 
Calcifying epithelial 
odontogenic tumorsa 
unknown 
Medullary carcinoma of 
the thyroida 
calcitonin 
Pulmonary alveolar 
proteinosisb 
lung surfactant protein C 
Atrial amyloidosisa atrial nutriuretic factor Inclusion-body myositisa amyloid  peptide 
Hereditary cerebral 
haemorrhage with 
amyloidosisb 
mutants of amyloid  
peptide 
Cutaneous lichen 
amyloidosisa 
keratins 
Pituitary prolactinoma prolactin Cataracta -crystallins 
Aortic medial 
amyloidosisa 
medin 
Corneal amyloidosis 
associated with trichiasisa 
lactoferrin 
a Predominantly sporadic although in some of these diseases hereditary forms associated with 
specific mutations are well documented 
b Predominantly hereditary although in some of these diseases sporadic cases are documented 
c 5% of cases are infectious (iatrogenic) 
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An increasing number of studies have shown that the pathogenic species in protein 
deposition diseases are not the mature fibrils, but the precursor species forming before 
the fibrils, such as oligomers and structured protofibrils [Bucciantini et al. 2002; 
Billings et al., 2005; Cleary et al., 2005; Lesnè et al., 2006; Haass and Selkoe, 2007; 
Koffie et al., 2009]. Nevertheless, in some cases amyloid fibrils are able to cause 
cellular dysfunction because they can trigger the inflammatory response, a detrimental 
phenomenon if it is chronic, and because they act as sources of more toxic and soluble 
low molecular weight aggregates [Gharibyan et al., 2007; Jan et al., 2011; Martins et 
al., 2008; Novitskaya et al., 2006; Selkoe, 2011; Wogulis et al., 2005; Stefani, 2010].  
 
1.2 Misfolded protein oligomers 
1.2.1 Oligomers and disease 
It has been shown that the severity of cognitive impairment in Alzheimer’s disease 
correlates with the levels of low-molecular-weight species of the Aβ peptide rather than 
with the amount of amyloid fibrils from the same peptide [Lue et al., 1999; McLean et 
al., 1999; Wang et al., 1999]. Soluble oligomeric forms of Aβ, including trimers and 
dimers, were found to be both necessary and sufficient to disrupt learned behavior 
[Cleary et al., 2005]. Moreover, transgenic mice show deficits in cognitive learning 
before the accumulation of significant amount of amyloid plaques [Moechars et al., 
1999; Larson et al., 1999; Billings et al., 2005; Lesné et al., 2006]. Yet, in mice models 
of Alzheimer disease, synapse loss was found to be higher near senile plaques from 
which oligomers are released [Koffie et al., 2009]. Lastly, genetic evidence provides 
support to the toxicity of the oligomers; indeed the “Artic” (E693G) mutation of the 
amyloid β precursor protein, associated with a heritable early-onset manifestation of 
Alzeimer’s disease, has been found to enhance protofibril, but no fibril, formation in 
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vitro [Nilsberth et al., 2001]. Similar arguments hold for α-synuclein and Parkinson’s 
disease [Kitada et al., 1998; Masliah et al., 2000; Winner et al., 2011], as well as TTR 
and its associated amyloidoses [Sousa et al., 2001]. 
Numerous experimental data have shown that oligomers formed by proteins 
unrelated to any disease, such as the N-terminal domain of HypF from E. coli (HypF-
N), the SH3 domain from bovine phosphatidylinositol 3′ kinase (PI3-SH3) and 
apomyoglobin from sperm whale, can be highly toxic to cultured cells, whereas the 
monomeric native states and the amyloid-like fibrils (all formed in vitro) display very 
little, if any, toxicity [Bucciantini et al., 2002; Sirangelo et al., 2004]. Therefore, 
oligomer toxicity seems to be a property linked to structural characteristics of the pre-
fibrillar aggregates and independent of the protein forming them. 
 
1.2.2 Dynamic and heterogeneous nature of oligomers 
The oligomers are characterized by a substantial instability and heterogeneity making a 
challenge to obtain molecular details at the residue level [Stefani, 2010; Bemporad and 
Chiti, 2012]. Nevertheless, a number of approaches and techniques have been recently 
introduced and allowed a deep molecular characterization of the oligomers [Bemporad 
and Chiti, 2012]. 
The aggregation process gives rise to the appearance of a wide range of oligomeric 
species structurally heterogeneous and in an ever-changing state of rearrangement. The 
description of these species is, therefore, strictly related to the time parameter and to the 
starting conditions. When aggregation starts from fully or largely unfolded monomers, 
the initial oligomers, forming during the nucleated conformational conversion, exhibit a 
large variety of conformations, with monomers still characterized by a disordered 
structure (Figure 1.3). Indeed, early aggregates with unstable β-sheet structure and a 
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poor level of order have been described for Aβ40 [Lee et al., 2011; Qi et al., 2008], α-
synuclein [Dusa et al., 2006] and the PI3-SH3 domain [Carulla et al., 2009]. If the 
aggregation process take origin from native-like state, the early aggregates are 
characterized by oligomers retaining monomers in a native-like conformation [Banci et 
al., 2005; Olofsson et al., 2004; Pagano et al., 2010]. It is therefore clear that the early 
forming species are reminiscent of the monomeric state from which they originate and 
are far from the amyloid structure, as shown also by their inability to bind amyloid 
specific dyes [Plakoutsi et al., 2005; Lee et al., 2011]. 
As the aggregation proceeds, the aggregates are subjected to a continuous structural 
reorganization and acquire amyloid-like properties, such as an extensive β-sheet content 
and ability to bind ThT and CR [Bemporad and Chiti, 2012]. Moreover, they increase in 
dimensions, compactness, stability, hydrophobic burial and order, still retaining a non 
fibrillar morphology (Figure 1.3), as it has been reported for Aβ40 and Aβ42 [Bitan et al., 
2003; Lee et al., 2011; Qi et al., 2008], α-synuclein [Kaylor et al., 2005] and the human 
muscle acylphosphatase [Calamai et al., 2005]. In addition, they decrease in dynamic 
fluctuations and oligomer surface per number of monomers [Bemporad and Chiti, 
2012]. Such conversion form unstructured or native-like oligomers into amyloid 
oligomers is inevitably accompanied by the generation of a variety of oligomeric 
species that differ in the extension of the β-sheet content, giving origin to a complex 
scenario of multiple species. 
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Figure 1.3. A schematic representation of the structural rearrangements occurring during 
oligomer formation. For simplicity, only aggregation starting from fully or largely unfolded 
monomers is considered. Amyloidogenic/hydrophobic segments are in green. The oligomer 
surface is drawn as a thin black when amyloidogenic/hydrophobic segments are buried and as a 
thick red dotted line when they are exposed to the solvent. While aggregation proceeds (left to 
right), a set of structural rearrangements take place and leads to growth of thin filaments, which 
eventually originate amyloid fibrils: the top and bottom arrows show the parameters that increase 
and decrease, respectively. Image taken from Bemporad and Chiti, 2012. 
 
The heterogeneous and dynamic nature of the oligomers is responsible for the 
differences in their structure and morphology, phenomenon called polymorphism 
[Kodali and Wetzel, 2007; Stefani, 2010]. Oligomer polymorphism concerns their size, 
shape, compactness, stability and secondary and tertiary structure content [Bemporad 
and Chiti, 2012]. In addition to these characteristics, it is important to note that different 
kind of oligomers can coexist at the same time in solution [Goldsbury et al., 2005; 
Gosal et al., 2005; Jain and Udgaonkar, 2011; Mastrangelo et al., 2006; Relini et al., 
2010] and even in vivo [Winner et al., 2011]. The importance of oligomer 
polymorphism reflects in the biological activity of the oligomers. Indeed, it has been 
shown that expression of different mutants of Aβ in Drosophila qualitatively leads to 
different pathologies [Iijima et al., 2008] and that different oligomers of α-synuclein 
and Aβ cause toxicity in cell cultures through different mechanisms [Danzer et al., 
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2007; Deshpande et al., 2006]. Finally, polymorphism is fundamental in determining 
the propagation of prion strain infectivity [Jones and Surewicz, 2005]. 
 
1.2.3 Structural determinants and mechanisms of oligomer cytotoxicity 
It has been observed that different oligomers formed by the same protein present 
different levels of cytotoxicity and that oligomers originated by different proteins are 
able to affect the cellular viability to the same extent, indicating that the toxicity of these 
species is due to their misfolded nature rather than to specific features of their amino 
acid sequences. The increasing number of studies, targeted to elucidate the fine 
oligomer structure, has allowed to shed light on the structural determinants of oligomer 
toxicity, i.e. the structural elements that are responsible for the ability of protein 
oligomers to interact with the cells and cause their dysfunction [Bemporand and Chiti, 
2012]. 
The degree of hydrophobic surface exposure seems to play an important role in 
oligomer-mediated toxicity. It has been observed that the increase of hydrophobic 
exposure in Aβ40 aggregates correlates with their ability to affect model membrane 
fluidity [Kremer et al., 2000]; such a positive correlation was also found in 
homopolymeric amino acid stretches between hydrophobicity and cytotoxicity of their 
aggregates [Oma et al., 2005]. In a recent study, two types of spherical oligomers 
formed by the HypF-N protein, similar in size, morphology and ThT binding, were 
found to have very different toxicities on cell cultures, with one species found to be 
nontoxic [Campioni et al., 2010]. Through the technique of the site-directed labeling 
with the fluorescent probe pyrene, it was found that the three most hydrophobic regions 
of the protein sequence are structured and buried in the nontoxic oligomers, whereas in 
the toxic oligomers the same regions are more solvent exposed and flexible [Campioni 
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Figure 1.4. Toxicity versus size of Aβ40 
(filled circles) and Aβ42 (empty circles) 
aggregates. Toxicity is measured by 
determining MTT reduction by cultured 
cells following their exposure to 
oligomers added to the extracellular 
medium. Aggregate toxicity was 
expressed as percentage of MTT 
reduction relative to untreated cells, 
where 0% and 100% values are two 
extremes of full cell death and full 
viability, respectively. All data were 
obtained at a peptide concentration in the 
range of 2.0-2.7 mM and aggregate size 
was expressed as mean molecular weight. 
All data points were fitted to a hyperbolic 
function of the form y = a * x/(b + x). 
Image taken from Bemporad and Chiti, 
2012. 
 
et al., 2010]. Moreover, it has been shown that prefibrillar aggregates of the E22G 
variant of the Aβ42 peptide bind strongly to 1-anilinonaphthalene 8-sulfonate (ANS), an 
indicator of hydrophobic exposure, and that changes in this property correlate 
significantly with changes in their cytotoxicity [Bolognesi et al., 2010]. In the same 
work, investigation on other protein systems indicated that this is a shared property of 
misfolded species. Another study has demonstrated that the degree of toxicity of highly 
amyloidogenic proteins expressed intracellularly increases with the exposure to the 
solvent of hydrophobic regions on the aggregates surface [Olzscha et al., 2011]. 
Recently, it has been reported that the interaction between Aβ and antibodies grafted 
with small hydrophobic portions of Aβ itself prevents amyloid formation by converting 
monomers and/or fibrillar intermediates into small complexes that are unstructured and 
benign on cell cultures [Ladiwala et al., 2012]. 
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Lately, particular attention has been paid to the size of the oligomers as a structural 
determinant of cytotoxicity. Indeed, it was found that Aβ42 pre-fibrillar aggegates of 
different sizes give rise to an inverse correlation between oligomer size and neuronal 
toxicity, with the smallest species showing the highest ability in causing cell 
dysfunction [Cizas et al., 2010]. In addition, it was found that three classes of small 
aromatic molecules can inhibit Aβ42 oligomer toxicity by converting the small 
oligomers into large aggregates, fibrils, and monomers, respectively [Ladiwala et al., 
2011]. Interestingly, the formation of larger assemblies of toxic oligomeric species of 
Aβ induced by other molecules, such as molecular chaperones has been found to result 
in a suppression of their toxicity [Ojha et al., 2011]. Finally, through the analysis of the 
toxicity levels of many oligomeric species of Aβ it has been observed that the 
cytotoxicity decreases with the increase of oligomer size (Figure 1.4) [Bemporad and 
Chiti, 2012].  
The higher ability of small soluble oligomers to cause cellular damage may reflect 
their greater diffusion capability and higher hydrophobic surface per number of 
monomers with respect to larger assemblies. In agreement with this hypothesis, the 
fibrils forming at the end of the aggregation process are characterized by a lower level 
of toxicity with respect to their precursors, as they display hydrophobic burial and mass 
increase [Haass and Selkoe, 2007; Keshet et al., 2010]. 
The mechanisms by which oligomers exert their toxicity is not clear but a 
prominent hypothesis suggests that the aggregates may expose flexible and hydrophobic 
regions on their surface that can mediate aberrant interactions with other proteins or cell 
membranes. Indeed, the toxicity of intracellularly forming aggregates was attributed to 
their ability to interact and alter the function of a number of cellular proteins [Olzscha et 
al., 2011], whereas the ability to cause cellular damage of exogenously added oligomers 
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Figure 1.5. Schematic representation of two different types of oligomers generated incubating 
HypF-N in different conditions of aggregation. Toxic oligomers (on top) characterised by a lower 
degree of packing and higher solvent exposure of the hydrophobic regions than the ones of the 
non-toxic species (bottom) are shown. Probably, these characteristics allow the interaction 
between toxic oligomers and membrane and subsequently dysregulation of Ca2+ levels. Image 
taken from Campioni et al., 2010. 
was found to result from a disruption of cell membranes and a consequent uptake of 
calcium (Figure 1.5) [Campioni et al., 2010; Zampagni et al., 2011].  
 
 
1.3 Homeostasis of the proteome 
1.3.1 Protein homeostasis network 
Protein homeostasis, or proteostasis, is the cellular process that governs the “life of 
proteins”, as it encompasses regulation and control of the translation, folding, 
translocation to different intracellular compartments, assembly or disassembly, and 
clearance of proteins [Balch et al., 2008]. Clearly, the maintenance of the proteome in 
its functional state has a fundamental importance for living cells and, for this reason, 
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several dedicated systems have been evolved. In this section a brief description of such 
systems will be given. 
Molecular chaperones include, for example, the families of the Hsp100s, Hsp90s, 
Hsp70s, Hsp60s, Hsp40s and the small heat shock proteins (sHsps). They can act in the 
cytosol or in specific cellular compartments such as the endoplasmic reticulum (ER) or 
the mitochondria [Young et al., 2004; Bukau et al., 2006]. All molecular chaperones 
interact promiscuously with a broad range of unfolded proteins, recognizing an 
increased exposure of hydrophobic amino acids [Bukau et al., 1996; Sharma et al., 
2008; Viitanen et al., 1992; Walter and Buchner, 2002]. Generally, they do not provide 
structural information for folding, but avoid unwanted molecular interactions, through 
controlled binding and release of nonnative proteins that involves, for some of them, 
ATP hydrolysis. Molecular chaperones also prevent the aberrant aggregation of 
unfolded, partially folded and misfolded proteins [Broadley et al., 2009], are able to 
solubilize and reactivate aggregated proteins [Weibezahn et al., 2005] and mediate the 
degradation of misfolded proteins [Pickart and Cohen, 2004]. 
Recent evidence has shown that extracellular counterparts to the intracellular 
molecular chaperones exist and are referred to as extracellular chaperones (ECs). 
Indeed, a series of glycoproteins, such as clusterin [Humphreys and Carver, 1999], 
haptoglobin [Yerbury et al., 2005] and α2-macroglobulin [French et al., 2008] have 
been found to be secreted and to act in a chaperone-like manner [Wilson et al., 2008]. In 
most cases, ECs share functional similarities with the sHsps, as they are able to stabilize 
misfolded proteins preventing their aggregation, but cannot refold independently 
proteins as they lack ATPase activity [Wyatt et al., 2013]. 
A universal and ancient mechanism where molecular chaperones and other proteins 
work in an integrated process is the heat shock response (HSR), so called because it was 
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initially described as an enhanced transcription of specific genes triggered by an 
increase in the temperature [Ritossa, 1962], and later recognized to be prompted by a 
variety of stresses, including oxidative stress, heavy metals, ethanol or other toxic 
substances [Courgeon et al., 1984; Heikkila et al., 1982; Michel and Starka, 1986; Yura 
et al., 1984]. Proteins involved in the HSR exert several and different functions, but 
they are predominantly molecular chaperones [Ellis et al., 1989; Young et al., 2004]. A 
related process, originating from the accumulation of misfolded proteins in the ER, is 
the unfolded protein response (UPR) [Walter and Ron, 2011].  
Improperly folded proteins are not allowed to leave the ER and are retrotraslocated 
into the cytosol for proteasomal degradation, a process called ER-associated 
degradation (ERAD) [Smith et al., 2011]. These proteins, once in the cytosol, are 
degraded by the ubiquitin-proteasome system (UPS) [Claessen et al., 2012].  
Protein degradation through UPS is the major pathway of non-lysosomal proteolysis 
of intracellular short-lived, mislocated, misfolded, mutant or damaged proteins 
[Sherman and Goldberg, 2001]. Firstly, a series of enzyme-mediated reactions identifies 
and covalently links abnormal proteins with multiple ubiquitin molecules as a signal for 
degradation. Then, ubiquitin-protein conjugates are recognized and degraded by the 
proteasome, which is a multisubunit protease [DeMartino and Slaughter, 1999]. The 
degradation products are short peptide fragments and amino acids that can be recycled 
to produce new proteins [Pickart, 2000].  
The degradation of intracellular components occurs thanks to autophagy, that 
mediates the degradation of intracellular components, such as single macromolecules 
and organelles, inside lysosomes [Mizushima et al., 2008], guaranteeing their renewal 
and, therefore, contributing to basal homeostasis [Bejarano and Cuervo, 2010].  
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All of the systems described here are strictly connected and interdependent on each 
other, and a continuous balance among them is necessary in order to ensure the 
homeostasis of the proteome. The importance of studying these systems in the context 
of a complex network that preserves cellular functionality is now emerging. Indeed, the 
comprehension of the mechanisms that govern the co-dependence of these systems 
could help to shed light on situations in which the proteostasis machinery fails 
[Morimoto and Cuervo, 2009]. 
 
1.3.2 Protein homeostasis and protein deposition diseases 
Deficiencies in the protein homeostasis can lead to a broad variety of human 
pathologies, including those associated with misfolding and aggregation of proteins 
(Figure 1.6) [Selkoe, 2003; Chiti and Dobson, 2006; Muchowski and Wacker, 2005]. 
Upon aging a decline of the proteostatic controls naturally occurs, due to changes in the 
transcriptional levels of chaperones, post-translational modifications, increase in protein 
oxidation, decrease in the protein degradation rate, etc. [Balch et al., 2008; Martinez-
Vicente et al., 2005]. The age-related deterioration of the proteostasis can in part 
explain the reason why many diseases are age-dependent [Lu et al., 2004; Zhang et al., 
2004; Massey et al., 2006; Erickson et al., 2006; Derham and Harding, 1997].  
Numerous studies have shown that chaperones and components of the ubiquitin-
proteasome system associate with inclusion bodies or extracellular plaques 
characteristic of protein deposition diseases, suggesting a general activation of the 
cellular quality control machinery in an attempt to face the accumulation of misfolded 
species [Barral et al., 2004; Wyatt et al., 2013]. The homeostatic capacity of the cells 
can be overwhelmed by the increasing amounts of misfolded proteins [Barral et al., 
2004; Gidalevitz et al., 2006] and, concomitantly, by a progressive reduction of the 
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efficiency of the quality control network, enhancing the imbalance and allowing further 
accumulation of toxic misfolded proteins.  
Moreover, disease processes themselves might cause, or worsen, chaperone 
deficiency. Indeed, it has been suggested that aggregate deposits are able to sequester 
molecular chaperones in a non-functional state, inhibiting their essential function in 
cellular processes [Schaffar et al., 2004; Barral et al., 2004; Satyal et al., 2000]. In 
addition, studies report that several cellular models of misfolding diseases do not 
promptly activate the cytosolic stress response upon overexpression of disease proteins 
[Duennwald and Lindquist, 2008; Magrane et al., 2005; Tagawa et al., 2007; Hay et al., 
2004; Cowan et al., 2003]. Similarly, a malfunctioning of the extracellular chaperone 
machinery has been observed to inevitably affect plasma protein solubility [Poon et al., 
2002; Pavliček and Ettrich, 1999; Yerbury et al., 2005]. 
If an age-related or disease-related decrease in chaperone activity contributes to 
pathology, restoring or maintaining proteostasis process should postpone or even 
prevent disease onset [Balch et al., 2008; Broadley and Hartl, 2009]. Indeed, a great 
number of studies have been done in agreement with this idea. It has been demonstrated 
that aggregation-mediated proteotoxicity was ameliorated by delaying the ageing 
process in Caenorhabditis elegans models of Huntington’s and Alzheimer’s diseases, 
acting at the level of proteostasis regulators of chaperones [Morley et al., 2002; Parker 
et al., 2005; Cohen et al., 2006]. The overexpression of certain chaperones, including 
Hsp70s and Hsp40s, suppresses aggregation-associated damage in numerous 
neurodegenerative disease models [Auluck et al., 2002; Tam et al., 2006; Kitamura et 
al., 2006; Behrends et al., 2006]. It has been reported that in transgenic mouse models 
of Alzheimer’s diseases the sHsp αB-crystallin has a cytoprotective effect, since it 
neutralizes the toxic Aβ oligomers [Ojha et al. 2011]. Also extracellular chaperones 
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have been shown to interact with oligomeric species [Yerbury et al., 2007; Yerbury et 
al., 2009] with benefic results for cells. Indeed, cerebrospinal fluid (CSF) samples from 
patients with Alzheimer’s disease were found to be more toxic to cultured 
neuroblastoma cells than normal CSF; interestingly, the addition of extracellular 
chaperones, such as clusterin, α2-macroglobulin and haptoglobin, suppressed this 
toxicity and the effect coincided with more efficient cellular uptake of Aβ [Yerbury and 
Wilson, 2010]. 
 
 
 
1.4 Multifactorial origin of neurodegeneration 
1.4.1 Immune system in the central nervous system 
It has been suggested that neurodegeneration associated with protein deposition 
diseases, such as Alzheimer's disease and Parkinson's disease, is a multifactorial 
 
 
Figure 1.6. Interplay between protein quality control (transitions from unfolded to intermediates to native 
and to misfolded states) and clearance mechanisms in protein conformation disease. Chaperones have a 
critical role to suppress the appearance of misfolded species and to enhance protein folding. The 
imbalance of misfolded species is associated with human disease. Images taken from Morimoto, 2008. 
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phenomenon [Mangialasche et al., 2010; Roodveldt et al., 2008]. Among the factors 
that have been proposed to affect these pathologies, the uncontrolled inflammatory 
response in the brain has arisen to a central role [Amor et al., 2010]. 
The central nervous system (CNS) is considered an “immune privileged” organ 
since it has developed strategies to limit the immune activation within the tissue itself, 
probably to avoid strong inflammatory reactions that can damage delicate, non-
regenerating cells such as neurons and oligodendrocytes [Ransohoff and Brown, 2012]. 
Firstly, it lacks of antigen-presenting cells that act as messengers between the 
innate and adaptive immunity in the periphery (performing antigen uptake, migration to 
draining lymph nodes and presentation to naive T cells) [Ransohoff and Brown, 2012]; 
secondly, it is surrounded by the blood-brain barrier (BBB), that limit the entry of 
immune elements [Carson et al., 2006]; finally, it is characterized by an anti-
inflammatory environment, with a high presence of inflammation-suppressive 
cytokines, such as interleukin-10 (IL-10), and gangliosides, which can be toxic to T 
cells [Strle et al. 2001; Irani, 1998]. 
Microglia and astrocytes represent the innate immune component in the CNS 
parenchyma [Aloisi, 2001; Dong and Benveniste, 2001] and deal directly with 
pathogens and tissue damage acting as the fundamental first line of defence [Ransohoff 
and Brown, 2012]. These cells cannot directly initiate adaptive responses, but can 
recruit cells of the adaptive immune system by secreting various cytokines and 
chemokines that induce adhesion molecules on the BBB [Amor et al., 2010].  
Microglia and astrocytes constantly survey the microenvironment and produce 
factors that influence surrounding neurons. Under physiological conditions, these cells 
exhibit a deactivated phenotype that is associated with the production of anti-
inflammatory and neurotrophic factors [Streit, 2002]. They can switch to an activated 
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status when they recognize highly conserved structural motifs, either from pathogens 
(pathogen-associated molecular patterns, or PAMPs) or from damaged or stressed 
tissues (danger-associated molecular patterns, or DAMPs). PAMPs include bacterial, 
viral and protozoal products, such as protein, lipid, nucleic acid and carbohydrate 
[Ransohoff and Brown, 2012]. DAMPs are endogenous signals, encompassing HSPs, 
uric acid, chromatin, adenosine and ATP, fibrinogen and aggregated, modified or 
misfolded proteins [Amor et al., 2010]. The recognition is mediated by pattern-
recognition receptors, such as the Toll-like receptors (TLRs), which are located on the 
plasma membrane or in endosomal compartments [O’Neill, 2004]. Upon activation, 
microglia and astrocytes release a variety of immune regulators, such as cytokines and 
chemokines, promoting an inflammatory response directed to tissue repair [Glass et al., 
2010].  
In a prototypical scenario, the engagement of TLRs evokes transcriptional 
activation of genes encoding interleukin-1 (IL-1) family cytokines. Pro-forms of the 
resulting peptides, for example pro-IL-1β, remain cytoplasmic until cleaved 
enzymatically by activated caspase-1 [Martinon and Tschopp, 2004]. The release of 
biologically active IL-1β elicits production of a secondary inflammatory cytokine 
cascade by both microglia and astrocytes [Chakraborty et al., 2010]. For example, IL-1β 
can induce expression of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) 
[Ransohoff and Brown, 2012]. 
Microglial cells are also the resident phagocytes of the brain [Perry and Gordon, 
1988]. Phagocytosis contributes to the maintenance of the integrity of the tissue, 
through the clearance of apoptotic cells and the promotion of the damage resolution. 
This process is also exploited to remove extracellular protein aggregates [Rogers et al., 
2002; Zhang et al., 2005]. Regarding astrocytes, they act in buffering CNS potassium 
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ions, removing and recycling potentially toxic glutamate, adjusting water balance, and 
modulating synaptic activity and blood flow [Nash et al., 2011]. 
 
1.4.2 Inflammatory response and protein deposition diseases 
Inflammation has been found to be linked to certain neurodegenerative disorders 
including Alzheimer's disease, Parkinson's disease and multiple sclerosis [Raine, 1994; 
Banati et al., 1998; McGeer et al., 1988]. The inflammatory response protects the tissue, 
promoting the insult resolution. However, when chronically sustained because of a 
persistent stimulation, it may become harmful and self-damaging. An over-activation of 
microglia and astrocytes is inevitably present in brains affected by neuropathologies and 
it has been observed in Parkinson's disease [Kim and Joh, 2006], Alzheimer's disease 
[McGeer et al., 2006] and Huntington’s disease [Masters and O’Neill, 2011]. 
Following activation, microglia cells change their morphology, express MHC 
antigens and become phagocytic [Hayes et al., 1987]. They secrete pro-inflammatory 
cytokines that amplify the inflammatory response by activating and recruiting other 
cells to the lesion, express chemokines and release nitric oxide, which mediates 
apoptosis [Dickson et al., 1993; Griffin et al., 1989]. Chronic microglia activation may 
lead to the recruitment of cells of the adaptive immune system into the CNS, resulting 
in neuronal damage [Amor et al., 2010]. This process is particularly harmful in the 
brain, since neurons are generally irreplaceable [Kim and Joh, 2006].  
An increasing number of studies have reported that amyloidogenic proteins/peptides 
and misfolded aggregates are potent immunostimulatory [reviewed in Masters and 
O’Neill, 2011]. Importantly, the microglial activation and inflammatory processes are 
thought to be largely caused by the aberrant protein oligomers accumulating throughout 
the pathological aggregation process [Roodveldt et al., 2011; Amor et al., 2010]. 
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Interestingly, it has been proposed that the innate immune system universally 
recognizes hydrophobicity as a damage-associated pattern, evolving its TLRs in order to 
react with the exposed hydrophobic portions of molecules [Seong and Matzinger, 2004]. 
Indeed, the TLRs are highly promiscuous and bind to a very large number of ligands. 
These ligands are structurally different, but most of them are either normally 
hydrophobic or prone to exposing large hydrophobic areas when they are damaged or 
modified [Seong and Matzinger, 2004]. 
 
1.4.3 Heat shock proteins as immune mediators 
Many studies have documented induction of Hsps in nerve cells and glia as the result 
chronic neurodegeneration and neuroinflammation. The inducible form of Hsp70 
accumulates in astrocytes, oligodendrocytes and microglia, following a variety of 
stresses [Richter-Landsberg and Goldbaum, 2003]. The expression of Hsp60 has been 
Figure 1.7. Extracellular Hsps as 
mediators of inflammation. By 
controlled vesicular exocytosis, a 
variety of Hsps are secreted in 
response to stress by different cells. 
A growing number of surface 
receptors, including CD91, 
scavenger receptors, pattern-
recognition receptors, CD40 and the 
chemokine receptor CCR5, relay 
signals given by extracellular Hsps 
and trigger production of a range of 
molecules with diverse functions in 
innate and adaptive immune 
responses. Adapted from van Noort, 
2008. 
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observed as a consequence of inflammatory cytokine stimuli in oligodendrocytes and 
astrocytes, and of inflammatory lesions during multiple sclerosis [Bajramovic et al., 
2000]. In addition, during neuroinflammation in multiple sclerosis and Alzheimer’s 
disease, oligodendrocytes have been found to produce the sHsp αB-crystallin [van 
Noort et al., 1995; Renkawek et al., 1994]. 
Evidence is now emerging that Hsps not only accumulate in brain cells following 
stress, but are secreted and act as extracellular signals for receptor-mediated signaling in 
a similar manner to other soluble mediators of inflammation [Calderwood et al., 2007] 
(Figure 1.7). The release of Hsps in the extracellular space seems to be a physiological 
phenomenon, since it occurs even under mild forms of stress in vivo. For example, 
Hsp70 is induced as an extracellular mediator in the CNS during exercise in humans 
[Lancaster et al., 2004]. In addition, Hsp60, Hsp70 and αB-crystallin have been 
observed in the cerebrospinal fluid of patients suffering from neurodegenerative 
disorders, but also in healthy controls [Ousman et al., 2007; Lancaster et al., 2004; Lai 
et al., 2006]. In agreement with this findings, several surface receptors have been found 
to recognize extracellular Hsps, and even fragments of Hsps [Habich et al., 2006; Wang 
et al., 2005]. 
Interestingly, exogenous Hsps, including Hsp32, Hsp70, Hsp90 and αB-crystallin, 
are able to activate microglia [Calderwood et al., 2007; Kakimura et al., 2002; 
Kakimura et al., 2001; Bhat and Sharma, 1999]. In vitro treatment of microglia with 
such Hsps generally induces production of nitric oxide, several cytokines including 
TNFα, TGFβ and IL-6 and chemokines [van Noort, 2008]. The microglial activation has 
also been observed in vivo by injecting exogenous Hsp90 into the hippocampus of rats 
[Takata et al., 2003]. Moreover, in several cases, microglial activation by exogenous 
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Hsps has been demonstrated to result in increased uptake and clearance of amyloid 
peptide aggregates [Kakimura et al., 2002; Kakimura et al., 2001; Takata et al., 2003]. 
Due to their anti-inflammatory effects, Hsps have been evaluated as therapeutic 
agents in a variety of human inflammatory diseases, such as rheumatoid arthritis 
[Vanags et al., 2006; van Eden, 2008; Panayi and Corrigall, 2008], psoriasis [Williams 
et al., 2008], diabetes [Huurman et al., 2008] and multiple sclerosis [Broadley et al., 
2009]. 
 
1.5 The model protein HypF-N 
1.5.1 Structural properties of HypF-N 
HypF-N is the N-terminal domain of the prokaryotic hydrogenase maturation factor 
HypF of Escherichia coli, a large multi-domain protein of about 82 kDa that is in 
charge of assisting the folding of [NiFe]-hydrogenases, enzymes involved in the 
hydrogen metabolism of prokaryotes [Colbeau et al., 1998]. HypF is constituted by an 
N-terminal acylphosphatase-like domain (residues 1-91), a sequence motif shared with 
enzymes catalysing O-carbamoylation reactions (residues 473-479) and two zinc-finger 
motifs similar to those found in the DnaJ chaperone (residues 109-134 and 159-184) 
[Casalot and Rousset, 2001]. The N-terminal domain is homologous in the sequence 
and structure to the acylphosphatase-like structural family. Acylphosphatases (AcPs) are 
small enzymes that catalyse the hydrolysis of carboxyl-phosphate bonds in 
acylphosphates [Stefani and Ramponi, 1995]. In spite of sharing about 22% and 50% of 
its sequence with human and E. coli AcP, respectively, HypF-N does not show any 
catalytic activity typical of AcPs [Chiti et al., 2001]. 
The native structure of this domain has been resolved by X-ray crystallography 
[Rosano et al., 2002] and displays a ferredoxin-like fold with a α/β topology, consisting 
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of a βαββαβ secondary structure (Figure 1.8). The domain is about 43x28x27 Å in size 
[Rosano et al., 2002] and has a compact and globular structure, targeted to avoid 
aggregation from its native state. Indeed, in order to disfavour intermolecular 
interactions, the protein presents very short or highly twisted edge β-strands, a β-bulge 
(71-72), a proline residue (Pro78) and a cluster of charged residues (Asp72, Glu75-
Arg76-Glu77), all structural properties that prevent interactions between different 
molecules [Rosano et al., 2002]. 
 
 
 
1.5.2 Aggregation of HypF-N in vitro 
Conditions that partially destabilize the native structure of HypF-N can induce its 
aggregation in vitro, and encompass low and high pH, mutations and the presence of a 
moderate amount of trifluoroethanol (TFE) [Chiti et al., 2001; Relini et al., 2004; 
Marcon et al., 2005; Campioni et al., 2008; Calloni et al., 2008; Ahmad et al., 2010]. 
 
Figure 1.8. Ribbon representation of 
HypF-N structure. The secondary 
structure elements are displayed in blue 
(α-helices) and green (β-strands) colours. 
The putative active site is also shown with 
the conserved residues Arg23 and Asn41, 
the bound phosphate (purple sticks) and 
the bound chloride ion (light blue sphere). 
The Cys7 residue shown in figure was 
found to adopt two alternative 
conformations both able to form right-
handed disulfides with a neighbouring 
molecule in the crystal. The figure was 
taken from Rosano et al., 2002. 
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A first work reported the formation of amyloid-like fibrils by incubating the protein in 
citrate buffer at pH 3.0 or in acetate buffer at pH 5.5 with 30% (v/v) TFE [Chiti at al., 
2001]. Electron microscopy images showed the presence of 7-9 and 12-20 nm wide 
fibrils in the samples incubated for 1 month at acidic pH, whereas in TFE the majority 
of the fibrils was 3-5 nm and 7-9 nm in width [Chiti at al., 2001]. In addition to the 
fibrillar morphology, these aggregates were found to bind to ThT and CR, resembling 
the amyloid-like properties [Chiti et al., 2001]. The aggregation process in 30% TFE 
was further investigated using AFM (Figure 1.9) and resulted to be a hierarchical path 
[Relini et al., 2004]. Initially globular structures with a height of 2-3 nm consistent with 
that of a small oligomers form; after 3 days of incubation in the aggregating conditions, 
the globules self-assemble into beaded chains with crescent-like appearance; these latter 
originate large rings after 5 days; subsequently the annular structures convert into 
ribbon-like fibers by opening and reorganizing their constituent globular units; for 
further assembly, after 8 days, supercoiled fibrils formed by a different number of 
protofilaments appear, and after eleven days the large majority of the structures 
observed are tangles of fibrils having a width of 3.5, 5.0 and 8.5 nm [Relini et al., 
2004], in agreement with previously reported TEM observations [Chiti et al., 2001]. 
These fibrils show a cross-β structure in the X-ray diffraction pattern, typical of amyloid 
fibrils [Relini et al., 2004].  
Oligomeric aggregates and fibrils were also able to form in 6-12% TFE [Marcon et 
al., 2005]. In these mildly denaturing conditions, HypF-N was found to be initially in a 
predominantly native-like conformation, with the partially folded state being poorly 
populated. A kinetic analysis revealed that molecules accessing such a partially folded 
state were able to originate the aggregation process. In the context of a physiological 
environment, this finding is significantly relevant, since it underlines the need of the 
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cells to constantly fight the propensity to aggregate for even the most stable proteins 
[Marcon et al., 2005]. 
The HypF-N aggregation process under acidic pH condition was investigated from 
the structural characterization of the amyloidogenic precursor state adopted by the 
protein to the description of the resulting aggregates. At low pH, precisely pH 1.7, 
HypF-N was found to be largely unfolded but still contain significant secondary 
structure elements and hydrophobic clusters [Campioni et al., 2008]. By increasing the 
ionic strength of the solution the aggregation of this precursor state was induced and 
amyloid-like protofibrils were detected in the samples, as revealed by ThT fluorescence 
and AFM [Campioni et al., 2008; Calloni et al., 2008; Campioni et al., 2012].  
The NMR analysis of the pH-denatured precursor state allowed to identify the 
regions of the sequence that form hydrophobic interactions and adopt secondary 
structure. Indeed, it was found that the regions spanning residues 23-34, 56-64, and 81-
82 form hydrophobic clusters, whereas the regions spanning residues 26-30, 56-61 and 
Figure 1.9. TM-AFM images of HypF-N 
aggregates formed in the presence of 
30% (v/v) TFE at pH 5.5. (a) After few 
hours of incubation, globular aggregates 
are observed. The scale bar represents 
100 nm. Inset: STM image of globular 
aggregates. The scale bar represents 10 
nm. (b) After three days of incubation, 
crescents and rings are observed. Inset: 
observation of a ring at higher resolution. 
The scale bars represent 400 nm. (c) 
Supercoiled fibrils observed after 8 days 
of incubation. (d)Tangles of the mature 
fibrils that represent the large majority of 
the structures observed after 11 days of 
incubation. Scale bars represent 500 nm 
(c-d). Images adapted from Relini et al., 
2004. 
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46-49 form α-helical structure. These latter regions correspond largely in the native 
conformation to helix α1, helix α2 and strand β3, respectively [Calloni et al., 2008]. By 
creating a set of variants, the regions of the sequence that play key roles in the 
conversion of the pH-denatured state of HypF-N into ThT-binding and β-sheet 
containing protofibrillar species were also identified (approximately residues 9-15, 27-
35, 46-48, and 58-60). These groups of residues correspond to the regions of the 
sequence that have the highest intrinsic aggregation propensity [Calloni et al., 2008]. 
The conversion of HypF-N into amyloid-like oligomers under conditions of acidic 
pH has been recently studied under the influence of different salts [Campioni et al., 
2012]. The AFM results show that, irrespective of the salt used, the aggregation process 
lead to the formation of bead-like oligomers with similar morphologies and heights. By 
contrast, the content of secondary structure and the exposure of hydrophobic clusters of 
the monomeric precursor state is greatly affected by the anions constituting the salts 
[Campioni et al., 2012]. 
A partially folded state of HypF-N, which subsequently assembles to form stable 
soluble oligomers, has been observed in condition of alkaline pH and low 
concentrations of TFE [Ahmad et al., 2010]. These aggregates are able to CR and ThT, 
contain extensive β-sheet structure and have a morphology similar to the HypF-N 
oligomers formed at low and nearly neutral pH [Ahmad et al., 2010]. 
 
1.5.3 Aggregation of HypF-N in vivo 
The aggregation process of HypF-N was also investigated in vivo, where several 
additional factors able to affect substantially the aggregation are present. In E. coli cells, 
wild-type HypF-N does not aggregate; conversely HypF-N variants engineered in order 
to destabilize the native structure precipitate into inclusion bodies after expression 
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[Calloni et al., 2005]. The aggregation of unstable mutants can be avoided by the 
insertion of mutations that increase the net charge and therefore reduce the polypeptide 
chain propensity to aggregate. Interestingly, the aggregating variants were found to be 
less stable than the soluble variants, indicating that the aggregation of this protein in 
vivo also requires partial unfolding of the native state [Calloni et al., 2005].  
In a recent study, by expressing wild-type HypF-N and 21 folding-incompetent 
mutants in E. coli, a significant inverse correlation was found between the solubility of 
the variants and their intrinsic propensity to form amyloid fibrils, suggesting that the 
physicochemical parameters (such as hydrophobicity, β-sheet propensity and charge) 
recognized to affect amyloid formation by fully or partially unfolded proteins in vitro 
are generally valid for situations in vivo [Winkelmann et al. 2010]. 
 
1.5.4 Cytotoxicity of oligomeric species formed by HypF-N 
As described above, the oligomeric species forming during the aggregation pathway of 
HypF-N share structural properties with the diseases related ones [Chiti et al., 2001; 
Relini et al., 2004; Marcon et al., 2005; Campioni et al., 2008]. Moreover, they are 
cytotoxic to cell cultures and animal models in the same manner of the pathology-
related pre-fibrillar aggregates [Bucciantini et al., 2002; Cecchi et al., 2005; Baglioni et 
al., 2006; Campioni et al., 2010; Zampagni et al., 2011]. 
Pre-fibrillar aggregates formed in 30% TFE have been found to reduce the viability 
of cell cultures, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) reduction inhibition assay (Figure 1.10), a generic indicator of cellular stress, 
and the trypan blue internalization assay [Bucciantini et al., 2002]. The levels of cell 
impairment caused by HypF-N oligomers were very similar to those reported for the 
disease-associated proteins, such as α-synuclein, Aβ1–42 and transthyretin [Bucciantini et 
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al. 2002]. In addition, the toxic effects were not observed when the cells were exposed 
to HypF-N aggregates incubated for several days in the aggregating condition and 
containing fibrillar species (Figure 1.10). 
HypF-N oligomers were found to cause an increase of reactive oxygen species 
(ROS) and free Ca
2+
 levels inside the cells, phenomena that can lead to apoptosis or 
necrosis, as shown in several studies [Bucciantini et al., 2004; Bucciantini et al., 2005; 
Cecchi et al., 2005]. These events are triggered by the ability of oligomers to interact 
and disrupt the cell membranes; indeed, it has been found that HypF-N formed in 30% 
TFE were able to permeabilize synthetic membranes [Relini et al., 2004; Canale et al., 
2006] and even plasma membranes of cultured cells [Bucciantini et al., 2004; 
Bucciantini et al., 2005; Cecchi et al., 2005]. An important mechanism in determining 
membrane permeabilization and calcium influx was identified in the activation of the 
glutamatergic channels, NMDA and AMPA receptors, following their interaction with 
HypF-N oligomers, with unspecific membrane permeabilization occurring later 
[Pellistri et al., 2008]. Noteworthy, a loss of cholinergic neurons was observed when 
Figure 1.10. Differential 
cytotoxicity of protofibrillar and 
fibrillar HypF-N aggregates. (a) Cell 
viability was checked by the MTT 
inhibition reduction test, after 
addition to the cell medium of 
either 20 µM native protein (●) or 
different concentrations of 
aggregates formed at different 
times of incubation at pH 5.5 in the 
presence of 30% (v/v) TFE: 20 µM 
(●), 5 µM (●), 1 µM (●), 0.2 µM (●) 
and 0.04 µM (●). Values are relative 
to untreated cells. Figure adapted 
from Bucciantini et al., 2002. 
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HypF-N pre-fibrillar aggregates were injected into rat brains [Baglioni et al., 2006], 
indicating that these species are toxic also in higher organisms. 
The recent finding that different types of HypF-N oligomers have different abilities 
to cause cellular impairment, with one species being nontoxic, has provided a unique 
opportunity to study and compare the structure and activity of toxic and nontoxic 
oligomeric aggregates [Campioni et al., 2010]. The toxic HypF-N oligomeric species 
were formed in 12% TFE and termed type A oligomers, whereas the nontoxic species 
were generated at low pH and called type B.  
Type A oligomers were found to decrease cellular viability in human neuroblastoma 
cells (SH-SY5Y) and mouse endothelial cells (Hend), as detected by MTT test, whereas 
type B were benign to these cells [Campioni et al., 2010]. Furthermore, type A 
oligomers penetrated the plasma membrane, induced a calcium influx into the cytosol, 
increased intracellular ROS production and lipid peroxidation, resulting in the activation 
of the apoptotic pathway, as indicated by the substantial increase of caspase-3 level and 
by the staining with the apoptotic marker Hoechst 33342. By contrast, type B oligomers 
were unable to cause such effects [Campioni et al., 2010; Zampagni et al., 2011]. 
Lately, it has been observed that type A oligomers, unlike type B, colocalize with post-
synaptic densities in primary rat hippocampal neurons, induce impairment of long term 
potentiation in rat hippocampal slices and impair spatial learning of rats in the Morris 
Water Maze test, mimicking the synaptotoxicity of Aβ aggregates [Tatini et al., 
unpublished]. 
As described above, the interaction of the oligomers with cell membranes is a 
primary event resulting in cytotoxicity and, therefore, the prevention of such interaction 
mediated by the shielding of glycosaminoglycans bound to cell membranes [Saridaki et 
al., 2012] results in a loss of toxicity of type A oligomers. 
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Further investigations have shown that oligomer cytotoxicity depends on the 
contributions of the physicochemical properties of both the aggregates and the cell 
membrane with which they interact [Evangelisti et al., 2012]. Indeed, by increasing the 
content of cholesterol and decreasing the one of ganglioside GM1 in cell membrane, 
type A oligomers become essentially benign, whereas type B oligomers become toxic 
[Evangelisti et al., 2012]. 
 
1.5.5 Structural determinants for HypF-N oligomer cytotoxicity 
The different biological properties of HypF-N type A and type B oligomers described in 
the previous section were found to arise from differences in the structure of the two 
types of aggregates [Campioni et al., 2010]. Type A oligomers were formed by 
incubating HypF-N for 4 hours in 50 mM acetate buffer, 12% (v/v) TFE, 2 mM DTT, 
pH 5.5 (condition A), whereas type B aggregates are generated by incubating the 
protein for 4 hours in a solution of 20 mM trifluoroacetic acid (TFA), 330 mM NaCl, 
pH 1.7 (condition B).  
The two types of oligomers appeared to be indistinguishable measuring their ability 
to bind to ThT and analysing their morphology through AFM [Campioni et al., 2010]. 
In order to shed light on the structural characteristics responsible for the different 
behavior of the oligomers, 18 HypF-N variants carrying a single cysteine residue 
located at different positions along the polypeptide chain were created and labelled with 
the fluorescent probe N-(1-pyrene)maleimide (PM). PM can be used to obtain 
information on the proximity between two labelled residues located on different protein 
molecules, because of its property to originate excited-state dimers, also called excimers 
[Betcher-Lange and Lehrer, 1978; Hammarström et al., 1997; Hammarström et al., 
1999; Krishnan and Lindquist, 2005]. Excimers form when the distance between two 
Chapter 1                                                                                                         Introduction 
 
39 
 
PM molecules is less than 10 Å; as a consequence, in the fluorescence emission 
spectrum, an excimer peak, indicated by the appearance of broad band at level of the 
440-470 nm region, is observed. Conversely, when the probes are distant, such a band is 
absent [Birks, 1967; Förster, 1969; Betcher-Lange and Lehrer, 1978; Hammarström et 
al., 1997; Hammarström et al., 1999; Krishnan and Lindquist, 2005].  
 
 
 
 
 
 
 
Figure 1.11. Structural differences between toxic and nontoxic oligomeric aggregates of HypF-N. 
(a) Excimer ratio of PM (related to the degree of structure formation) versus number of labeled 
residue for toxic (red lines) and nontoxic (blue lines) oligomers of HypF-N. (b) II/IIII ratio of pyrene 
(a correlate of the degree of solvent exposure) versus number of labeled residue for toxic (red lines) 
and nontoxic (blue lines) oligomers. (c) Hydropathy profile of the HypF-N sequence. The three 
panels show that in nontoxic aggregates, unlike the toxic aggregates, the three hydrophobic regions 
of the sequence are structured and buried inside the oligomers. Image adapted from Campioni et al., 
2010. 
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Each labelled mutant was then allowed to aggregate in condition A and in condition 
B and the PM fluorescence emission spectra of the resulting samples were acquired. 
From these spectra, the ratio of the excimer to monomer fluorescence intensities (FI440 
/FI375) was obtained for each labelled position (Figure 1.11). This approach revealed 
that the regions involved in the formation of the structural core of the aggregates are the 
same in the two types of oligomers and correspond to the three major hydrophobic 
regions of the HypF-N sequence (Figure 1.11). However, the excimer ratio profile 
resulting from type B oligomers was characterized by higher values with respect to the 
ones obtained for type A aggregates, indicating a more compact structure and a tight 
packing of the type B aggregates with respect to type A oligomers.  
In addition, type A aggregates were found to have a stronger affinity for the 
fluorescent probe ANS than the type B oligomers, suggesting that the degree of 
exposure to the solvent of hydrophobic surface is greater in the toxic species. In 
conclusion, the ability of the oligomers to cause cellular dysfunction was linked to the 
level of structural flexibility and solvent-exposure of the hydrophobic residues of the 
oligomers. These structural properties allow the oligomeric species to interact and 
damage cell membranes, leading ultimately to cell death [Campioni et al., 2010].  
 
1.6 Aim of the thesis 
For the experimental work presented in this thesis we took advantage of the ability of 
HypF-N to form oligomeric intermediates with structural and functional properties that 
resemble those associated with protein deposition diseases and that are, in addition, 
relatively easy to form, stable, amenable to structural analysis and producible in two 
forms, toxic and nontoxic. In the first chapter dedicated to the results (Chapter 2), we 
show that chaperones, such as αB-crystallin, Hsp70, α2-macroglobulin, clusterin and 
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haptoglobin, are able to neutralize the toxicity of the oligomers and that such behavior 
derives from their ability to interact with the oligomers and promote their further 
assembly, in the absence of any disaggregation or structural reorganization of the 
aggregates. In addition to showing a novel mechanism used by chaperones to control 
protein homeostasis and to suggesting strategies against protein depositions diseases, 
these results put forward oligomer size as a structural determinant of protein oligomer 
toxicity.  
In Chapter 3 we show that an increase of the surface hydrophobicity of the 
oligomers can have the unexpected result of lowering the toxicity of the aggregates and 
that this phenomenon arises from the ability of the hydrophobic surface to promote the 
formation of larger assemblies, resembling the mechanism used by molecular 
chaperones and described in Chapter 2. In addition, the data confirm the essential role of 
the size in determining the oligomeric ability of damaging cells. Most importantly, we 
illustrate that the level of toxicity of the aggregates is explicable on the basis of 
superficial hydrophobicity and size, only if these two parameters are considered 
together as forces that act and cooperate simultaneously. 
In Chapter 4 we present results on the ability of TTR to suppress the toxicity of 
HypF-N oligomers by binding and inducing the formation of larger clusters of 
aggregates, similarly to well established chaperones. The results confirm the efficacy of 
such mechanism detoxifier of misfolded oligomers and underline again the dimension 
as structural parameter affecting oligomer toxicity. Moreover, the chaperone-like 
activity has to be enrolled among the functions of TTR. 
Finally, in Chapter 5 results on the ability of HypF-N oligomers to trigger a pro-
inflammatory response will be presented. Interestingly, the nontoxic species were found 
to be stronger inducers of inflammation with respect to the toxic oligomers. In addition, 
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the nontoxic oligomers and the assemblies neutralized by chaperones exert the ability to 
induce inflammation without affecting cellular viability. These first results, although 
they need to be further proved, suggest that the inflammation process should not be 
underestimated in approaching to degenerative diseases. 
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Chapter 2 
MOLECULAR MECHANISMS USED BY CHAPERONES TO REDUCE THE 
TOXICITY OF ABERRANT PROTEIN OLIGOMERS 
2.1 Introduction 
The ability of living systems to maintain their peptides and proteins in soluble, native 
and functional states is the result of a wide variety of physicochemical and 
conformational characteristics of these macromolecules that have been selected by 
evolution [Dobson, 2003; Monsellier and Chiti, 2007] and it is also attributable to an 
array of dedicated biological mechanisms that together ensure protein homeostasis 
[Balch et al., 2008; Powers et al., 2009], as described in section 1.3. The cellular 
machinery dedicated to the maintenance of proteostasis includes ribosomes, molecular 
chaperones, the ubiquitin-proteasome system, the heat shock response, the unfolded 
protein response, endoplasmic reticulum associated degradation, autophagy, etc. 
[Voellmy and Boellmann, 2007; Kapoor and Sanyal, 2009; Kubota, 2009; Hoseki et al., 
2010; Bejarano and Cuervo, 2010]. The failure of this machinery to function effectively 
causes a wide variety of pathological conditions, included those associated with the 
misfolding of proteins that can lead to aggregate accumulation both in the cytosol and in 
the extracellular space [Selkoe, 2003; Chiti and Dobson, 2006]. 
Molecular chaperones are proteins that play a central role in the avoidance of 
protein misfolding and aggregation [Bejarano and Cuervo, 2010; Morimoto, 2008; 
Young et al., 2004; Weibezahn et al., 2005; Hartl et al., 2011]. Most known chaperones 
are intracellular and act in the cytosol or in specific cellular compartments such as the 
ER or the mitochondria [Young et al., 2004; Bukau et al., 2006], but some chaperones 
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are secreted and are collectively referred to as extracellular chaperones [Wilson et al., 
2008]. The variety of molecular chaperones are known to have a range of different 
functions, including assisting in the folding process of newly synthesised proteins or 
temporarily misfolded proteins [Young et al., 2004], inhibiting the aggregation of 
unfolded, partially folded and misfolded proteins [Broadley et al., 2009], causing the 
disaggregation of small aberrant protein aggragates [Weibezahn et al., 2005] and 
mediating the degradation of misfolded proteins [Pickart and Cohen, 2004]. However, 
little is known about about their ability to suppress the toxicity of aberrant protein 
oligomers, which are considered the major deleterious species in protein misfolding 
diseases. 
In this study we have examined the effects of five chaperones (human αB-crystallin 
and Hsp70 as intracellular chaperones, and human clusterin, haptoglobin and α2-
macroglobulin as extracellular chaperones) on the toxicity of extracellularly added 
oligomers formed by three different peptides/proteins A42, IAPP and HypF-N. We 
have focused our attention on small oligomers as these are highly toxic and thought to 
be the major deleterious species in a range of protein misfolding diseases [Chiti and 
Dobson, 2006; Selkoe, 2008]. We show that all five chaperones suppress completely, or 
decrease markedly, the toxicity of all oligomers examined here, with significant effects 
observed even at molar ratios of protein:chaperone as low as 500:1. In the light of these 
observations we have carried out experiments to elucidate whether the chaperones cause 
a structural modification of the oligomers at the single residue level, their gross 
disaggregation or their further assembly; we will show that the chaperones bind to the 
oligomers and promote their clustering into larger aggregates, providing an explanation 
to why they are efficient at such low concentrations. 
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2.2 Results 
The cellular biology experiments here described were acquired in collaboration with the 
group of Prof. Cristina Cecchi of the University of Florence. AFM measurements were 
performed by the group of Prof. Annalisa Relini of the University of Genoa. This work 
have been published in June 2012 by Proceedings of the National Academy of Sciences 
of the United States of America [Mannini et al., 2012]. 
 
2.2.1 Chaperones suppress the toxicity of oligomers formed by different proteins  
Toxic oligomers were generated from three different peptides/proteins, A42, IAPP and 
HypF-N, as described previously [Lambert et al., 2001; Cecchi et al., 2008; Campioni 
et al., 2010]. They were incubated in the cell culture medium for 1 hour and then added 
to SH-SY5Y cultured cells, at 12 µM monomer concentration. All three types of 
oligomers were found to decrease the MTT reduction of the SH-SY5Y cells by 30-40%, 
demonstrating their toxic nature (Figure 2.1A-C). They were then subjected to the same 
procedure but incubated for 1 hour in the cell culture medium containing either αB-
crystallin, Hsp70, clusterin, haptoglobin or α2-macroglobulin prior to addition to SH-
SY5Y cells (protein:chaperone molar ratios were 5:1, 5:1, 10:1, 15.1 and 100:1, 
respectively). In each case the cells were found to reduce MTT to levels similar to 
untreated cells or to cells treated with the native proteins (Figure 2.1A-C). By contrast, 
when the three types of oligomers were incubated in cell culture medium for 1 hour 
with hen egg white lysozyme (HEWL) or bovine serum albumin (BSA), proteins that 
are not expected to possess chaperone properties, the oligomers were found to maintain 
their toxicity (Figure 2.1A-C). 
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These results therefore indicate that all the five chaperones examined here can 
suppress or decrease markedly the toxicity of oligomers formed by three different 
peptides and proteins, with such generic suppression being specific for chaperones 
relative to other proteins. 
 
 
 
 
Figure 2.1. Suppression of protein oligomer toxicity by chaperones. Preformed oligomers of 
HypF-N (A), Aβ42 (B) and IAPP (C) were resuspended in the cell culture medium, incubated for 1 
hour at a corresponding monomer concentration of 12 µM in the absence or presence of the 
indicated chaperones and control proteins (protein:chaperone molar ratios were 5:1, 5:1, 10:1, 
15:1 and 100:1, respectively; protein:HEWL and protein:BSA molar ratio was 5:1) and then added 
to SH-SY5Y cells. Cell viability was expressed as percent of MTT reduction in treated cells with 
respect to untreated cells (taken as 100%). The values shown are means  SD of three 
independent experiments carried out in triplicate. An asterisk indicates a significant difference (p 
 0.01) relative to the experiment without chaperones. 
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2.2.2 Chaperones reduce protein oligomer toxicity even at very low concentration  
In order to investigate the means by which chaperones suppress the toxicity of protein 
oligomers and the resulting effects on the cells, we chose to focus on oligomers formed 
by one specific protein, HypF-N. Under different experimental conditions, HypF-N 
aggregates into toxic (type A) or nontoxic (type B) oligomeric forms, which are 
morphologically similar and bind ThT to similar levels, making it possible to have a 
powerful control system [Campioni et al., 2010]. In addition, differences in structure of 
toxic and nontoxic oligomers have been detected by means of fluorescence spectra of 
PM-labelled oligomers [Campioni et al., 2010], providing a valuable spectroscopic 
method for probing the conformational changes experienced by the oligomers following 
their exposure to chaperones (see below). 
The experiments described above for toxic (type A) HypF-N oligomers were 
repeated by varying the concentrations of each of the five chaperones in the 1 hour pre-
incubation solution, while maintaining constant the HypF-N concentration. The results 
show that the ability of each of the five chaperones to suppress the toxicity of HypF-N 
oligomers decreased with the chaperone concentration (Figure 2.2). However, all 
chaperones had significant effects even at HypF-N:chaperone molar ratios of 500:1, 
becoming ineffective only at molar ratios of 2000:1 (Figure 2.2). Given the size of 
HypF-N oligomers observed with atomic force microscopy (2-6 nm) it can be estimated 
that HypF-N oligomers do not contain more than 10-20 molecules [Campioni et al., 
2010], showing that chaperones are able to suppress toxicity at greatly sub-
stoichiometric concentrations, that is with far less than one chaperone molecule per 
oligomer. 
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2.2.3 Chaperones prevent the interaction of oligomers with cellular membranes  
Type A HypF-N oligomers have been shown to impair cell membrane and cause an 
influx of Ca
2+
 ions from the extracellular space into the cytosol, which triggers a 
complex cellular cascade eventually leading to apoptosis [Zampagni et al., 2011]. We 
therefore carried out experiments to identify the cellular mechanism by which the 
chaperones studied here are able to suppress oligomer-mediated toxicity. Pre-incubation 
of type A oligomers with each of the five chaperones in the culture medium for 1 hour, 
prior to addition to the cells, was found to inhibit the increase of intracellular Ca
2+
 
levels caused by the oligomers, with the degree of inhibition increasing with time of 
pre-incubation (Figure 2.3). 
 
 
Figure 2.2. Suppression of HypF-N oligomer toxicity by chaperones at different 
protein:chaperone molar ratios. HypF-N oligomers were incubated for 1 hour in the absence (о) 
or presence of the indicated chaperones and at the indicated HypF-N:chaperone molar ratio and 
then added to SH-SY5Y cells. The scale on the x axis is logarithmic. 
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Figure 2.3. Representative confocal scanning microscope images showing intracellular Ca2+ levels 
in SH-SY5Y cells. Preformed oligomers of HypF-N were resuspended in the cell culture medium, 
incubated in the absence or presence of the indicated chaperones for the indicated time lengths 
and then added to SH-SY5Y cells for 1 hour. The figure also shows top panel images obtained with 
untreated cells, cells exposed for 1 hour to the native protein, nontoxic HypF-N oligomers and 
toxic oligomers. The kinetic plots show the mean fluorescence per cell associated with 
intracellular Ca2+ versus time elapsed after oligomer pre-incubation with each chaperone. In all 
images the green fluorescence arises from the intracellular Fluo3 probe bound to Ca2+. Ca2+ influx 
from the extracellular medium to the cytosol mediated by the oligomers was inhibited by the 5 
chaperones with an effect dependent on the time of pre-incubation of the oligomers with the 
chaperones. 
 
 
Chapter 2                                                               Chaperones suppress oligomer toxicity 
 
50 
 
The cellular dysfunction generated by the toxic oligomers is also manifested as 
increases in the levels of intracellular ROS and in caspase-3 activity, and as a release of 
intracellular calcein from cells, with all these events following the Ca
2+
 influx 
[Zampagni et al., 2011]. Pre-incubation of preformed type A oligomers in the culture 
medium for 1 hour with each of the five chaperones, prior to addition to the cells, was 
able to abolish to a very substantial degree all the effects generated by the oligomers, 
again with the extent of inhibition again being dependent on the time of pre-incubation 
(data not shown). 
It is therefore evident that all five chaperones examined here can inhibit the initial 
biochemical events induced by toxic type A HypF-N oligomers, namely the influx of 
Ca
2+
, thus eliminating the occurrence of later effects, manifested as oxidative stress, 
membrane leakage and apoptosis. In addition, the observed dependence of the degree of 
protection on the time of pre-incubation indicates that the chaperones generically reduce 
toxicity by interacting with the oligomers, rather than through a separate protective 
pathway mediated by direct interaction of the chaperones with the cells. 
Overall, therefore, these findings reveal that the deleterious effects of adding toxic 
HypF-N oligomers to the extracellular medium of the cells can be abolished by 
chaperones only if the chaperone-oligomer interactions occur at the early stages of 
incubation, before the oligomers are able to interact with the cell membranes. 
 
2.2.4 Evaluation of chaperone-promoted oligomer endocytosis 
It is well known that extracellular chaperones interact with misfolded proteins and 
favour their clearance via endocytosis mediated by the lipoprotein receptor-related 
proteins 1 and 2 (LRP-1 and LRP-2) or CD163 [Hammad et al., 1997; Fabrizi et al., 
Chapter 2                                                               Chaperones suppress oligomer toxicity 
 
51 
 
2001; Kristiansen et al., 2001]. In principle, therefore, it is possible that extracellular 
chaperones suppress the toxicity of the HypF-N oligomers via interaction with them, 
endocytosis and degradation. This possibility was however excluded in our system, as 
shown by confocal microscopy and anti-HypF-N antibodies to monitor the transfer of 
HypF-N from the extracellular space to the cytosol (Figure 2.4). Indeed, we have found 
that preformed toxic oligomers of HypF-N, unlike the native protein and nontoxic 
oligomers, are internalised following pre-incubation for 1 hour in the absence of 
chaperones. The images show that the green fluorescence arising from anti-HypF-N 
antibodies appears inside the cells (coloured red) only upon treatment with the toxic 
oligomers (Figure 2.4A). Analysis of the confocal images at median planes indicated 
that many of the aggregates are present inside the cells, rather than outside or attached 
to the membrane (Figure 2.4B). 
When the experiment was repeated by pre-incubating the type A oligomers in the 
presence of each chaperone under the same conditions, little or no HypF-N entry was 
observed. The oligomers are predominantly detected, similarly to images obtained using 
nontoxic oligomers in the absence of chaperones, outside the cells or attached to the 
membrane but not within the cells (Figure 2.4A), as confirmed by analysing the 
confocal images at median planes parallel to the coverslip (Figure 2.4B). These 
observations show that the chaperones inhibit oligomer internalisation, at least under the 
conditions used here, rather than stimulating their intracellular degradation following 
endocytosis. 
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2.2.5 Chaperones do not dissolve preformed oligomers 
Three possible non-exclusive molecular mechanisms can be hypothesised to explain 
how chaperones suppress the toxicity of the oligomers: (i) the chaperones disassemble 
preformed oligomers; (ii) they bind to oligomers and promote their assembly into larger 
and innocuous aggregates, (iii) they catalyse a structural reorganisation of the toxic 
oligomers into nontoxic forms.  
To investigate whether chaperones disaggregate oligomers, we took advantage of 
the ability of the HypF-N oligomers to bind to ThT and increase its fluorescence 
[Campioni et al., 2010]. The presence of native HypF-N or free chaperones causes at 
Figure 2.4. Representative confocal microscopy images showing the internalisation of HypF-N 
oligomers within SH-SY5Y cells. Preformed oligomers of HypF-N were resuspended in the cell 
culture medium, incubated for 1 hour in the absence or presence of αB-crystallin, Hsp70, clusterin, 
haptoglobin or α2-macroglobulin and then added to SH-SY5Y cells. After plasma membrane 
permeabilisation with a 3% glycerol solution, counterstaining was performed with Alexa Fluor 
633-conjugated wheat germ agglutinin to detect the plasma membranes (red) and with 1:1000 
diluted rabbit polyclonal anti-HypF-N antibodies and 1:1000 diluted Alexa Fluor 488-conjugated 
anti-rabbit secondary antibodies (green) to detect the oligomers. (B) Quantification of the green 
fluorescence arising from HypF-N oligomers inside the cells (median planes). The values reported 
are means ± S.D. of three independent experiments. An asterisk indicates a significant difference (p 
 0.01) relative to the experiment with oligomer and without chaperones.  
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most only negligible increases in ThT fluorescence (Figure 2.5). By contrast, HypF-N 
oligomers incubated for 1 hour in a phosphate buffer at neutral pH, cause a 6/7-fold 
increase of ThT fluorescence, and pre-incubation of the oligomers in the same buffer for 
1 hour with each of the chaperones did not change the observed ThT fluorescence 
emission intensity (Figure 2.5). These results indicates that the chaperones do not 
suppress the toxicity of the oligomers by promoting their disaggregation.  
 
 
 
 
 
Figure 2.5. Chaperones do not disaggregate HypF-N oligomers. ThT fluorescence at 485nm 
(excitation 440nm) in the presence of native HypF-N, αB-crystallin, α2-macroglobulin, clusterin, 
haptoglobin, Hsp70, HypF-N oligomers after 1 hour incubation in phosphate buffer in the 
absence or in the presence of each chaperone. The ratio between the ThT fluorescence in the 
presence (F) and absence (F0) of proteins is reported; data are means ± SD of three independent 
experiments.  
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2.2.6 Chaperones bind to and assemble the oligomers into larger species 
To investigate whether chaperones bind to the oligomers and promote their further 
assembly, we first used AFM. Discrete oligomers with a height of 2–6 nm were 
observed by AFM in the absence of chaperones (Figure 2.6A), but significantly larger 
aggregates are evident with αB-crystallin (Figure 2.6B) or α2-macroglobulin (Figure 
2.6C), used here as representative chaperones. On higher magnification of these images, 
the aggregates appear as clusters of oligomers (Figure 2.6D). In some cases, more 
complex structures are observed, consisting of very large aggregates of irregular shape 
with typical heights of a few tens of nanometers, often surrounded by clusters of more 
distinct oligomers. Large assemblies are not observed in samples containing only 
chaperones (Figure 2.6E,F).  
The AFM data show that chaperones promote the assembly of the oligomers into 
larger species, but do not provide information on whether or not the chaperones remain 
bound to them. The oligomers can also be observed with confocal microscopy as, unlike 
free chaperones, they adhere to the glass coverslips (Figure 2.6G). Images obtained 
using oligomers pre-incubated for 1 hour with αB-crystallin or α2-macroglobulin show 
larger aggregates and co-localisation of the chaperones with the large oligomer clusters 
(Figure 2.6H,I). Although this technique has a resolution that enables only visualisation 
of clusters of oligomers or areas enriched with oligomers (not individual oligomers), it 
shows that the chaperones are bound to the large clusters of oligomers. 
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Figure 2.6. Assembly of oligomers induced by chaperones. (A-C) AFM images (left, height data; 
right, amplitude data) showing HypF-N oligomers pre-incubated for 1h in phosphate buffer 
without (A) or with B-crystallin (B) or α2-macroglobulin (C); control images of α2-
macroglobulin (E) and B-crystallin (F) alone; scan size, 630 nm. (D) Enlargement of a 250x250 
nm portion of (B). Z range: 10 nm (A), 13 nm (B, D), 25 nm (C), 6 nm (E), 10 nm (F). (G) 
Representative confocal microscope images showing HypF-N oligomers without chaperones and 
treated with anti- α2-macroglobulin (red), anti-B-crystallin (red) or anti-HypF-N (green) 
antibodies, as indicated. The absence of red fluorescence indicates the absence of cross-reaction. 
(H,I) Images showing HypF-N oligomers incubated with B-crystallin (H) or α2-macroglobulin 
(I) and treated with the same three antibodies, as indicated. The co-localization of oligomers and 
chaperones is shown in the merge images (yellow). 
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The binding between oligomers and the chaperones αB-crystallin or α2-
macroglobulin was also investigated through immuno-dot blot assays. Different 
quantities of αB-crystallin, α2-macroglobulin, native HypF-N, or lysozyme were bound 
to nitrocellulose membranes; the membranes were then saturated with milk, treated with 
preformed type A oligomers and then with rabbit polyclonal anti-HypF-N antibodies 
and anti-rabbit secondary antibodies conjugated with horseradish peroxidase. Dose-
dependent binding of oligomers was detected to immobilized chaperones but not to 
immobilized lysozyme (Figure 2.7A). As expected, strong binding of anti-HypF-N 
antibodies to immobilized native HypF-N treated with HypF-N oligomers was detected. 
Dot blots of membranes treated with PBS, rather than preformed oligomers, were not 
detected, confirming that antibody binding is specific for HypF-N (Figure 2.7B). 
 
 
 
 
Figure 2.7. Binding of 
chaperones to HypF-N oligomers 
detected by immuno-dot blot 
assay. Membranes with different 
quantities of immobilized B-
crystallin or α2-macroglobulin 
(0.5, 1, 2.5, 5 µg), lysozyme (1, 5 
µg) and HypF-N (1 µg) were 
treated with 50 µg/ml 
preformed HypF-N oligomers (A) 
or PBS (B). Anti-HypF-N 
antibody treatment reveals the 
presence of the oligomers bound 
to the chaperones. 
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In another experiment, type A HypF-N oligomers were incubated in the presence of 
each chaperone for 1 hour and the resulting mixture was centrifuged to separate the 
soluble (supernatant, SN) and insoluble (pellet, P) fractions. These fractions were then 
analysed separately by SDS-PAGE. In the control samples containing oligomers or αB-
crystallin alone, the HypF-N monomer (MW ~10.5 kDa) and the αB-crystallin 
monomer (MW ~20 kDa) were found only in the P and SN fractions, respectively 
(Figure 2.8A). In the sample containing both species, the HypF-N band was found only 
in the P fraction, whereas αB-crystallin was found to partition between the P and SN 
fractions (Figure 2.8A). This finding indicates that a fraction of αB-crystallin is bound 
to the oligomers. Moreover, the αB-crystallin found in the P fraction remains tightly 
associated with the oligomers after re-suspension of the pellet and further incubation 
(Figure 2.9). Similar results were obtained using α2-macroglobulin (Figure 2.8B). The 
results, therefore, confirm that binding occurs between the oligomers and all five 
chaperones studied here, making it possible to pellet the otherwise soluble chaperones 
through centrifugation. 
Fluorescence spectra of the SN fractions collected in each experiment were also 
acquired (Figure 2.8C,D). The SNs obtained from the samples where both oligomers 
and chaperones were present yielded fluorescence spectra that were less intense than the 
corresponding samples in which only the chaperone was present, confirming that a 
fraction of the chaperone population had been separated through centrifugation. 
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Figure 2.8. Binding of chaperones to HypF-N oligomers. (A) SDS-PAGE analysis of the P and SN 
fractions of samples containing HypF-N oligomers (lanes 2,3), B-crystallin (lanes 4,5) and oligomers 
with B-crystallin (lanes 6,7). The bands at ~10 and 20 kDa indicate monomeric HypF-N and B-
crystallin, respectively. The HypF-N concentration was 48 µM. (B) SDS-PAGE analysis for α2-
macroglobulin; conditions and lanes as in (A). The α2-macroglobulin bands range from ~ 60 kDa to ~ 
160 kDa. (C) Intrinsic fluorescence spectra of the SN fractions of samples containing HypF-N oligomers 
(dotted line), B-crystallin (solid line) and oligomers with B-crystallin (dashed line). The spectrum of 
HypF-N oligomers has been subtracted from that of chaperone plus oligomers to clear the contribution 
of the former. All spectra are the means of three experiments. (D) Intrinsic fluorescence analysis of α2-
macroglobulin. Conditions and spectra as in (C). 
 
Figure 2.9. The binding between B-crystallin and 
HypF-N oligomers is stable. Preformed HypF-N 
oligomers were incubated for 1 hour with B-
crystallin. The resulting mixture was then 
centrifuged and the SN and P fractions analysed 
with SDS-PAGE (lanes 2,3). A fraction of B-
crystallin remains in the SN, whereas a fraction is in 
P (lanes 2,3), due to the binding to the HypF-N 
oligomers. A P fraction of a similarly prepared 
sample was resuspended in phosphate buffer (pH 
7.0) as before, incubated for 1 hour, centrifuged 
and then analysed with SDS-PAGE (lanes 4,5). All 
the chaperone is found in the P fraction, while the 
SN fraction is empty. This result indicated that the 
binding between B-crystallin and HypF-N 
oligomers was stable because of the same amount 
of chaperone in the P fraction after washing it. The 
bands at ~ 10 and 22 kDa indicate HypF-N and B-
crystallin monomers, respectively. 
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Similar experiments of SDS-PAGE (Figure 2.10A,B,C) and intrinsic fluorescence 
measurements (Figure 2.10D,E,F) were acquired by treating the oligomers with Hsp70 
(Figure 2.10A,D), clusterin (Figure 2.10B,E) and haptoglobin (Figure 2.10C,F). The 
results obtained indicate that a binding occurs also between these chaperones and HypF-
N oligomers.  
 
 
 
 
 
 
 
 
 
 
Figure 2.10. Binding of Hsp70 (A,D), clusterin (B,E) and haptoglobin (C,F) to HypF-N oligomers. (A) 
SDS-PAGE of the insoluble (P) and soluble (SN) fractions obtained from samples containing 
preformed HypF-N type A oligomers (lanes 2, 3), Hsp70 (lanes 4, 5) and preformed type A 
oligomers treated for 1 hour with Hsp70 (lanes 6, 7). HypF-N concentration was 48 µM (monomer 
concentration). The bands at ~ 10 and 70 kDa indicate HypF-N and Hsp70 respectively. (B) SDS-
PAGE analysis for clusterin; conditions and lanes as in (A). The bands at ~ 10 kDa and bands 
ranging from 36 to 66 kDa indicate HypF-N and clusterin, respectively. Under reducing conditions, 
the α and β subunits of Clu co-migrate to about 36 kDa and lesser amounts of unprocessed (single 
chain) and variably glycosylated clusterin are also visible at higher molecular weights. (C) SDS-
PAGE analysis for haptoglobin; conditions and lanes as in (A). The bands at ~ 10 kDa and bands 
ranging from 14 to 70 kDa indicate HypF-N and haptoglobin, respectively. Haptoglobin generates a 
wide range of bands due to its varied polymeric structure [Hooper and Peacock, (1976)]. (D) 
Intrinsic fluorescence spectra of the SN fractions obtained after centrifugation of samples 
containing preformed HypF-N type A oligomers (dotted line), Hsp70 (solid line) and HypF-N type A 
oligomers + Hsp70 (dashed line). The spectrum of HypF-N oligomers has been subtracted from that 
of Hsp70 + HypF-N oligomers to eliminate its contribution. All spectra are the means of three 
independent experiments. (E) Intrinsic fluorescence analysis of clusterin. Conditions and spectra as 
in (D). (F) Intrinsic fluorescence analysis of haptoglobin. Conditions and spectra as in (D). 
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Overall, the AFM data indicate that chaperones promote the assembly of the 
oligomers into larger species, whereas the other analyses indicate that the chaperones 
are bound to the assembled oligomers. The finding prompted by SDS-PAGE and 
intrinsic fluorescence that a small fraction of chaperones is bound to the oligomers, 
suggests that chaperones act as nucleation sites for the assembly of oligomers into larger 
species and explains why they are effective in suppressing their toxicity even at highly 
sub-stoichiometric concentrations. 
 
2.2.7 The molecular structure of the oligomers is preserved in the large complexes 
with chaperones  
As a next step we set out to assess if chaperones promote a structural reorganisation of 
the oligomers at the molecular level, in addition to inducing an assembly of the 
oligomers. First, examination with Fourier transform infra-red (FTIR) spectroscopy 
 
Figure 2.11. Lack of secondary structure reorganization of HypF-N oligomers following 
treatment with chaperones. FTIR amide I spectra of HypF-N oligomers after incubation without 
(black) and with αB-crystallin (red) or α2-macroglobulin (purple). In the table on the right the 
results of the curve fitting are reported. 
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indicates that no secondary changes appear to have occurred following the incubation 
for 1 hour of the oligomers with either B-crystallin or 2-macroglobulin, excluding 
significant changes of secondary structure (Figure 2.11). 
To address possible changes in the packing of the hydrophobic groups, we took 
advantage of the ability to discriminate between toxic and nontoxic HypF-N oligomers 
through the measurement of the fluorescence properties of oligomers labelled with PM 
at different positions in the sequence. This method consists in creating HypF-N variants 
containing a single cysteine at different positions along the sequence, label them with 
PM and allow the labelled mutants to aggregate. When two pyrene molecules are close 
to each other (within 10 Å of distance), excited state dimers called excimers form and 
can be detected because they give rise to the appearance of a peak in the emission 
spectrum of pyrene centred at 440-470 [Birks et al., 1967; Hammarström et al., 1999; 
Krishnan and Lindquist, 2005]. Monitoring the intensity of the excimer band can be 
used to obtain information on the spatial distance between labelled positions in the 
oligomers. It has been shown that toxic and non toxic HypF-N oligomers can be 
discriminated through the measurement of their PM emission spectra [Campioni et al., 
2010]. In particular, the fluorescence spectra of nontoxic oligomers labelled with PM at 
certain positions within the hydrophobic regions of the HypF-N sequence show a strong 
excimer band that is, conversely, very weak in the corresponding spectra obtained with 
PM-labelled toxic oligomers [Campioni et al., 2010]. 
Chapter 2                                                               Chaperones suppress oligomer toxicity 
 
62 
 
The three mutants containing a single cysteine residue at positions 25, 55 and 87, all 
located in the major hydrophobic regions, were therefore labelled with PM, allowed to 
aggregate to form type A or type B oligomers under their respective conditions, and 
then transferred to phosphate buffer at pH 7.0 for 1 hour in either the presence or the 
Figure 2.12. Lack of structural reorganization of HypF-N oligomers following treatment with 
chaperones. Fluorescence emission spectra of HypF-N oligomers labelled with PM at positions 25 
(top graphs), 55 (middle graphs) and 87 (bottom graphs). The HypF-N concentration was 12 µM. 
The spectra refer to oligomers incubated in 20 mM phosphate buffer, pH 7.0 without (black) and 
with B-crystallin (red) or 2-macroglobulin (purple). For comparison, the corresponding spectra 
of nontoxic oligomers are reported in each graph (green). The spectra are normalized to the 
intensity of the peak centred at 375 nm. The vertical lines at 440 nm indicate the position of the 
excimer band.  
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absence of chaperones. The fluorescence spectra obtained for the type A oligomers 
labelled at each position after such incubation with or without αB-crystallin or α2-
macroglobulin are very similar and all show the absence of an excimer band (Figure 
2.12). By contrast, the spectra obtained for type B oligomers labelled at each position 
after incubation in the absence of chaperones all show the presence of an excimer band 
 
 
 
 
 
Figure 2.13. Lack of structural reorganization of HypF-N oligomers following treatment with 
chaperones. (A) Fluorescence emission spectra of samples containing HypF-N oligomers labeled 
with PM at positions 25 (top), 55 (middle) and 87 (bottom). Mutants of HypF-N containing a 
single cysteine at either position 25, 55 or 87 were labeled with PM, incubated to form the toxic 
oligomers and then 4-fold diluted, to a corresponding monomer concentration of 12 µM, into 20 
mM phosphate buffer, pH 7.0, 25 °C. The spectra refer to a 1 hour incubation under these latter 
condition in the absence (black) and in the presence of Hsp70 (A), clusterin (B) or haptoglobin (C) 
(pink). The spectra have been normalized to the intensity of the peak centered at 375 nm. Spectra 
of nontoxic oligomers (green) labelled at the same positions are also reported [Campioni et al., 
2010]. 
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(Figure 2.12), indicating a tighter packing of the polypeptide chain at these sites within 
the nontoxic oligomers [Campioni et al., 2010]. Similar data were obtained with Hsp70, 
clusterin and haptoglobin (Figure 2.13A,B,C). 
These results reveal that lack of toxicity resulting from exposure to chaperones cannot 
be attributed to the conversion of type A oligomers into type B oligomers. They do not, 
however, rule out the possibility that the toxic type A oligomers convert into a different 
type of nontoxic oligomers and thus, to address this possibility, we extended our 
analysis to oligomers formed from 1:1 mixtures of HypF-N monomers labelled with PM 
at different positions. Indeed, the pattern of excimer ratio values obtained from a well 
defined oligomer type, after uniform PM labelling at various positions and in 1:1 
mixtures of differently labeled positions, is unique and represents a molecular signature 
of the oligomer type, as the intensity of the excimer band reflects in each case the 
spatial distance between labeled positions [Birks, 1967; Hammarström et al. (1999); 
Krishnan and Lindquist, (2005)]. We have labelled 5 positions in the HypF-N sequence 
Figure 2.14. Lack of structural reorganization of HypF-N oligomers following treatment with 
chaperones. Ratios between the PM fluorescence intensities measured at 440 nm (excimer 
peak) and 375 nm (PM monomer peak) for HypF-N oligomers prepared with 1:1 mixtures of 
HypF-N chains PM-labelled at positions 10, 25, 47, 55 and 87 and incubated without (left panel) 
and with B-crystallin (middle panel) or 2-macroglobulin (right panel). The total HypF-N 
concentration was 12 μM. The SD of at least two independent experiments are reported in 
brackets.  
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(residues 10, 25, 47, 55, 87) and made all possible 1:1 mixtures, therefore obtaining 
excimer ratios for a total of 15 differently labelled HypF-N type A oligomers. The 
patterns of 15 excimer ratio values obtained in the presence of αB-crystallin or α2-
macroglobulin are essentially identical to the pattern obtained in the absence of 
chaperones (Figure 2.14), indicating that the spatial distribution of residues in the 
oligomers is preserved following interaction with the chaperones. 
 
2.3 Discussion 
The data presented here show that a representative set of chaperones can inhibit 
extremely efficiently the toxicity of protein oligomers formed by very different peptides 
and proteins. This behaviour results from the ability of the chaperones to bind to 
oligomers and promote their further assembly into larger species, in the absence of any 
significant reorganisation of their internal molecular structure. This mechanism of 
action is extremely effective as it allows the chaperones to suppress toxicity at highly 
substoichiometric levels, and remain protective even at molar ratios of client 
protein:chaperone as high as 500:1. 
These data also suggest that the size of extracellular protein aggregates correlates 
inversely with their toxicity. The binding and sequestration of the misfolded proteins 
within larger clusters is very likely to cause both a reduction of the exposure of the 
hydrophobic surfaces of the oligomers and a of their diffusional mobility, both of which 
are expected to lead to the inhibition of their toxicity. In addition, this behaviour is 
reminiscent of the formation of large aggresomes and inclusion bodies in eukaryotic and 
bacterial cells, respectively [Kopito, 2000; Sabate et al., 2010], indicating such 
processes as an effective strategy to handle protein aggregates and ultimately facilitate 
their clearance. 
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The ability of molecular chaperones to suppress the toxicity of preformed protein 
oligomers in the generic manner detected in this study adds to the well established 
functions of molecular chaperones to facilitate folding of proteins, to inhibit their 
aggregation and to disaggregate or promote clearance of protein aggregates. In all the 
experiments performed in this work the oligomers are formed before addition of the 
chaperones showing that the protective action of the latter can also include the 
neutralisation of toxic oligomers after they are formed. This effect represents an 
additional protective mechanism to add to our current understanding of the concept of 
protein homeostasis.  
Proteins are soluble mainly because a number of sequence and structural 
characteristics have evolved to achieve this requirement [Dobson, 2003; Monsellier and 
Chiti, 2007]. Chaperones act to counteract the inevitable failure of proteins to remain 
soluble and their protective actions occur at multiple levels, including facilitating 
protein folding and the degradation of protein aggregates, and inhibiting both protein 
aggregation and the toxicity of protein aggregates. The levels of misfolded proteins and 
toxic aggregates are usually low enough to permit these protective mechanisms to 
neutralise their potential effects. However, once this system is overwhelmed, e.g. by 
mutation, aging and other causes, these toxic effects can lead to malfunction and 
disease. Chaperones can buffer the formation of protein aggregates and their deleterious 
effects in living systems, explaining why, for example, the accumulation of fibrillar 
aggregates and associated smaller oligomers does not lead to manifest clinical signs of 
disease until the amyloid burden becomes unsustainable [Lachmann and Hawkins, 
2006; Petersen, 2010]. The generic ability of chaperones to suppress the toxicity of 
protein aggregates formed by very different peptides and proteins, and to do so at very 
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low concentrations, indicate that they can act as efficient guardians against a 
multiplicity of protein aggregates, rather than a single species, when the protein 
homeostasis system is close to being overwhelmed. 
These data also suggest that Nature may well be instructing us how to fight against 
protein misfolding diseases: the structure, function and mechanism of action of 
molecular chaperones may serve to guide the design of therapeutic interventions against 
diseases originating from the failure of protein homeostasis. Indeed, the finding that 
natural molecular chaperones can inhibit the toxicity of aberrant protein aggregates, 
after they are formed, with broad specificity and at very low concentrations, suggests 
that therapeutics based on the same type of intervention could be effective against such 
diseases, even at stages of the disease when the populations of toxic misfolded species 
have reached significant levels. 
 
2.4 Materials and Methods 
2.4.1 Cloning of the HypF-N gene, protein expression and purification 
The gene for HypF-N was cloned by Dr. Giulia Calloni in a modified pQE30-Xa 
plasmid (Qiagen S.p.A., Milano, Italy), in which the DNA stretch coding for the factor 
Xa cleavage site was substituted by a sequence coding for the thrombin cleavage site 
(pQE30-Th). As a result of this changing, the purified protein has the N-terminal Met 
residue substituted by a Gly-Ser dipeptide attributed to positions 0 and 1, respectively.  
Cultures of E. coli XL1 Blue cells harbouring the pQE30-Th/HypF-N plasmid were 
grown overnight at 37 °C in LB medium with 100 μg/ml ampicillin (Sigma-Aldrich) 
under shaking. The cells were then diluted 1:10 in fresh medium and grown at 25°C 
until the optical density at 600 nm (OD600) reached ~ 0.6. Protein expression was 
Chapter 2                                                               Chaperones suppress oligomer toxicity 
 
68 
 
induced overnight at 25°C by means of 1 mM isopropyl β-Dthiogalactoside (IPTG) 
from Inalco (Milano, Italy). Cells were harvested by centrifugation, resuspended in 40 
ml of lysis buffer (50 mM sodium phosphate, 300 mM NaCl, 10 mM imidazole at pH 
8.0) and then lysed by 1 hour incubation with 1 mg/ml lysozyme in ice, followed by 
sonication at 40 kHz (five cycles of 30s each spaced by 30s in ice). The cell lysate was 
applied at 4 °C to an affinity chromatography column packed with the HIS-Select 
Nickel Affinity Gel (Sigma-Aldrich) previously equilibrated with lysis buffer at 4 °C. 
The column was washed with 50 mM phosphate buffer, 300 mM NaCl, 20 mM 
imidazole, pH 8.0, 4 °C, equilibrated in 50 mM phosphate buffer, 50 mM NaCl, pH 8.0 
and then incubated overnight at 4 °C with 50 units of human thrombin (Sigma-Aldrich). 
Fractions containing pure HypF-N separated from the His-tag were eluted at 4 °C with 
50 mM phosphate buffer, 50 mM NaCl, 10 mM imidazole, pH 8.0 and checked by 
SDS-PAGE. The purest fractions were buffer-exchanged (5 mM acetate buffer, 2 mM 
dithiothreitol (DTT), pH 5.5) and concentrated at 4 °C using an ultrafiltration cell with a 
3000 Da cut-off cellulose membrane (Millipore, Billerica, MA). Protein concentration 
was assessed by optical absorption (ε280 = 12,490 M cm
-1
) and stock solutions were 
stored at -20 °C in 5 mM acetate buffer, 2 mM DTT, pH 5.5. 
 
2.4.2 Chaperones 
Human Hsp70 was purified as described [Roodveldt et al., (2009)]. The vector 
pET24d(+) (Novagen, Madison, USA) containing the αB-crystallin gene was a gift from 
J. A. Carver (University of Adelaide, Australia). Human αB-crystallin was expressed 
and purified as described previously [Waudby et al., 2010]. Human clusterin, α2-
macroglobulin and haptoglobin were purified as described [Wilson and Easterbrook-
Smith, 1992; French et al., 2008; Yerbury et al., 2005]. 
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2.4.3 Formation of protein oligomers 
Oligomeric aggregates of HypF-N were prepared by incubating the protein for 4 hour at 
25 °C and at a concentration of 48 µM in 50 mM acetate buffer, 12% (v/v) TFE, 2 mM 
DTT, pH 5.5 (condition A). Nontoxic oligomers used as controls were prepared by 
incubating the protein for 4 hour at 25 °C and at a concentration of 48 µM in 20 mM 
TFA, 330 mM NaCl, pH 1.7, (condition B). Oligomers were centrifuged at 16100 rcf 
for 10 min, dried under N2 and resuspended in cell culture media in the absence of cells 
(for cell biology tests) or in 20 mM potassium phosphate buffer at pH 7.0 (for 
biophysical/biochemical analysis). As reported, no significant dissolution of the 
oligomers or change in morphology/structure could be detected after this procedure 
[Campioni et al., 2010]. Native HypF-N was diluted to a final concentration of 12 µM 
into the same media. A42 and IAPP were obtained from Sigma-Aldrich (St. Louis, 
MO). Oligomers formed by Aβ42 and IAPP were prepared as previously described 
[Lambert et al., 2001; Cecchi et al., 2008 ] and resuspended in cell culture media to 
obtain a final peptide concentration of 12 µM. Native Aβ42 and IAPP were diluted to 12 
µM into the same cell culture media. All oligomers were then incubated in the 
appropriate media for 1 hour at 37°C while shaking, in the absence or presence of 
chaperones, and then added to cultured cells or subjected to biophysical/biochemical 
analysis. The HypF-N(Aβ42/IAPP):chaperone molar ratio was 5:1 (αB-crystallin), 5:1 
(Hsp70), 10:1 (clusterin), 15:1 (haptoglobin) and 100:1 (α2-macroglobulin), unless 
stated otherwise (HypF-N, Aβ42, IAPP, αB-crystallin, Hsp70 are considered as 
monomers, clusterin and haptoglobin as α dimers and α2-macroglobulin as a tetramer, 
according to the functional oligomeric state). 
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2.4.4 Cell cultures 
Human SH-SY5Y neuroblastoma cells (A.T.C.C., Manassas, VA, USA) were cultured 
in Dulbecco’s Modified Eagle’s Medium (DMEM) F-12 Ham with 25 mM N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES) and NaHCO3 (1:1) 
supplemented with 10% fetal bovine serum (FBS), 1.0 % glutamine and antibiotics. The 
cell culture was maintained in a 5.0% CO2 humidified atmosphere at 37 °C and grown 
until 80% confluence for a maximum of 20 passages. 
 
2.4.5 MTT reduction assay 
The effect of protein oligomers incubated in the absence or presence of the chaperones 
on cell viability was assessed using SH-SY5Y cells. Preformed oligomers of HypF-N, 
Aβ1-42 and IAPP (12 µM monomer concentration) were incubated for 1 hour in the 
absence or presence of αB-crystallin, Hsp70, clusterin, haptoglobin, α2-macroglobulin, 
HEWL or BSA (HypF-N:chaperone molar ratios as described in section 2.4.3, HypF-
N:HEWL and HypF-N:BSA molar ratios were 5:1), and then added to SH-SY5Y cells. 
The cells, seeded in 96-well plates, were treated for 24 hours at 37°C with the 
aggregates. The cell cultures were then incubated with 0.5 mg/ml MTT solution at 37°C 
for 4 hours and subsequently with cell lysis buffer (20% SDS, 50% N,N-
dimethylformamide, pH 4.7) at 37°C for 3 hours. Absorbance values of blue formazan 
were determined at 590 nm and cell viability was expressed as percent of MTT 
reduction in treated cells as compared to untreated cells (assumed as 100%).  
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2.4.6 Measurement of intracellular Ca
2+
 
Preformed HypF-N oligomers (12 µM monomer concentration) were incubated for 1 
hour in the cell culture medium without or with αB-crystallin, Hsp70, clusterin, 
haptoglobin or α2-macroglobulin (HypF-N:chaperone molar ratios were 5:1, 5:1, 10:1, 
15:1 and 100:1, respectively) and then added to SH-SY5Y cells seeded on glass 
coverslips for 60 min at 37°C. To detect intracellular Ca
2+
, cells were then loaded with 
10 µM fluo3-AM (Molecular Probes, Milan , Italy) , as described previously [Campioni 
et al., 2010; Zampagni et al., 2011]. Cells were also treated with nontoxic HypF-N 
oligomers or the native protein (12 µM monomer concentration). Cell fluorescence was 
analysed by confocal Leica TCS SP5 scanning microscope (Mannheim, Germany) 
equipped with an argon laser source for fluorescence measurements at 488 nm and 633 
nm and a Leica Plan Apo 63X oil immersion objective. A series of optical sections 
(1024X1024 pixels), 1.0 µm in thickness, were taken through the cell depth for each 
examined sample. The confocal microscope was set at optimal acquisition conditions, 
e.g. pinhole diameters, detector gain and laser powers. Settings were maintained 
constant for each analysis. 
 
2.4.7 Cell internalisation of HypF-N aggregates 
Preformed HypF-N oligomers (12 µM monomer concentration) were incubated for 1 
hour in the cell culture medium with no cells in the absence or presence of each 
chaperone (HypF-N:chaperone molar ratios as above) and then added to SH-SY5Y cells 
seeded on glass coverslips for 60 min at 37°C. Cells were also treated with nontoxic 
HypF-N oligomers or the native protein (12 µM monomer concentration). Confocal 
scanning microscope images were acquired as described [Campioni et al., 2010]. To 
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quantify the green fluorescence intensity arising from HypF-N oligomers inside the 
cells, the images were analysed at median planes parallel to the coverslip for 10-22 cells 
using ImageJ software (NIH, Bethesda, MD, USA). The intracellular fluorescence 
intensity was expressed as (Fobs/FA)•100, where Fobs and FA represent the fluorescence 
values of cells treated with the analysed sample and type A oligomers, respectively, in 
both cases after subtraction of the baseline value determined for untreated cells. 
 
2.4.8 Thioflavin T assay 
Pre-formed oligomers of HypF-N (48 µM monomer concentration) were incubated in 
the absence or presence of each chaperone for 1 hour (HypF-N:chaperone molar ratios 
as described above) and then added to a solution of 25 μM ThT dissolved in 25 mM 
phosphate buffer at pH 6.0, in order to obtain a 3.7-fold molar excess of dye. Final 
HypF-N protein concentration was 6 μM. The steady-state intensity of fluorescence 
emission at 485 nm (excitation at 440 nm) was recorded at 37 °C. Samples containing 
only native HypF-N or only chaperone, both at the corresponding concentrations, were 
also tested. 
 
2.4.9 Atomic force microscopy 
HypF-N oligomers were formed and then incubated without or with chaperones in the 
conditions detailed above. Samples were diluted from 5 to 100 times; 10 l aliquots of 
the diluted samples were deposited on freshly cleaved mica and dried under mild 
vacuum. Tapping mode AFM images were acquired in air using a Multimode SPM, 
equipped with “E” scanning head (maximum scan size 10 m) and driven by a 
Nanoscope IV controller, and a Dimension 3100 SPM, equipped with a ‘G’ scanning 
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head (maximum scan size 100 m) and driven by a Nanoscope IIIa controller (Digital 
Instruments, Bruker AXS GmbH, Karlsruhe, Germany). Single beam uncoated silicon 
cantilevers (type OMCL-AC160TS, Olympus, Tokyo, Japan) were used. The drive 
frequency was between 290 and 310 kHz, the scan rate was between 0.4 and 0.8 Hz. 
Aggregate sizes were measured from the height in cross section of the topographic 
AFM images. The heights reported in the results result from the obtained values being 
multiplied by a shrinking factor of 2.2, which was evaluated comparing the heights of 
native HypF-N under liquid and after drying. 
 
2.4.10 Confocal microscopy analysis for binding of HypF-N oligomers with 
chaperones 
Preformed oligomers of HypF-N (48 µM monomer concentration) were incubated in the 
absence or presence of αB-crystallin or α2-macroglobulin (HypF-N:chaperone molar 
ratios were 5:1 and 100:1, respectively) for 1 hour in 20 mM potassium phosphate 
buffer at pH 7.0 and then centrifuged for 10 min at 16100 rcf. The pellet (P) was 
resuspended in a solution containing 1:4000 rabbit polyclonal anti-HypF-N (Primm, 
Milan, Italy), goat polyclonal anti-αB-crystallin or goat polyclonal anti-α2-
macroglobulin antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) for 30min at 
37°C. After centrifugation for 10min at 16100 rcf, samples were washed in PBS, 
centrifuged again and incubated with 1:1000 diluted Alexa Fluor 488-conjugated anti-
rabbit secondary antibody (Molecular Probes, Milan, Italy) for 30min at 37°C. Samples 
were than washed in PBS and incubated with 1:4000 Texas red-conjugated anti-goat 
secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 30 min at 37°C. 
After centrifugation, samples were washed in PBS and the P was resuspended in 20 µl 
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PBS and spotted on glass coverslips. In another series of experiments oligomers were 
incubated with 1:4000 goat polyclonal anti-αB-crystallin or anti-α2-macroglobulin 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) for 30min at 37°C, centrifuged, 
washed in PBS and re-incubated with 1:4000 Texas red-conjugated anti-goat secondary 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Confocal microscope images 
were acquired as described [Campioni et al., 2010]. 
 
2.4.11 Immuno-dot blot assay 
Samples of chaperones (0.5, 1, 2.5, 5 µg), lysozyme (1, 5 µg) and HypF-N (1 µg) were 
spotted onto nitrocellulose membrane (Bio-Rad, Hercules, CA) and allowed to dry. 
After blocking with a 5% (w/v) skim milk powder solution in PBS, the membranes 
were incubated for 2 h at 37°C in PBS with or without 50 µg/ml of HypF-N preformed 
oligomers, washed three times (5 min each) in PBS and incubated with rabbit 
polyclonal anti-HypF-N antibodies (Primm, Milan, Italy). The membranes were then 
incubated with secondary anti-rabbit antibodies conjugated with horseradish peroxidase, 
followed by enhanced chemiluminescence with the Immun-Star HRP 
Chemiluminescence kit (Bio-Rad, Hercules, CA). After the treatments with primary and 
secondary antibodies, the membranes were washed three times (5 min each) in PBS 
containing 0.1 % (v/v) Tween 20. 
 
2.4.12 SDS-PAGE 
Preformed HypF-N oligomers, αB-crystallin and α2-macroglobulin were incubated for 1 
hour in 20 mM potassium phosphate buffer at pH 7.0 in isolation and in combination 
(48 µM HypF-N, HypF-N:chaperone molar ratios was 5:1 for αB-crystallin and 100:1 
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for α2-macroglobulin). Samples were then centrifuged for 10 min at 16100 rcf. Aliquots 
of the P and SN fractions were subjected to SDS-PAGE analysis as described 
[Laemmli, 1970] using 15% polyacrylamide gels. 
 
2.4.13 Intrinsic fluorescence 
Intrinsic fluorescence spectra of the SN fractions collected for SDS-PAGE were 
acquired at 37°C using a Perkin-Elmer LS 55 spectrofluorimeter (Wellesley, MA) and a 
2X10 mm quartz cell, an excitation wavelength of 280 nm. The spectrum of HypF-N 
oligomers was subtracted from that of the chaperone in the presence of HypF-N 
oligomers and all the spectra were normalized to the maximum fluorescence intensity of 
the chaperone spectrum. 
 
2.4.14 FTIR spectroscopy 
Preformed HypF-N oligomers were incubated for 1 hour in 20 mM potassium 
phosphate buffer at pH 7.0 with or without αB-crystallin or α2-macroglobulin (48 µM 
HypF-N, HypF-N:chaperone molar ratios was 5:1 and 100:1 respectively) and then 
centrifuged and resuspended in D2O twice to achieve a final volume of 20 µL and a 
final protein concentration of ~15 mg mL
-1
. The 20 µL sample was deposited on a KBr 
window in a semipermanent liquid cell and the FTIR spectra were recorded at room 
temperature using an FT/IR 4200 spectrophotometer (Jasco, Tokyo, Japan). The system 
was purged with N2 starting from 15 min before spectra recording. The background 
spectra were subtracted and the resulting spectra were baseline corrected and smoothed. 
Curve fitting on the spectra was performed using the Spectra Manager software (Jasco, 
Tokyo, Japan). 
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2.4.15 Pyrene fluorescence 
HypF-N variants carrying a single cysteine residue were labelled with PM as previously 
described [Campioni et al., 2010], incubated under conditions A and B in homogeneous 
or 1:1 mixtures and then diluted 4-fold into 20 mM potassium phosphate buffer at pH 
7.0. Fluorescence emission spectra of these samples were acquired and analyzed as 
previously described [Campioni et al., 2010] before and after 1 hour incubation in the 
absence or presence of chaperones. HypF-N concentration was 12 µM (monomer 
concentration). HypF-N:chaperone molar ratios was 5:1 for αB-crystallin and 100:1 for 
α2-macroglobulin. 
 
2.4.16 Statistical analysis 
All data were expressed as mean  standard deviation (SD). Comparisons between 
different groups were performed using ANOVA followed by Bonferroni’s post-
comparison test. A p value lower than 0.05 was considered statistically significant. 
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Chapter 3 
TWO SIDES OF THE SAME COIN: HYDROPHOBICITY AND SIZE AS 
STRUCTURAL DETERMINANTS OF MISFOLDED OLIGOMER TOXICITY 
3.1 Introduction 
As described in section 1.2, it is increasingly recognized that the pathogenic species in 
protein deposition diseases are not the mature fibrils, but the early oligomeric species 
that precede their formation [Chiti and Dobson, 2006]. Oligomers formed by HypF-N 
are a widely studied system in this regard. Indeed, a number of characteristics render 
this protein domain particularly useful for the characterization of its protein misfolded 
oligomers. First, monomeric HypF-N is readily able to form spherical oligomers and 
amyloid-like fibrils in vitro, under conditions that destabilize its native state or promote 
its cooperative unfolding into partially structured species [Chiti et al., 2001; Relini et 
al., 2004; Marcon et al., 2005; Campioni et al., 2008] Second, the oligomers that form 
in the early stages of the aggregation process have the same morphological, structural 
and tinctorial features as those formed by disease-related peptides and proteins [Marcon 
et al., 2005; Campioni et al., 2008] and impair cell viability when added to the 
extracellular medium of cultured cells [Bucciantini et al., 2002; Bucciantini et al., 2004; 
Cecchi et al., 2005; Campioni et al., 2010; Zampagni et al., 2011; Evangelisti et al., 
2012] and when injected into rat brains [Baglioni et al., 2006; Zampagni et al., 2011]. 
Finally, perhaps most importantly, HypF-N oligomers are sufficiently stable to maintain 
their morphological and structural properties when transferred to conditions that are 
very different from those that promote their formation, allowing a detailed biophysical 
and biological characterisation of their structural properties and toxicity, respectively 
[Campioni et al., 2010]. 
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As reported in section 1.5.5, two protocols have been established to convert native 
HypF-N into stable oligomers, which were named type A and type B, respectively 
[Campioni et al., 2010; Zampagni et al., 2011; Evangelisti et al., 2012; Tatini et al., 
unpublished]. The two oligomeric forms share a similar morphology and size, as 
detected with AFM, consisting of small spherical species with a 2-6 nm diameter; they 
also bind the amyloid diagnostic dye ThT to a similar extent, albeit such binding is 
weaker than that commonly observed for amyloid fibrils [Campioni et al., 2010]. In 
spite of the similar size, morphology and ThT binding, only type A oligomers were 
found to be toxic to cells. When added to the extracellular medium of cultured neuronal 
and endothelial cells, type A oligomers, unlike type B, were found to decrease the 
mitochondrial MTT reduction activity, to cause an influx of extracellular calcium to the 
cytosol and to induce apoptosis [Campioni et al., 2010; Zampagni et al., 2011]. They 
were also cause cognitive impairment in animal models, with type B oligomers 
producing no effect [Tatini et al., unpublished]. 
In an attempt to elucidate the structural origin of the different toxicities of type A 
and B oligomers, it has been shown, using site directed pyrene labeling, that the three 
main hydrophobic regions of the HypF-N sequence spanning approximately residues 
22-34, 55-59 and 75-87 are structured and buried in type B oligomers, whereas the same 
regions are more flexible and solvent-exposed in type A oligomers [Campioni et al., 
2010]. In a following study, it was found that the further assembly of type A oligomers 
into large aggregates mediated by molecular chaperones can suppress their toxic activity 
[results reported in Chapter 2]. These two reports indicated that the flexibility and 
solvent exposure of hydrophobic moieties and the small size are important structural 
determinants of HypF-N oligomer toxicity. 
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Here we have increased, using site-directed mutagenesis, the hydrophobicity of the 
three main hydrophobic regions of HypF-N found to have a different solvent exposure 
in the two oligomer types, with an aim of investigating the effect of such mutations on 
the superficial hydrophobicity of the oligomers, on their size and on the toxicity of the 
resulting oligomeric species. We will show that the single or multiple substitutions of a 
charged amino acid with an apolar one affect both the solvent-exposure hydrophobicity 
of the HypF-N oligomers and their size, producing counteracting effects on the toxicity 
of the resulting species. 
 
3.2 Results 
3.2.1 Effect of hydrophobic mutations on HypF-N structure 
The following five variants have been designed replacing glutamate or arginine residues 
with leucine within the three main hydrophobic regions of the HypF-N sequence: R23L, 
E55L, E87L, R23L/E55L and R23L/E87L. These mutants contain basically the same 
 
Figure 3.1. Hydropathy profile of the wt and mutant HypF-N sequences. The graphs show the 
comparison between the hydropathy profile of three variants carrying a single mutation and the 
wt protein. The hydropathy profiles were calculated using the Roseman hydrophobicity scale 
[Roseman, 1988]. 
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three mutations, in isolation or in combination, which are individually able to increase 
the level of hydropathy of each single region involved (Figure 3.1). We decided to 
substitute charged residues with apolar residues rather than opposite replacements, 
because it has been shown that the introduction of mutations within the hydrophobic 
core of HypF-N alters drastically the protein stability and causes protein aggregation 
into the inclusion bodies following the expression in E. coli [Calloni et al., 2005]. In an 
attempt to avoid this phenomenon, we chose variants whose conformational stability 
was preliminary estimated using FoldX, an algorithm based on an empirical formula 
derived from the experimentally determined values of free energy change of the 
unfolding transition in the absence of denaturant (GU-F 
H2O) of over 1000 single 
mutants from different proteins [Guerois et al., 2002].  
The native structure of the variants was studied using far-UV circular dichroism 
(CD). Figure 3.2 reports the native structure of wt HypF-N with the mutated residues 
Figure 3.2. (A) Structure of wt HypF-N with the residues involved in the mutations highlighted: 
Arg23, Glu55 and Glu87 all substituted with leucine. (B) Far-UV CD spectra of wt and mutants of 
HypF-N acquired under native conditions. 
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highlighted (Figure 3.2A) and the CD spectra of mutant and wt proteins (Figure 3.2 B). 
All the variants are characterized by a spectrum typical of a folded α/β protein, with a 
broad negative minimum in the region between 210 and 220 nm, and similar to the 
spectrum obtained for the wt protein and previously reported [Calloni et al., 2008; 
Campioni et al., 2008]. Hence, the introduction of the hydrophobic mutations does not 
alter significantly the native structure of the protein variants. 
 
3.2.2 Effect of the hydrophobic mutations on the aggregation kinetics of HypF-N 
Type A and type B oligomers of wt and mutant HypF-N were obtained by incubating 
HypF-N at a protein concentration of 48 µM in (i) 50 mM acetate buffer, 12% (v/v) 
TFE, 2 mM DTT, pH 5.5 (condition A) and in (ii) 20 mM TFA, 330 mM NaCl, pH 1.7 
(condition B) for 4 hours at 25 °C. Under these two conditions, the aggregation kinetics 
of every variant was measured by using ThT, a fluorescent probe able to bind the cross-
β structure typical of amyloid aggregates and to increase its fluorescence emission 
intensity upon binding [Krebs et al., 2005]. At regular time intervals, aliquots of the 
samples were mixed with a ThT solution and time-course measurements of the 
fluorescence intensity were obtained (Figure 3.3) and fitted with a single exponential 
function (equation 3.2, section 3.4.4).  
Apparent aggregation rate constants (kagg) were calculated for all aggregation kinetic 
traces and are reported in Figure 3.4 for the proteins incubated in condition A (left) and 
B (right). 
In condition A, the kagg values measured for both the wt protein and the variants are 
similar, with the exception of E87L, which presents a higher kagg value with respect to 
the wt protein. In condition B, all mutants do not have significantly different kagg values 
from that of the wt protein in the same condition. These results show that the aggregates 
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formed by the hydrophobic mutants bind the amyloid specific dye ThT indicating the 
presence of intermolecular β-sheet structure typical of amyloids. Moreover, the 
development of amyloid structure follows apparent mono-exponential kinetics in the 
absence of a lag phase, typical of the oligomers that precede fibril formation. Finally, 
Figure 3.3. Representative aggregation time-courses of wt and variants of HypF-N measured by 
ThT fluorescence under conditions A (top panels) and B (bottom panels). All data points were 
blank-subtracted and normalized to the maximum fluorescence intensity observed at the 
apparent plateau. Red lines represent the best fit to a single-exponential function (equation 3.2). 
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the rate of the aggregation process does not appear to be affected by the introduction of 
the hydrophobic mutations, which the exception of the E87L variant in condition A. 
 
 
 
3.2.3 Biological activity of the oligomers formed by the hydrophobic variants 
The biological activity of the oligomeric aggregates formed by the hydrophobic variants 
under condition A and B was assessed on human neuroblastoma SH-SY5Y cell cultures. 
For this purpose, the aggregates were transferred from the aggregation mixtures to a 
physiological medium through centrifugation and then added to the cell culture media. 
The viability of the cells treated with these aggregates was monitored by performing the 
MTT reduction inhibition assay, a generic biochemical test used to estimate the level of 
the cellular physiological stress [Mosmann, 1983]. Control experiments with the cells 
exposed to the native proteins were also carried out. Figure 3.5 shows the results 
obtained and expressed as a percentage of the value measured for the untreated cells.  
Figure 3.4. Apparent rate constants of aggregation (kagg) of wt and variants in condition A (left) 
and B (right). Aggregation time courses were fitted with a single exponential function and the kagg 
values for all experiments were determined. Data are means of, at least, 4 independent 
experiments. Error bars correspond to the standard errors of the means. 
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As previously reported, type A and B oligomers generated by wt HypF-N cause a 
30% reduction and no reduction in the viability of SH-SY5Y cells, respectively 
[Campioni et al., 2010]. Interestingly, the cells treated with oligomers formed under 
condition A by hydrophobic variants of HypF-N show higher viability levels than the 
cells treated with oligomers formed in the same condition by the wt protein. However, it 
is important to note that the introduction of a single mutation in position 55 or 87 (E55L 
and E87L) and of a double mutation in positions 23 and 87 (R23L/E87L) seems to 
revert completely, or almost completely in the latter case, the toxic effect of the wt 
oligomers; by contrast, the R23L and R23L/E55L variants keep the ability to reduce the 
cellular viability, albeit to a lower extent with respect to the wt oligomers. 
The oligomers formed by the variants in condition B maintained the MTT reduction 
unaltered, with the exception of the R23L mutant, which slightly affects the cellular 
viability. Generally, in condition B the introduction of the hydrophobic mutations taken 
Figure 3.5. MTT reduction assay on SH-SY5Y cells treated with wt and mutant proteins in their 
native state (grey bars), after aggregation in condition A (red bars) and B (blue bars). Error bars 
correspond to standard errors of the means of 10 independent experiments. Single, double and 
triple asterisks refer to p values lower than 0.05, 0.01 and 0.001, respectively, with respect to wt 
oligomers formed under corresponding conditions. 
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here in consideration does not alter significantly the biological activity of the 
aggregates. Similar experiments performed by treating the cells with native proteins 
show in all cases the inability of these proteins in their native structure to cause cellular 
dysfunction. 
 
3.2.4 Staining of the nuclei with Hoeschst 
Experiments with the apoptotic marker Hoechst 33342 were also carried out on SH-
SY5Y cells following the exposure to the various oligomeric variants and appeared to 
be in agreement with the MTT test data. This marker binds to the highly condensed 
chromatin present in the nuclei of apoptotic cells giving rise to a strong fluorescent 
signal and allowing the visualization of fragmented nuclei. After the treatment with the 
native proteins and with type A and B aggregates, the cells were stained with the dye 
and visualized by fluorescence microscopy. The images obtained are shown in Figure 
3.6. The nuclei of the cells treated with wt type A oligomers appear condensed and give 
rise to a high florescence signal, whereas such signal is generally reduced, to different 
extents, in cells treated with the mutant type A oligomers, with the R23L and the 
R23/E55L oligomers being the most effective in causing apoptosis. By contrast, the 
cells treated with the mutated type B oligomers, as well as with the wt type B oligomers 
appear to have a morphology and fluorescence intensity similar to those of untreated 
cells, with the exception of the cells treated with R23L type B oligomers. In all the 
experiments performed by exposing the cells to the native proteins no significant 
change in the morphology and in the fluorescence intensity of the treated cells is 
observed compared to the untreated ones. 
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Figure 3.6. Hoechst 33342 staining of SH-SY5Y cells treated with monomeric native proteins, 
aggregates formed by wt and hydrophobic mutants of HypF-N under conditions A and B. The upper 
image show the untreated cells.  
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3.2.5 Measurement of level of intracellular Ca
2+  
We also monitored the alteration of the membrane permeability by measuring the levels 
of intracellular Ca
2+
 ions following the exposure of the cells to the various oligomeric 
variants. Indeed, the influx of Ca
2+
 ions from the extracellular space into the cytosol
 
across the membrane has been recognized to be an early damage in cells exposed to 
harmful protein oligomers [Orrenius et al., 2003; Demuro et al., 2005; Bojarski et al., 
2008], including HypF-N wt type A oligomers [Canale et al., 2006; Zampagni et al., 
2011]. Taking advantage of the ability of the fluorescent probe fluo3-acetoxymethyl-
ester (Fluo3-AM) to bind Ca
2+
 ions and consequently give rise to a green fluorescence 
signal, we evaluated the level of intracellular Ca
2+
 in SH-SY5Y cells after 1 hour of 
incubation in presence of native proteins or oligomers formed by the variants under 
conditions A and B. Confocal microscopy images were acquired (Figure 3.7A) and the 
intensity of the fluorescence signal was expressed as a fractional change with respect to 
the fluorescence measured in cells treated with wt type A aggregates (Figure 3.7B). 
Oligomers formed in condition A by all the mutants, with the exception of the R23L 
and R23L/E55L mutants, do not induce an increase in cytosolic free Ca
2+
, unlike 
oligomers formed by the wt protein. In condition B, both the wt and mutated oligomers 
do not cause any change in the intracellular Ca
2+
 levels, again with the exception of the 
R23L variant oligomers, whose effect is, however, lower than the one provoked by the 
wt type A oligomers. In similar experiments performed treating the cells with the native 
proteins no increase in intracellular Ca
2+
 ions was detected. 
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Figure 3.7. (A) Dysregulation of 
cytosolic Ca2+ analysis on SH-
SY5Y cells treated with 
aggregates formed by wt and 
hydrophobic mutants of HypF-N. 
Confocal microscopy images of 
the intracellular free Ca2+ levels 
after 1 hour of treatment with 
monomeric native proteins, 
aggregates formed by wt and 
hydrophobic mutants of HypF-N 
in conditions A and B. The upper 
image show the untreated cells. 
The green fluorescence arises 
from the intracellular Fluo3 
probe bound to Ca2+. (B) 
Quantification of fluorescence 
arising from intracellular Ca2+ 
levels with respect to the 
fluorescence observed in cells 
treated with type A wt 
oligomers. Error bars 
correspond to standard errors of 
the means of 3 independent 
experiments The asterisks refer 
to p values lower than 0.05 with 
respect to wt oligomers formed 
under corresponding conditions.  
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3.2.6 Effect of the mutations on the superficial hydrophobicity of the oligomers  
To the purpose of shedding light on the link between the biological activity and the 
structure of the oligomeric HypF-N aggregates, we focused on structural parameters, 
such as the hydrophobic surface exposure and the size. 
The exposure to the solvent of hydrophobic surfaces of the wt and mutated 
oligomers formed in conditions A and B was tested by evaluating their ability to bind to 
the fluorescent probe 8-anilinonaphthalene-1-sulphonate (ANS). ANS binds to solvent-
exposed hydrophobic clusters, and, following this binding, a strong increase of its 
fluorescence emission intensity and a blue shift of its maximum emission wavelength 
(λmax) are observed [Semisotov et al., 1991; Cardamone and Puri, 1992]. The 
fluorescence emission spectra of ANS acquired in the presence of aggregates obtained 
in conditions A and B and their λmax values are shown in Figure 3.8. All the variant 
oligomers formed in condition A are able to bind to ANS because for all of them it was 
possible to register an increase of ANS emission intensity, even though to different 
extents. However, with respect to the wt type A oligomers, the aggregates formed by 
E55L and R23L/E55L HypF-N show an increase in the intensity of the emission 
spectrum, whereas the oligomers generated by the E87L and R23L/E87L variants give 
origin to ANS spectra characterized by a lower, but still comparable to the wt oligomer 
spectrum, intensity. A peculiar behavior is observed for the R23L variant oligomers, 
whose spectrum is markedly reduced compared to that of the wt oligomers (Figure 
3.8A). A notable blue shift of the λmax value is observed for the oligomers formed by all 
mutants compared to the wt oligomers, again with the exception of the R23L variant, 
which is characterized by a less blue-shifted λmax value (Figure 3.8C).  
Type B oligomers formed by all the variants are able to bind to ANS, and the 
spectra recorded for the single and double variants show a very weak and more 
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prominent increase of the fluorescence intensity compared to the wt type B oligomers, 
respectively (Figure 3.8B). These results are in agreement with the λmax values observed: 
the oligomers formed by the single mutants have λmax values comparable to that ones of 
the wt oligomers, whereas the aggregates formed by the double mutants show more 
blue-shifted λmax values with respect to the wt type B oligomers (Figure 3.8D). 
Figure 3.8. ANS binding to wt and hydrophobic variant type A and B oligomers (A,B). Fluorescence 
emission spectra of ANS in the presence of the aggregates of the wt protein (black) and 
hydrophobic variants formed in condition A (red) (A) and B (blue) (B). Wavelength of maximum 
emission fluorescence (λmax)registered for wt and hydrophobic oligomers of HypF-N in condition A 
(C) and B (D). Error bars correspond to standard errors from values of three different experiments.  
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These data show that the introduction of the hydrophobic mutations generates a 
strong increase in the exposure to the solvent of the hydrophobic surfaces of the 
oligomers aggregated in condition A, with the exception of the R23L mutation. An 
increase of this magnitude is not observed in the case of the mutant oligomers formed in 
condition B. 
 
3.2.7 Effect of the mutations on the size of the oligomers  
In order to qualitatively estimate the size of the type A and B mutated aggregates, 
turbidimetry and static light scattering (SLS) measurements were performed. 
Turbidimetry measures the loss of intensity of the light in the direction of propagation 
of the incident beam following the passage through a solution, and this phenomenon is 
due to light scattering caused by particles suspended in solution. Through the 
determination of the turbidity it is possible to estimate qualitatitevely the size of the 
particles in solution. Therefore, the turbidimetry at 500 nm was recorded for all the 
oligomers formed in conditions A and B, as shown in Figure 3.9A and 3.9B, 
respectively. The type A oligomers formed by the mutants are characterized by a 
similar, in the case of the E87L mutant, or higher light scattering than the wt type A 
aggregates. The only exception to this trend is represented by the R23L oligomers 
which show a lower intensity of the light scattered with respect to the wt oligomers 
(Figure 3.9A). By contrast, type B mutated oligomers are generally able to scatter the 
light to a similar extent of the wt aggregates formed under the same conditions, again 
with the exception of the R23L mutant, whose oligomers present a lower ability in 
scattering the light. 
These results were confirmed by SLS measurements, as reported in Figure 3.9C and 
3.9D, for the conditions A and B, respectively. In this technique the total amount of 
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light scattered by the sample is measured by a detector at an angle different from 0 or 
180°with respect to the incident light; hence, unlike turbidimetry, it is a direct 
measurement of the deviated light. The variants oligomerized in condition A, with the 
exception of the R23L mutant, are able to scatter the light to a greater extent with 
respect to the wt type A oligomers, whereas the values registered for the type B 
aggregates formed by the mutants are similar to those of the wt type B oligomers, with 
Figure 3.9. Measurements of turbidometry and SLS of HypF-N oligomers. The values of 
turbidimetry at 500 nm for the wt and variant oligomers formed in condition A (A) and B (B); 
error bars correspond to standard error values of three different experiments. Mean count rate 
expressed in kilocounts per second (kcps) of the type A (C) and type B (D) oligomers formed by 
wt and variants. 
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the R23L oligomers having the lowest values. Taken together these results suggest that 
the oligomers formed in condition A by the hydrophobic mutants are bigger in size than 
the wt aggregates, with the exception of the R23L oligomers, which shows smaller 
dimensions than those of the wt oligomers. Conversely, the introduction of the 
hydrophobic mutations seems to maintain generally unaltered the dimensions of the 
aggregates generated in condition B. 
 
3.2.8 Correlation between superficial hydrophobicity, size and toxicity 
Interestingly, the surface hydrophobicity of all the studied oligomers determined by the 
ANS λmax value significantly correlates with the size of the oligomers, as indicated by 
the SLS intensity. In Figure 3.10A the λmax value and the intensity of scattered light of 
the twelve oligomeric species studied here, i.e. wt and five mutant of type A oligomers 
(shown in red) and wt and five mutant of type B oligomers (shown in blue), were 
plotted and fitted to a linear equation of the form: 
  
          (Eq. 3.1) 
 
where q and m represent the intercept and the slope of the straight line, respectively. 
The linear correlation coefficient (R) is 0.88842, corresponding to a p value lower than 
0.001, therefore indicating that the correlation is statistically significant. This point out 
that an increase in the of exposure of hydrophobic surfaces causes an increase of the 
size of the oligomers. Since these two factors increase and decrease, respectively, the 
oligomer toxicity, no correlation is observed between either parameter and toxicity. 
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In Figure 3.10B the same plot was reported highlighting the oligomeric species that 
do not cause cellular damage (in green) and those affecting the cell viability to different 
extents (in pink), as determined by the MTT test results. It is worthy to note that the 
nontoxic oligomers are located above the straight line representing the best fit to 
equation 3.1, whereas the toxic aggregates are below this line. This partitioning of the 
data points in the two regions of the graph indicates that a combination of high 
hydrophobicity and small size contributes to a high toxicity, whereas a combination of 
low hydrophobicity and high size determined no toxicity. This result shows that the 
toxicity of the oligomers is influenced by both their superficial hydrophobicity and their 
size and, most importantly, is finely modulated according to specific levels of these two 
Figure 3.10. (A) Light scattering intensity expressed in kilocounts per second (kcps) versus the 
wavelength of the ANS maximum emission fluorescence (λmax) of the type A (red) and type B 
(blue) oligomers formed by wt and mutants. All the values were analysed with a procedure of 
best fitting and the solid line represents the best fit to equation 3.1. (B) Same plot as in (A): the 
green dots correspond to aggregates characterized by MTT reduction values > 97%; the pink dots 
correspond to oligomers showing values of MTT reduction ranging from 70% to 90%. 
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structural determinants, which cooperate simultaneously in determining the biological 
activity of the aggregates. 
 
3.3 Discussion 
3.3.1 The introduction of hydrophobic mutations generates oligomers displaying 
different levels of toxicity 
Increasing evidence suggests that oligomers, rather than mature amyloid fibrils, are 
the pathogenic species in protein deposition diseases [Chiti and Dobson, 2006; Jhan and 
Radford, 2008]. For this reason, it is essential to investigate at a structural level which 
determinants are responsible for the toxicity of such species. Efforts in this direction can 
help to identify new therapeutical targets for the treatment of these pathologies.  
In this study the importance of hydrophobic surface exposure and size as structural 
determinants of the biological activity of the aggregates has been taken into account 
through the study of a set of HypF-N variants characterized by mutations replacing 
hydrophilic residues with hydrophobic ones. We found that the introduction of the 
hydrophobic mutations studied here in the sequence of HypF-N alters neither the native 
structure of the proteins, as reported by far-UV CD measurements, nor the aggregation 
process promoting the oligomer formation under conditions A and B as shown by ThT 
fluorescence kinetics. By contrast, the biological activity is significantly affected by the 
insertion of the hydrophobic mutations. It seems, therefore, that the introduction of the 
mutations originates a pool of oligomeric variants characterized by different degrees of 
toxicity and these functional differences have to be related to differences in the 
structures and/or morphology of the aggregates.  
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3.3.2 Structural determinants of the oligomer toxicity: the double role of the 
superficial hydrophobicity  
The structural analysis of the oligomers was based on two parameters, both recognized 
to play important roles as determinants of aggregate toxicity: the surface hydrophobic 
exposure and the size. An increase in the exposure of hydrophobic oligomeric surface is 
associated with a greater ability of the aggregates to cause cellular dysfunction [Kremer 
et al., 2000, Oma et al., 2005, Bolognesi et al., 2010, Olzscha et al., 2011; Krishnan et 
al., 2012] and this phenomenon is also observed in the case of the wt type A and B 
HypF-N oligomers, as described previously [Campioni et al., 2010]. By contrast, it is 
recognized that there is an inverse correlation between toxicity and oligomer size [Cizas 
et al., 2010; Ladiwala et al., 2011; Ojha et al., 2011; Bemporad and Chiti, 2012; 
Chapter 2] and, again, this is also observed for wt type A oligomers [Chapter 2].  
According to the condition of aggregation and to the site of the mutation, the 
introduction of hydrophobic mutations affects, to various extents, the superficial 
hydrophobicity, causing consequently changes in the size of the type A and B 
aggregates. The explanation to these data can be found considering that the increase of 
hydrophobicity is accompanied by the increase in the dimensions of the aggregates. The 
increase in the exposure of hydrophobic surface seems to make the oligomers more 
sticky, facilitating their interaction and giving rise to the formation of bigger species 
unable to exert their toxic effects. Hence, it is reasonable to hypothesize that the 
increase of the solvent-exposed hydrophobic surface of a misfolded protein oligomer 
can have, according to its extension, a double counteracting effect on the oligomeric 
ability to cause cellular dysfunction, being responsible for toxicity or benignity. 
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3.3.3 Structural determinants of the oligomer toxicity: the importance of the size  
The reduction in the ability of causing cellular dysfunction mediated by the increase in 
the dimensions observed in the cases of type A E55L, E87L, R23L/E55L and 
R23L/E87L oligomers confirms that the size is a pivotal determinant of the oligomer 
toxicity. It has long been known that the fibrils, bigger in dimensions than the oligomers 
preceding their formation, have, unlike the latter, a lower, if any, toxicity [Chiti and 
Dobson, 2006]. Moreover, recent studies show that oligomer size plays a key role in 
causing oligomer toxicity. The ability of Aβ40 and Aβ42 oligomers to decrease the MTT 
reduction in cultured cells was found to correlate inversely with the molecular weight of 
the oligomers, with the small species having the highest toxicity [Bemporad and Chiti, 
2012]. It was also found that Aβ42 oligomers of different sizes give rise to an inverse 
correlation between oligomer size and neuronal toxicity, again with the smallest species 
exhibiting the highest ability in causing cell damage [Cizas et al., 2010]. In addition, 
agents able to cause the further assembly of toxic oligomers into larger species, such as 
aromatic small molecules [Ladiwala et al., 2011] or molecular chaperones [Chapter 2; 
Ojha et al., 2011], suppress the toxicity of these aggregates. Larger assemblies are 
harmless because they have a lower diffusional mobility, which prevent them from 
interacting and disrupting cell membranes, and because they have a lower 
surface/volume ratio. 
 
3.3.4 Cooperation of structural oligomeric characteristics in determining the 
ability to cause cell dysfunction 
Although this study recognizes the importance of the superficial hydrophobicity and of 
the size as determinants of oligomer toxicity, the data on the biological effects presented 
here cannot be explained solely on the basis of either parameter considered individually. 
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To make an example, the increase in the size observed in type A E55L and R23L/E55L 
oligomers is similar, but their ability in affecting the cell viability is different, even if in 
both cases it is lower than that of wt type A oligomers. Type A E55L oligomers are not 
toxic at all, whereas type A R23L/E55L aggregates are able to cause a 20% reduction of 
the viability. In order to explain these differences in toxic behaviour, both size and 
hydrophobicity have to be taken into account. Indeed, type A R23L/E55L oligomers 
maintain a higher degree of superficial hydrophobicity with respect to type A E55L 
oligomers, which can be responsible of its higher degree of toxicity.  
In Figure 3.10B, all the twelve oligomeric species studied here were reported in a 
graph plotting their light scattering against their ANS λmax value, indicating the size and 
the superficial hydrophobicity, respectively, and highlighted according to their ability to 
reduce the cellular viability. It is interesting to note that specific combinations of the 
values of these two parameters determine the biological activity of the aggregates. They 
indeed seem to cooperate and contribute with their extent to the resulting biological 
activity of the oligomers. In aggregates having similar sizes, differences in toxicity are 
due to differences in the hydrophobic surface exposure, and this is the case for type A 
E55L and type A R23L /E55L oligomers described above, but also the case for wt type 
A and wt type B oligomers [Campioni et al., 2010]. Conversely, in aggregates having 
the same level of hydrophobicity, the ability to provoke cell damage is associated with a 
reduction in the dimension, and this is the case for wt type B and type A R23L 
oligomers.  
In conclusion, the biological activity of the oligomeric species studied here is not 
explainable on the basis of the superficial hydrophobicity or the size if these two 
parameters are considered separately. Oligomer toxicity results from the combination of 
several structural and morphological determinants. Understanding the contribution of 
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each of these determinants can help to clarify the pathogenesis of protein deposition 
diseases and the molecular mechanism by which oligomers are harmful to cells. 
 
3.4 Materials and methods 
3.4.1 Site-directed mutagenesis 
Mutations in the HypF-N gene were generated by using the QuikChange site-directed 
mutagenesis kit (Stratagene, La Jolla, CA). The three single variants R23L, E55L and 
E87L were created and then used as templates to obtain the double variants R23L/E55L 
and R23L/E87L. The entire genes were sequenced to ensure the presence of the desired 
mutation.  
 
3.4.2 Preparation of HypF-N oligomers 
HypF-N was expressed and purified as described in section 2.4.1. The expression and 
purification protocol of the mutants was similar to the one described for the wt protein. 
After purification, these mutants were buffer-exchanged by ultrafiltration in 20 mM 
phosphate buffer, 2 mM DTT at pH 8.0 and stored at -20°C. 
Oligomeric aggregates of HypF-N were prepared by incubating the protein, wt or 
mutated, for 4 hour at 25 °C and at a concentration of 48 µM in two different 
experimental conditions: (i) 50 mM acetate buffer, 12% (v/v) TFE, 2 mM DTT, pH 5.5 
(condition A) and (ii) 20 mM TFA, 330 mM NaCl, pH 1.7, (condition B). For cellular 
biology experiments, the oligomers were centrifuged at 16100 rcf for 10 min, dried 
under N2 and resuspended in cell culture media to a final concentration equal to the 
initial one. In order to check the concentration, aliquots of these samples were taken and 
diluted 1:5 in a solution of 8 M guanidine chloride and incubated under vigorous 
shaking for 1 hour at 37 °C. Protein concentration was then assessed by optical 
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absorption. The remaining samples were diluted in DMEM to a final protein 
concentration of 12 µM concentration. 
 
3.4.3 Far-UV CD measurements 
Far-UV CD measurements were performed using a Jasco J-810 spectropolarimeter 
(Tokyo, Japan) equipped with a thermostated cell holder attached to a Thermo Haake 
C25P water bath (Karlsruhe, Germany). In all cases a 1 mm path length quartz cell was 
used. The spectra were acquired at 19 M final protein concentration, 25 °C in the 
following conditions: (i) 5 mM acetate, 2 mM DTT, pH 5.5 for wt, (ii) 20 mM 
phosphate buffer, 2 mM DTT, pH 8.0 for the variants. In all cases, the spectra were 
blank-subtracted and converted to molar ellipticity per residue units.  
 
3.4.4 Thioflavin T kinetics assay  
Samples of wt HypF-N or mutated were incubated at a protein concentration of 48 μM 
in condition A and B. At different time points, aliquots of each sample were added to a 
solution of 25 μM ThT (Sigma-Aldrich) dissolved in 25 mM phosphate buffer at pH 
6.0, in order to keep a 3.7-fold molar excess of dye. The final protein concentration was 
6 µM. The steady-state intensity of fluorescence emission at 485 nm (excitation at 440 
nm) was recorded at 25 °C using 2x10 mm path-length cell and a Pelkin-Elmer LS 55 
spectrofluorimeter (Wellesley, MA, USA), equipped with a thermostated cell holder 
attached to a Thermo Haake C25P water bath (Karlsruhe, Germany). The ratio between 
the ThT emission in the presence (F) and absence (F0) of HypF-N is reported as a 
function of time and fitted to the following monoexponential function: 
 
                                     F/F0(t) = a + b·e 
– k agg· 
t
         (Eq. 3.2) 
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where a is the plateau value, b is the amplitude of the exponential phase and kagg is the 
apparent rate of the protein aggregation process. For comparison, the data reported in 
the Figure 3.3 were normalised to their plateau values and fitted again to Eq. 3.2.  
 
3.4.5 Cell cultures 
Human SH-SY5Y neuroblastoma cells (A.T.C.C., Manassas, VA, USA) were cultured 
as described in section 2.4.4. 
 
3.4.6 MTT assay 
The toxic effect of the aggregates formed in conditions A and B by hydrophobic 
mutants and wt HypF-N was assessed by the MTT assay. SH-SY5Y cells were plated in 
a 96-well plate and treated for 24 hours at 37°C with 12 μM of the aggregates or native 
proteins either wt or variants of HypF-N. The cell cultures were then incubated with 0.5 
mg/ml MTT solution at 37°C for 4 hours and subsequently with cell lysis buffer (20% 
SDS, 50% N,N-dimethylformamide, pH 4.7) at 37°C for 3 hours. Absorbance values of 
blue formazan were determined at 590 nm and cell viability was expressed as percent of 
MTT reduction in treated cells as compared to untreated cells (assumed as 100%). 
Native HypF-N and its hydrophobic variants was tested as describe above. Data are 
expressed as mean  standard error of the mean (SEM). Comparisons between the 
different groups were performed by ANOVA followed by Bonferroni’s t-test. P values 
< 0.05, 0.01 and 0.001 are indicated by single, double and triple asterisks, respectively. 
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3.4.7 Hoeschst staining test 
The apoptotic effect of aggregate treatments on SH-SY5Y cells was evaluated using 2'-
[4-ethoxyphenyl]-5-[4-methyl-1-piperazinyl]-2,5'-bi-1H-benzimidazole trihydrochloride 
trihydrate (Hoeschst 33342) dye staining assay. 
Briefly, SH-SY5Y cells were plated on glass cover slips and treated for 24 hours with 
12 µM of the aggregates formed by either wt protein of HypF-N or its hydrophobic 
variants. Subsequently, the cells were incubated with 20 µg/ml Hoechst 33342 dye for 
15 minutes at 37 °C and then were fixed in 2.0% buffered paraformaldehyde for 10 min 
at room temperature. Blue fluorescence micrographs of cells were obtained under UV 
illumination in an epifluorescence inverted microscope (Nikon, Diaphot TMD-EF) with 
an appropriate filter set. Furthermore, native HypF-N and its native hydrophobic 
variants was tested as described above.  
 
3.4.8 Analysis of cytosolic Ca
2+ 
dyshomeostasis  
Ca
2+
 dyshomeostasis was evaluated on SH-SY5Y cells cultured on glass cover slip 
using Fluo3-AM (Molecular Probes, Eugene, OR). The cell cultures were exposed to 12 
µM of HypF-N aggregates prepared as described above for 60 minutes at 37°C. The 
cells were then treated for 30 minutes at 37 °C with 10 μM Fluo3-AM, 0.01% (w/v) 
pluronic acid F-127 (Sigma-Aldrich). The fluorescence was detected with an excitation 
of 488 nm by collecting the emitted fluorescence with the confocal scanning system 
(confocal Leica TCS SP5 scanning microscope, Mannheim, Germany). 
To quantify the signal intensity of each fluorescent probe, a variable number of cells 
(10 to 22) were analyzed in each experiment using the ImageJ software (NIH, Bethesda, 
MD, USA), and the fluorescence intensities expressed as fractional changes above the 
resting baseline, ΔF/F, where F is the average baseline fluorescence in control cells 
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(assumed as 100%) and ΔF represents the fluorescence changes over the baseline in 
cells exposed to different treatments. Comparisons between the different groups were 
performed by ANOVA followed by Bonferroni’s t-test. A p value < 0.05 was 
considered statistically significant. 
 
3.4.9 ANS fluorescence 
Oligomeric aggregates of wt and mutated HypF-N were prepared by incubating the 
proteins for 4 hours at 25 °C at a concentration of 48 µM in conditions A and B. 
Aliquots of ANS (Sigma-Aldrich) dissolved in 50 mM acetate, 12% (v/v) TFE, pH 5.5 
or in 20 mM TFA, 330 mM NaCl, pH 1.7 were added to type A and type B aggregates, 
respectively, in order to obtain a final 3:1 molar excess of dye. Fluorescence spectra 
were acquired at 25 °C, immediately after addition of ANS, using a 10 x 2 mm quartz 
cell and the equipment described in section 3.4.4, with an excitation wavelength of 380 
nm. Optical absorption spectra were acquired for all the samples using a Jasco V630 
spectrophotometer (Tokyo, Japan) and a 1 mm quartz cell and the fluorescence 
intensities of the spectra were corrected for inner filter effects with the formula reported 
by Lakowicz: 
 
                                F  Fe p  10 
(Abs      Abs    /2    (Eq. 3.3) 
 
where F is the corrected fluorescence, Fexp is the experimentally observed fluorescence, 
Absex corresponds to the value of absorbance at the ANS excitation wavelength and 
Absem are the values of absorbance recorded at the same wavelengths of the 
fluorescence emission spectrum [Lakowicz, 1999]. 
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3.4.10 Turbidimetry 
Oligomers of wt and mutated HypF-N were prepared by incubating the proteins in 
conditions A and B. Subsequently, the absorbance of the samples at 500 nm was 
measured using a Jasco V-630 spectrophotometer (Tokyo, Japan) and a cell path of 1 
mm. All the values were blank-subtracted. 
 
3.4.11 Static light scattering 
Oligomeric aggregates of wt and mutated HypF-N were prepared by incubating the 
proteins for 4 hours at 25 °C at a concentration of 48 µM in conditions A and B. SLS 
measurements were performed at 25 °C using the Malvern Zetasizer Nano S instrument 
(Malvern, Worcestershire, UK) with fixed parameters, equipped with a Peltier 
temperature controller. Disposable polystyrene cells having a 1 cm path length were 
used. 
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Chapter 4 
TRANSTHYRETIN SUPPRESSES THE TOXICITY OF PROTEIN MISFOLDED 
OLIGOMERS  
4.1 Introduction 
Transthyretin (TTR) is a homotetrameric protein with a total molecular mass of 55 kDa, 
that is synthesized in the liver, choroid plexus of the brain, and retina of the eye 
[Soprano et al., 1985; Stauder et al., 1986]. In the plasma TTR transports thyroxine (T4) 
and the retinol binding protein (RBP), whereas in the cerebrospinal fluid TTR is the 
primary transporter of T4 [Reixach et al., 2008; Buxbaum and Reixach, 2009]. TTR is 
also one of 30 human proteins associated with amyloidosis [Westermark et al., 2007]. 
Amiloidogenesis of wild-type TTR occurs in the heart of 10-25% of human older than 
80 years, resulting in senile systemic amyloidosis (SSA), often leading to congestive 
heart failure [Tanskanen et al. 2008; Lie et al., 1988]. TTR fibrillogenesis is accelerated 
by the presence of any of the approximately 100 different amyloidogenic mutations 
responsible for early-onset TTR amyloidoses [Sekijima et al., 2005; Connors et al., 
2003; Jacobson et al., 1997a; Jacobson et al., 1997b]. These mutations are responsible 
for the impairment of thermodynamic and/or kinetic stability of native tetrameric TTR 
[Sekijima et al., 2005], leading to autosomal dominant disorders, including familial 
amyloid neuropathy (FAP), familial amyloid cardiomyopathy (FAC) and the rare 
central nervous system amyloidoses [Garzuly et al., 1996; Connors et al., 2003].  
In spite of its link to human pathology, an anti-amyloidogenic effect that prevents 
fibril formation of A disease has been proposed for TTR. In 1982 it was first found 
that TTR is bound to A plaques in Alzheimer’s disease (AD) brains [Shirahama et al., 
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1982]. This parallels TTR to all known extracellular chaperones, which are known to be 
associated with A deposits [Powers et al., 1981; Bauer et al., 1991; Kida et al., 1995]. 
11 years later, it was found that amyloid fibril formation of A40 is inhibited in vitro by 
the human cerebrospinal fluid (CSF) [Wisniewski et al., 1993]. The protein of the CSF 
responsible for such inhibition was found to be TTR, through the formation of stable 
complexes between A40 and TTR, either as a dimer of a monomer [Schwarzman et al., 
1994]. In the same study it was also found that purified human TTR inhibited A28 fibril 
formation in vitro [Schwarzman et al., 1994]. Overexpression of human TTR in 
transgenic C. elegans models of AD expressing human A42 led to a lower amount of 
A deposits positive to the amyloid-specific dye Thioflavin S in the muscle cells of the 
nematodes [Link, 1995]. Similarly, overexpression of human TTR or gene knockout of 
murine TTR in mice overexpressing human A led to a decrease and increase of the A 
deposits in the mice brains, respectively [Choi et al., 2007; Buxbaum et al., 2008]. 
Importantly, reduction of amyloid deposition following overepxression of human TTR 
also led to significant cognitive improvement of the AD mice [Buxbaum et al., 2008]. 
Analyses of the interaction between human TTR and Aβ have showed that TTR 
binds to all forms of Aβ: monomers, oligomers and fibrils [Buxbaum et al., 2008; Costa 
et al., 2008; Liu and Murphy, 2006; Du and Murphy, 2010]. The binding is highly 
dependent on the quaternary structure of TTR with monomeric TTR binding Aβ with 
higher affinity than tetrameric TTR [Du and Murphy, 2010]. Moreover, the binding 
occurs with higher affinity for A oligomers, aggregates and fibrils with respect to A 
monomers [Liu and Murphy, 2006; Buxbaum et al., 2008; Du and Murphy, 2010]. In 
addition to inhibiting A fibril formation by monomeric A, TTR was shown to bind to 
preformed A oligomers and fibrils and reduce their toxicity to murine primary neurons 
and human neuroblastoma SH-SY5Y cells [Li et al., 2011].  
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In the light of the results obtained so far, one can hypothesise that TTR can act as an 
endogenous detoxifier of protein oligomers with potential pathological effects, in 
addition to inhibiting amyloid fibril formation. However, it is not clear if such an effect 
occurs only on A oligomers or more generically on protein misfolded oligomers. In 
addition, previous data do not offer any insight into the mechanism by which TTR 
inhibit oligomer toxicity and on the TTR form responsible for such an effect. We have 
previously shown that the cytotoxicity of protein oligomers formed by A, IAPP and 
HypF-N can be suppressed by molecular chaperones, with three of the five tested 
chaperones being extracellular [Chapter 2]. In particular, it was shown that the 
chaperones inhibit the toxicity of the oligomers by binding to them and promoting their 
clustering into large aggregates, in the absence of any disaggregation and structural 
reorganisation within the individual oligomers. In this study we have examined the 
ability of three types of TTR having different tetramer stability, i.e. human TTR 
(hTTR), mouse TTR (mTTR) and an engineered monomer of human TTR carrying the 
V30M substitution with the additional F87M and L110M mutations (M-TTR), to 
suppress the toxicity of extracellularly added oligomers formed by three different 
peptides/proteins, i.e. A42, IAPP and HypF-N. mTTR is the most stable homotetramer 
that cannot dissociate into partially unfolded monomers [Reixach et al., 2008]; hTTR 
also forms stable tetramers but has the ability to dissociate into monomers [Colon and 
Kelly, 1992], whereas M-TTR basically exists as a stable monomer [Jiang et al., 2001; 
Du and Murphy, 2010; Bourgault et al., 2011]. We will show that the three types of 
TTR display different protective effects against oligomer-induced cytotoxicity. 
Following this observation we have gained molecular insight into the underlying 
mechanism by which suppression occurs, showing that TTR-mediated protection 
correlates with the capability of this protein to adopt a monomeric state, to bind to the 
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oligomers and promote their clustering into larger aggregates in the absence of any 
structural reorganisation. 
 
4.2 Results 
The cellular biology experiments were acquired in collaboration with the group of Prof. 
Cristina Cecchi of the University of Florence. AFM measurements were performed by 
Bruno Tiribilli of the Consiglio Nazionale delle Ricerche (CNR) in Florence. 
 
4.2.1 TTRs prevent oligomer-induced cytotoxicity and apoptosis in SH-SY5Y cells  
We incubated oligomers formed from A42, IAPP and HypF-N in the cell culture 
medium in the absence or presence of hTTR, mTTR or M-TTR for 1 hour, then added 
the resulting samples to SH-SY5Y cells and measured the resulting cell viability using 
the MTT reduction assay. All three types of oligomers confirmed their toxic action (Fig. 
1A-C), as previously demonstrated [Chapter 2]. The cells treated with oligomers 
preincubated with hTTR and M-TTR were found to reduce MTT to levels similar to 
untreated cells, to cells treated with the native proteins or to cells treated with oligomers 
preincubated with haptoglobin, a known extracellular chaperone used here as a positive 
control of oligomer toxicity inhibitor (Figure 4.1A-C). Conversely, mTTR only shows a 
small and non-significant protective effect (Figure 4.1A-C). In addition, when the three 
oligomer types were incubated in the cell culture medium for 1 hour with proteins that 
are not expected to possess chaperone properties, such as hen egg white lysozyme 
(HEWL) or bovine serum albumin (BSA), the oligomers were found to maintain their 
toxicity (Figure 4.1A-C). 
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These results indicate that hTTR and M-TTR can suppress or decrease markedly the 
toxicity of oligomers formed by three different peptides and proteins, with a suppression 
that is specific for TTRs with respect to other proteins. 
 
 
 
 
 
 
Figure. 4.1. Suppression of protein oligomer toxicity by TTRs. Preformed oligomers of HypF-N 
(A), Aβ42 (B) and IAPP (C) were resuspended in the cell culture medium, incubated for 1 hour at 
a corresponding monomer concentration of 12 µM in the absence or presence of the indicated 
TTRs (protein:TTR molar ratio was 10:1), human haptoglobin (protein:haptoglobin molar ratio 
was 15:1), HEWL (protein:HEWL molar ratio was 5:1), or BSA (protein:BSA molar ratio was 5:1) 
and then added to SH-SY5Y cells. Cell viability was expressed as percent of MTT reduction in 
treated cells with respect to untreated cells (taken as 100%). The values shown are means  SD 
of three independent experiments carried out in quadruplicate. The double asterisk indicates a 
significant difference (p  0.01) relative to the experiment with oligomers only. 
 
A 
B 
C 
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4.2.2 Monomeric TTR reduces protein oligomer toxicity even at very low 
concentration  
To the aim of understanding the origin of the different ability of TTRs in suppressing 
the toxicity of protein oligomers and the resulting effects on the cells, we have decided 
to concentrate our effort on the toxic oligomers of HypF-N. This protein represents a 
useful model system since it forms morphologically similar oligomers but 
distinguishable on the basis of their biological activity in toxic (type A, the same used in 
the present work) and non toxic (type B) and, consequently, on the basis of the their fine 
structure [Campioni et al., 2010]. Both the two types of oligomers possess their own 
and well characterized structural profile, as highlighted by the fluorescent probe PM 
[Campioni et al., 2010], making possible to probe structural changes experienced by the 
aggregates following their exposure to TTRs. Finally, HypF-N oligomers appear to be 
highly stable, making them easy to handle in our experiments [Campioni et al., 2010].  
The different abilities of TTRs to prevent cell death detected by MTT tests were 
confirmed by the analysis of the chromatin condensation with the apoptotic marker 
Hoechst 33342 and by the measurements of caspase-3 activity, another indicator of 
apoptosis (data not shown). In addition, the MTT test was repeated by varying the 
concentration of each TTR in the 1 hour preincubation solution, while maintaining 
constant that of HypF-N. M-TTR was found to suppress the toxicity of HypF-N 
oligomers even at low concentration with an efficacy similar to haptoglobin and α2-
macroglobulin, two well known extracellular chaperones (Figure 4.2). M-TTR remained 
significantly efficient even at an HypF-N:TTR molar ratio of 400:1, becoming 
ineffective only at a molar ratio of 1000:1 (Figure 4.2). hTTR is also effective, but only 
at higher concentrations; indeed, hTTR was significantly efficient until an HypF-N:TTR 
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molar ratio of 40:1, becoming ineffective at molar ratios of 100:1 or higher. Conversely, 
mTTR did not show any protective effect, even at low molar ratios (Figure 4.2). 
 
 
 
 
 
 
 
4.2.3 The molecular structure of HypF-N oligomers is preserved in the complexes 
with TTRs  
To shed light on the different behaviour of the TTRs and on the molecular mechanism 
by which they exert their protection against HypF-N oligomers we investigated the 
oligomeric state and the molecular structure of HypF-N oligomers after the 
preincubation with TTRs. To assess whether the oligomers can be dissolved by the 
different types of TTR, we exploited the ability of the HypF-N oligomers, unlike native 
HypF-N, to bind to ThT and increase its fluorescence [Campioni et al., 2010] (Figure 
4.3). HypF-N oligomers incubated for 1 hour in a phosphate buffer at neutral pH cause a 
7/8-fold increase of ThT fluorescence, and the same increase was observed when the 
oligomers were preincubated in the same buffer for 1 hour with the different TTRs 
Figure 4.2. Dose-dependent suppression of HypF-N oligomer toxicity by TTRs. Preformed 
oligomers of HypF-N were resuspended in the cell culture medium, incubated for 1 hour in the 
absence (●) or presence of the indicated TTRs/chaperones and HypF-N:TTR/chaperone molar 
ratios and then added to SH-SY5Y cells. TTRs were always considered as tetramers in all HypF-
N:TTR molar ratio values. The scale on the x axis is logarithmic. Cell viability was expressed as 
percent of MTT reduction in treated cells with respect to untreated cells (taken as 100%). The 
values shown are means  SD of three independent experiments carried out in triplicate. 
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(Figure 4.3). To exclude the possibility that TTRs bind ThT, we also analysed samples 
containing only TTRs under identical conditions, detecting no increase of ThT 
fluorescence in these cases (Figure 4.3). Overall, these results show that HypF-N 
oligomers remain stable and do not undergo disaggregation after TTR treatment. 
 
 
 
 
 
 
Subsequently, we verified if the oligomers are structurally re-organised at the 
molecular level by TTRs (Figure 4.4). To this aim we took advantage of the possibility 
to determine the degree of packing of the oligomers through the acquisition of 
fluorescence spectra of oligomers labelled with PM. In particular, the fluorescence 
spectra of nontoxic type B oligomers formed by HypF-N labelled with PM at position 
25, 55 or 87 show an excimer band that is very weak in the corresponding spectra 
obtained with PM-labelled toxic type A oligomers [Campioni et al., 2010]. Three 
variants of HypF-N containing a single cysteine residue at position 25, 55 and 87 were 
therefore labelled with PM, allowed to aggregate and then transferred to phosphate 
Figure 4.3. TTRs do not dissolve HypF-N oligomers. ThT fluorescence at 485 nm (excitation 440 
nm) in the presence of the indicated protein components following preincubation for 1 hour in 
20 mM phosphate buffer at pH 7.0 in the absence or presence of different types of TTR. The ratio 
between the ThT fluorescence in the presence (F) and absence (F0) of proteins is reported; data 
are means ± SD of three independent experiments. The HypF-N concentration was 48 µM (in 
monomer units) and the HypF-N:TTR molar ratio was 10:1. 
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buffer at neutral pH for 1 hour with or without the different types of TTR. The 
fluorescence spectra acquired for the oligomers in either the presence or absence of the 
TTRs were very similar and none of them showed an excimer band (Figure 4.4). 
Moreover, the ratio of the exicimer-to-monomer fluorescence intensity (FI440nm/FI375nm) 
did not change for following preincubation with any TTR, remaining lower in all cases 
than the corresponding value measured for the nontoxic oligomers (Figure 4.4). These 
results therefore reveal that none of the TTRs studied here is able to promote a 
structural re-organization of the toxic HypF-N oligomers. 
 
 
 
 
 
 
Figure 4.4. TTRs do not remodel HypF-N oligomers. Fluorescence emission spectra of samples 
containing HypF-N oligomers labeled with PM at positions 25 (top), 55 (middle) and 87 
(bottom) were acquired at 12 μM HypF-N concentration following 1 hour of incubation in the 
absence (green) or in the presence (pink) of hTTR (left panels), mTTR (middle panels) or M-TTR 
(right panels). The molar ratio of HypF-N:TTR was 10:1. For comparison, the corresponding 
spectra of nontoxic oligomers are reported in each graph (black). The spectra have been 
normalized to the intensity of the peak centered at 375 nm. On the right, the exicimer-to-
monomer fluorescence intensity (FI440nm/FI375nm) of each sample and of the nontoxic oligomers 
[Campioni et al., 2010] is reported. 
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4.2.4 TTRs bind to the oligomers 
To determine whether TTRs bind to the oligomers we used TTR-derived intrinsic 
fluorescence and sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE). HypF-N oligomers sediment at a relatively low centrifugal force; therefore, if 
the TTRs are able to bind to the oligomers and the interaction between them is stable, 
the concentration of the TTRs in the supernatant will decrease following centrifugation, 
depending on the strength of the interaction. HypF-N oligomers and TTRs were 
incubated in isolation or in combination for 1 hour in phosphate buffer at pH 7.0 and 
each resulting sample was centrifuged to separate the pellet fraction (P), which contains 
the TTR bound to the oligomers, from the supernatant (SN), which contains the soluble 
unbound TTR. The amount of TTR in the SN was measured by its intrinsic fluorescence 
(Figure 4.5A-C). The fluorescence spectra of the SNs collected from the samples where 
oligomers and hTTR or M-TTR were present were less intense than the corresponding 
ones in which only the TTRs were present, indicating that a fraction of hTTR, and to a 
greater extent M-TTR, is bound to the oligomers. In contrast, the fluorescence spectrum 
of the SN collected from the sample containing oligomers and mTTR was similar to the 
corresponding one in which only mTTR was present. 
As a further evidence of the binding, the P and SN fractions collected in each 
experiments were also analysed by SDS-PAGE. In the samples containing oligomers or 
TTR alone, the HypF-N monomer (MW ~10.5 kDa) and the TTR monomer (MW ~15 
kDa) were found only in the P and SN fractions, respectively (Figure 4.5D-F). In the 
sample containing both HypF-N oligomers and M-TTR, the HypF-N band was present 
only in the P fraction, whereas M-TTR was found to partition between the P and SN 
fractions (Figure 4.5F). This result confirms that a small fraction of M-TTR is bound to 
the oligomers. Similar results, but to a lower extent, were obtained with hTTR (Figure 
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4.5D). In contrast, we found mTTR only in the SN fraction, suggesting that mTTR did 
not bind to HypF-N oligomers (Figure 4.5E). These results show that TTRs have a 
different ability to bind to the oligomers. Interestingly, such ability correlates with the 
capability of TTR to adopt the monomeric state.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. TTRs binds to HypF-N oligomers. (A-C) Intrinsic fluorescence spectra of the SN 
fractions obtained after centrifugation of samples containing preformed HypF-N oligomers (blue), 
TTR (red) and HypF-N oligomers + TTR (purple). For hTTR (A), mTTR (B) and M-TTR (C) the 
fluorescence emission spectra (excitation at 280 nm) were acquired at 37°C. The spectrum of 
HypF-N oligomers has been subtracted from that of TTR + HypF-N oligomers to eliminate its 
contribution. (D-F) SDS-PAGE analysis of the insoluble (P) and soluble (SN) fractions obtained 
from samples containing preformed HypF-N oligomers (lanes 2, 3), TTR (lanes 4, 5) and 
preformed oligomers treated for 1 hour with TTR (lanes 6, 7) for hTTR (D), mTTR (E) and M-TTR 
(F). The HypF-N concentration was 48 µM (in monomer units) and the molar ratio of HypF-N:TTR 
was 10:1. 
A 
D 
B C 
F E 
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4.2.5 The binding of TTRs to the oligomers promotes their assembly into larger 
species 
To investigate whether the binding of TTRs to the oligomers promotes their further 
assembly, we first used AFM. Discrete HypF-N oligomers with a height of 1–4 nm 
were observed by AFM in the absence of TTR (Figure 4.6A), but significantly larger 
aggregates were evident in the presence of M-TTR and, to a lower extent, of hTTR 
(Figure 4.6A). More complex structures were observed in the presence of M-TTR, 
consisting of very large aggregates of irregular shape with typical heights of a few tens 
of nanometers. Large assemblies were not observed in samples containing oligomers 
with mTTR (Figure 4.6A), or in samples containing only TTR (data not shown). 
As an additional evidence of the ability of TTRs to promote oligomer assembly, we 
took advantage of turbidimetry measurements at 500 nm, which revealed a similar 
trend. As reported in Figure 4.6B the oligomers incubated in the presence of h-TTR and 
to a greater extent the ones incubated in presence of M-TTR show a higher light 
scattering than the aggregates incubated in absence of TTR or in the presence of m-
TTR. 
The AFM and turbidity results show that M-TTR and hTTR promote the assembly 
of the HypF-N oligomers into larger species. 
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4.3 Discussion 
4.3.1 TTR inhibits the cellular dysfunction caused by protein misfolded oligomers  
TTR was shown to inhibit aggregation and amyloid plaque formation of A, the peptide 
associated with AD. Such inhibition was observed in vitro, using SDS-PAGE, 
transmission electron microscopy, laser light scattering and measurements of ThT 
Figure 4.6. Assembly of HypF-N oligomers induced by TTRs. (A) AFM images and corresponding 
height analysis of HypF-N oligomers preincubated with or without TTRs. Preformed oligomers 
of HypF-N were resuspended in phosphate buffer pH 7.0, incubated for 1 h at a corresponding 
monomer concentration of 48 µM in the absence or presence of the indicated TTRs (HypF-
N:TTR molar ratio was 10:1) and then deposited on mica; the scan size is 1 µm. Z range: 5 nm 
(oligomers), 24 nm (oligomers + hTTR), 6 nm (oligomers + mTTR), 36 nm (oligomers + M-TTR). 
(B) Measurements of turbidimetry at 500 nm of HypF-N oligomers incubated with or without 
TTRs and TTRs alone. Conditions as in (b) of HypF-N oligomers preincubated with or without 
TTRs and TTRs alone. Absorbance at 500 nm was measured at 48 μM HypF-N and at a HypF-
N:TTR molar ratio of 10:1. Error bars correspond to standard error values of at least six 
indipendent experiments. 
A B 
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fluorescence and Congo red birefringence under cross-polarised light [Schwarzman et 
al., 1994; Liu and Murphy, 2006; Du and Murphy, 2010]. It was also observed in vivo, 
using nematode and mouse models genetically modified to overexpress human TTR or 
to have the endogenous TTR gene knocked out; indeed, these transgenic animals were 
found to accumulate a lower and greater amount of A plaques, respectively [Link, 
1995; Choi et al., 2007; Buxbaum et al., 2008]. 
Analyses carried out in vitro on the interaction between TTR and Aβ have shown 
that TTR binds monomeric A, explaining its ability to prevent aggregation of the 
peptide [Schwarzman et al., 1994; Costa et al., 2008; Du and Murphy, 2010]. However, 
TTR-A binding occurs with higher affinity for aggregated A, such as oligomers and 
fibrils, relative to monomeric A, with monomeric TTR exhibiting stronger binding 
than tetrameric TTR [Liu and Murphy, 2006; Buxbaum et al., 2008; Du and Murphy, 
2010]. The high affinity between monomeric TTR and aggregated A suggests an 
important role for such an interaction. Indeed, TTR was shown to bind to preformed A 
oligomers and reduce their toxicity to murine primary neurons and human 
neuroblastoma SH-SY5Y cells [Li et al., 2011]. In such studies, TTR-mediated toxicity 
suppression was not due to the ability of TTR to inhibit A aggregation, but to act on 
preformed oligomers. 
Here, we found that TTR is able to suppress the toxicity of extracellularly added 
oligomers formed by three different peptides/proteins, namely A42, IAPP and HypF-N, 
adding two proteins to the preliminary observation obtained with A42 [Li et al., 2011]. 
TTR was found to inhibit the influx of Ca
2+
 caused by the oligomers, thus eliminating 
the occurrence of later effects, manifested as oxidative stress, membrane leakage and 
apoptosis. In addition, the observed dependence of the degree of protection on the time 
of preincubation indicates that TTR suppresses oligomer toxicity by interacting with the 
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oligomers, rather than through a separate protective pathway mediated by direct 
interaction of TTR with the cells. Overall, therefore, these findings reveal that the 
interaction of misfolded protein oligomers with cell membrane and the following 
deleterious effects, can be abolished by the presence of TTR. 
The three types of TTR examined here, namely hTTR, mTTR and M-TTR, were 
found to display different protective effects against oligomer-induced cytotoxicity. 
Indeed, monomeric M-TTR was able to protect SH-SY5Y neuroblastoma cells and rat 
primary neurons against oligomer-induced cytotoxicity; the highly stable tetrameric 
mTTR only showed a small and non significant protective effect, whereas the less stable 
tetrameric hTTR had intermediate rescuing effects between the two forms, or displayed 
a protective action slower or at higher concentrations than M-TTR. Hence, the ability of 
TTR to protect neuronal cells and neurons against misfolded protein oligomers 
correlates with the ability of the protein to adopt a monomeric state. 
 
4.3.2 TTR promotes the formation of larger assemblies of oligomers  
To shed light on the molecular mechanism by which TTR exerts its protection, we 
focused on HypF-N oligomers, probing their oligomeric state and molecular structure 
after the incubation with TTRs in vitro. Using ThT fluorescence we found that TTR 
does not disaggregate the preformed oligomers. Nor does it appear to promote a 
structural re-organization of the discrete oligomers, as shown by site-directed pyrene 
labelling. Rather, TTR was found to bind to the oligomers, as determined with SDS-
PAGE and intrinsic fluorescence, and promote their further assembly into larger 
aggregates, as shown by AFM and turbidimetry. The ability of TTR to bind to and 
further assemble preformed HypF-N oligomers correlated again with its ability to adopt 
a monomeric state, as the efficiency of such process followed the same order as that 
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found for toxicity suppression, i.e. M-TTR > hTTR > mTTR. These data also suggest 
that the size of extracellular protein aggregates is an inverse correlate of their toxicity. 
The TTR-induced oligomer clusters are characterized by a reduction in their exposed 
hydrophobic surface and diffusional mobility, both of which are expected to reduce 
their toxicity to cells, in agreement with previous findings [Chapter 2; Chapter 3; Ojha 
et al., 2011; Ahmed et al., 2010; Cizas et al., 2010; Bemporad and Chiti, 2012]. 
Overall, the molecular mechanism through which monomeric TTR protects the cells 
against the deleterious effects of protein aggregation seems to involve two different 
levels of intervention, that is inhibition of protein aggregation and fibril formation, as 
previously demonstrated [Schwarzman et al., 1994; Liu and Murphy, 2006; Du and 
Murphy, 2010; Link, 1995; Choi et al., 2007; Buxbaum et al., 2008], and neutralisation 
of protein oligomer toxicity once the oligomers are formed, as shown here. Such a dual 
protective behaviour has also been demonstrated for a number of proteins that have 
been widely recognised as molecular chaperones, such as B-crystallin, Hsp70 (both 
with and without ATP), clusterin, 2-macroglobulin and haptoglobin [Chapter 2], 
suggesting that TTR can also act as an ATP-independent, extracellular chaperone. The 
early observation that TTR is tightly bound to A plaques in AD patients, which 
remained without significant follow-up for years, [Shirahama et al., 1982], is also 
reminiscent of the behaviour of extracellular chaperones, as they all have been found 
associated with extracellular A deposits in such patients [Powers et al., 1981; Bauer et 
al., 1991; Kida et al., 1995].  
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4.4 Materials and methods 
4.4.1 Formation of protein oligomers 
HypF-N was expressed and purified as described in section 2.4.1. Toxic HypF-N 
oligomers were generated by incubating the protein for 4 hour at 25 °C and at a 
concentration of 48 µM in 50 mM acetate buffer, 12% (v/v) TFE, 2 mM DTT, pH 5.5. 
Aβ42 and IAPP oligomers were produced as reported [Lambert et al., 2001; Cecchi et 
al., 2008] and resuspended in the cell culture medium to 12 μM. HypF-N oligomers 
were centrifuged at 16100 rcf for 10 min, dried under N2 and resuspended in cell culture 
media in the absence of cells (for cell biology tests) or in 20 mM potassium phosphate 
buffer at pH 7.0 (for biophysical/biochemical analysis). Native proteins were diluted to 
a final concentration of 12 µM into the same media. Oligomers were then incubated in 
the appropriate media for 1 hour at 37 °C while shaking, in the absence or presence of 
each TTR, and then added to cultured cells or subjected to biophysical/biochemical 
analysis. The protein:TTR molar ratio was 10:1, unless stated otherwise (hTTR, mTTR 
and M-TTR are considered as tetramers).  
 
4.4.2 Preparation of TTRs 
hTTR, mTTR and M-TTR were prepared and purified in an Escherichia Coli expression 
system as described elsewhere [White and Kelly, 2001; Jiang et al., 2001; 
Hammarstrom et al., 2003]. The three protein variants were purified by gel filtration on 
a Superdex 75 column (Amersham Biosciences) in 10 mM phosphate buffer, 100 mM 
KCl, 1 mM EDTA pH 7.6 before each experiment to ensure that no aggregates were 
present in the starting material. Liquid chromatography-electrospray ionization mass 
spectrometry was used to confirm the molecular weight of the proteins. 
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4.4.3 Cell cultures  
Human SH-SY5Y neuroblastoma cells (A.T.C.C., Manassas, VA) were cultured as 
described in section 2.4.4. 
 
4.4.4 MTT reduction assay 
The effect of protein oligomers on cell viability was assessed using SH-SY5Y cells 
seeded in 96-well plates, and using the MTT assay as described in section 2.4.5. 
Preformed oligomers of HypF-N, Aβ42 and IAPP (12 µM monomer concentration) were 
incubated for 1 hour in the absence or presence of hTTR, mTTR, M-TTR, haptoglobin, 
HEWL or BSA (protein:TTR molar ratio was 10:1 unless otherwise stated; 
protein:haptoglobin, protein:HEWL and protein:BSA molar ratio was 5:1), and then 
added to the cells. Each TTR (1.2 µM tetramer concentration) or 12 µM native HypF-N, 
Aβ42 and IAPP were also used as controls.  
 
4.4.5 Thioflavin T assay 
Preformed HypF-N oligomers (12 µM monomer concentration) were incubated for 1 
hour at 37 °C under shaking in the presence or absence of each TTR (HypF-N:TTR 
molar ratio as described above). Aliquots of these samples were added to a solution of 
25 μM ThT dissolved in 25 mM phosphate buffer at pH 6.0, in order to obtain a 3.7-fold 
molar excess of dye. Final protein concentration was 6 μM. The steady-state intensity of 
fluorescence emission at 485 nm (excitation at 440 nm) was recorded at 37 °C using a 
Perkin-Elmer LS 55 spectrofluorimeter (Wellesley, MA) equipped with a thermostated 
cell holder attached to a Haake F8 water bath (Karlsruhe, Germany). Each TTR (1.2 µM 
tetramer concentration) and 12 µM native HypF-N were also used as controls. 
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4.4.6 Pyrene fluorescence emission spectra 
HypF-N variants carrying a single cysteine residue were labeled with PM as previously 
described [Campioni et al., 2010], converted into toxic aggregates as previously 
reported [Campioni et al., 2010] and then 4-fold diluted into 20 mM potassium 
phosphate buffer at pH 7.0. Fluorescence emission spectra of these samples were 
measured after 1 h of incubation at 37 °C under shaking in the absence and presence of 
each TTR. The spectra were acquired at 12 μM HypF-N concentration, 37 °C, with an 
excitation of 344 nm using a Perkin-Elmer LS 55 spectrofluorimeter (Wellesley, MA) 
equipped with a thermostated cell holder attached to a Haake F8 water bath (Karlsruhe, 
Germany), and a 1.5 × 1.5 mm quartz cell. The spectra have then been normalized to the 
intensity of the peak centered at 375 nm. 
 
4.4.7 Intrinsic fluorescence 
HypF-N oligomers and each TTR incubated in isolation and in combination as 
described before were centrifuged for 10 min at 16100 rcf. The intrinsic fluorescence of 
the SNs were measured at 37 °C with excitation at 280 nm using a Perkin-Elmer LS 55 
spectrofluorimeter (Wellesley, MA) equipped with a thermostated cell holder attached 
to a Haake F8 water bath (Karlsruhe, Germany), and a 2  10 mm quartz cell. The 
spectrum of HypF-N oligomers has been subtracted from that of TTR+HypF-N 
oligomers.  
 
4.4.8 SDS-PAGE 
HypF-N oligomers and each TTR incubated in isolation and in combination as 
described before were centrifuged for 10 min at 16100 rcf. P and SN aliquotes were 
collected and mixed with 4× sample buffer with 20 % 2-mercaptoethanol. SDS-PAGE 
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analysis was performed in accordance with Laemmli [Laemmli, 1970] using a 16% 
polyacrylamide gels. Proteins were visualized by Coomassie Blue staining (0.1% 
Coomassie Blue, 10% acetic acid, 40% methanol). 
 
4.4.9 Atomic force microscopy 
HypF-N oligomers were incubated for 1 hour at 37 °C under shaking in 20 mM 
potassium phosphate buffer at pH 7.0, in the presence or absence of each TTR. Samples 
were diluted 1000-fold and immediately deposited on a freshly cleaved mica substrate 
and dried under a gentle nitrogen flux. Non-contact AC mode atomic force microscopy 
(AFM) images were acquired in air using a PicoSPM microscope equipped with an AC-
mode controller (Molecular Imaging, Phoenix, AZ). Rectangular non-contact cantilever 
(model NSG01, NT-MDT Moscow, Russia), with typical resonance frequency of 150 
Khz, were used. Oligomer sizes were measured from the height in cross section of the 
topographic AFM images. The reported heights result from the obtained values 
multiplied by a shrinking factor of 2.2, which was evaluated comparing the heights of 
native HypF-N under liquid and after drying. 
 
4.4.10 Turbidimetry 
HypF-N oligomers (12 µM monomer concentration) were incubated for 1 hour at 37 °C 
under shaking in 20 mM potassium phosphate buffer at pH 7.0 in the absence or 
presence of each TTR. Samples containing TTRs were also used as controls. 
Subsequently, the absorbance of the samples at 500 nm was measured using a Jasco V-
630 UV-Vis Spectrophotometer (Tokyo, Japan) and a cell path of 0.1 cm. All the 
measurements were blank-subtracted.  
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4.4.11 Statistical analysis 
Data was expressed as mean  standard deviation (SD). Comparisons between different 
groups were performed using ANOVA followed by Bonferroni’s post-comparison test. 
A p value lower than 0.05 was considered statistically significant. 
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Chapter 5 
GLIAL INFLAMMATORY RESPONSE TRIGGERED BY MISFOLDED PROTEIN 
OLIGOMERS AND THE ROLE OF HSPS AS IMMUNE MEDIATORS 
5.1 Introduction 
Increasing evidence suggests that the neurodegeneration associated with protein 
deposition diseases, such as Alzheimer's disease, Parkinson's disease, Hungtington’s 
disease and spongiform encephalopathies, is the result of many causes. Indeed, these 
neurodegenerative pathologies are characterized by such a complex nature that the 
scientific community has begun to consider targeting single molecules or processes as 
ineffective for therapeutic purposes [Mangialasche et al., 2010]. Recently, the chronic 
inflammatory response, caused by a massive activation of microglial cells in the brain, 
has been established as a central process in the onset and progression of these 
pathologies. In fact, it has been observed in brains affected by Parkinson's disease [Kim 
and Joh, 2006], Alzheimer's disease [McGeer et al., 2006] and Huntington’s disease 
[Masters and O’Neill, 2011]. 
It has been suggested that the trigger factor of the innate response is the exposure of 
hydrophobic surfaces [Seong and Matzinger, 2004]. Such an exposure is a property 
shared by amyloidogenic proteins/peptides and misfolded aggregates, which are strong 
inducers of inflammation in agreement with this hypothesis [Masters and O’Neill, 
2011]. In particular, the early forming oligomers, that are thought to be the major 
pathogenic species in protein deposition diseases, having a high degree of superficial 
hydrophobicity, are believed to be highly responsible for the activation of the 
inflammatory process [Roodveldt et al., 2011; Amor et al., 2010]. 
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Following these considerations, we have investigated the inflammatory response 
triggered by misfolded oligomers, taking advantage of the well-known property of the 
HypF-N aberrant oligomers to be toxic or benign according to the conditions in which 
they form [Campioni et al., 2010]. Moreover, we also investigated the role of two Hsps, 
αB-crystallin and Hsp70, as immune mediators in the CNS, since they are released in 
the extracellular space and act as signal molecules for the immune system in a cytokine- 
of chemokine- manner [van Noort, 2008; Chen and Cao, 2010]. This aspect is 
particularly interesting in the contest of the injury caused by aberrant oligomers; indeed, 
Hsps have also been found to interact with misfolded oligomers, clustering them and 
making them harmless [Ojha et al., 2011; Chapter 2]. 
The results presented in this chapter show that the toxic and the nontoxic HypF-N 
oligomers are able to activate microglia in a different manner, even though they both 
trigger a pro-inflammatory response. In addition, the nontoxic oligomers and the 
assemblies of the toxic oligomers neutralized by chaperones have an ability to induce 
inflammation without affecting cellular viability.  
 
5.2 Results 
5.2.1 The viability of microglia cells is affected by HypF-N oligomers 
The ability of type A and type B oligomers to cause cell death has been assessed by 
means of the MTT assay on a variety of cell lines, including the neuroblastoma cells 
(SH-SY5Y) [Campioni et al., 2010; Chapter 2], mouse endothelial cells (Hend) 
[Campioni et al., 2010], chinese hamster ovarian cells (CHO) [Saridaki et al., 2012] and 
human embryonic kidney 293 cells (HEK293) [Mannini et al., 2012]. In all these 
experiments, the cells were treated with a 12 µM concentration of HypF-N aggregated 
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either in condition A or in condition B and the biological activity of the resulting 
oligomers was found to be different: whereas type B oligomers did not affect the 
cellular viability, type A aggregates reduced the viability by 30-40% with respect to the 
untreated cells.  
We first checked the response of microglia cells to the administration of type A and 
type B oligomers, using the same MTT reduction inhibition assay. The oligomers 
aggregated under the two distinct conditions were centrifuged, resuspended in the cell 
culture medium and then added to murine N13 microglia cells. The results, displayed in 
Figure 5.1 as a percentage of the value measured for the untreated cells, show that at the 
HypF-N concentration of 12 µM, the two types of oligomers presented a difference in 
the biological activity, with the type A aggregates being able to cause a 40% decrease in 
the viability and the type B ones maintaining unaltered the mitochondrial ability to 
reduce MTT. This result confirms the different ability of the two oligomers to cause cell 
dysfunction, even in the case of murine N13 microglia cells. 
In order to enable the direct comparison of the inflammatory response triggered by 
type A and type B oligomers, we looked for conditions in which both types of 
aggregates do not affect the cellular viability. Therefore, MTT tests were repeated by 
decreasing the concentration of the aggregates (Figure 5.1). Lower concentrations of 
type B oligomers did not alter the viability, whereas type A aggregates showed a dose-
dependent effect, reaching very low levels of cytotoxicity and not significantly different 
from the ones of untreated cells at the concentration of 0.7 µM (Figure 5.1). These 
viability data allow to study the immunological properties of type A and B aggregates in 
conditions in which they display different biological activities, i.e. at concentrations 
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ranging from 12 to 3 µM and in conditions in which they are both unable to cause 
cellular damage (0.7 µM). 
 
 
 
 
 
 
 
 
5.2.2 HypF-N oligomers trigger a pro-inflammatory response 
The inflammatory response to type A and B oligomers was evaluated by measuring the 
release of a series of key cytokines in N13 cells by means of ELISA assays. We 
measured the release of three pro-inflammatory cytokines, i.e. IL-6, TNF-α and IL-1β, 
and the release of IL-10, recognized as an anti-inflammatory cytokine. The cells were 
incubated with exogenously added type A and B oligomers at a concentration in which 
they maintain their different biological activity (3 or 4 µM, as stated). As shown in 
Figure 5.1. MTT reduction assay on murine N13 cells treated with different concentrations of 
type A (red bars) and B (blue bars) oligomers. Error bars correspond to standard errors of the 
means of 2 independent experiments. Single, double and triple asterisks refer to p values lower 
than 0.05, 0.01 and 0.001, respectively with respect to untreated cells. 
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Figure 5.2, both types of oligomers were able to induce the release of the three pro-
inflammatory cytokines to a different extent.  
The release of IL-6 was moderately induced by type A and B oligomers but it was 
substantially lower than the release stimulated by lipopolysaccharide (LPS), used here 
as a positive control (Figure 5.2A). Indeed, LPS is a major constituent of the outer cell 
membrane of Gram-negative bacteria and it is recognized to induce the secretion of pro-
inflammatory cytokines in microglia [Kettermann et al., 2011]. In addition, type A and 
type B aggregates were found to trigger the release of not significantly different 
amounts of IL-6 (Figure 5.2A). The TNF-α response observed for HypF-N type A and 
type B oligomers was found to be greater than that induced by LPS (Figure 5.2B). 
Moreover, as observed in the case of IL-6 release measurement, type A and type B 
oligomers were able to induce the TNF-α release to a similar extent (Figure 5.2B). The 
treatment of the microglial cells with HypF-N oligomers cause a significant rise in IL-
1β levels relative to the untreated cells only in the case of type A oligomers (Figure 
5.2C). By contrast, the amount of this cytokine in the culture supernatants of cells 
treated with the medium alone was found to be not significantly different from the 
amount detected after type B oligomers treatment (Figure 5.2C). In addition, the release 
of IL-1β was found to be higher in cells stimulated by type A oligomers with respect to 
cells incubated with type B oligomers (p value < 0.05) (Figure 5.2C). Finally, the 
release of IL-10 was also tested on N13 cells, but no amount of this cytokine was 
detected after the incubation of the cells with both types of HypF-N aggregates (data not 
shown). 
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The release of pro-inflammatory mediators, such as IL-6, TNF-α and IL-1β, 
indicates that HypF-N oligomers trigger a pro-inflammatory response. Conversely, the 
lack of stimulation of the IL-10 secretion suggests that they are not able to induce the 
release of this anti-inflammatory signal. Moreover, at a concentration in which the 
oligomers have different abilities to damage the cells, type A and type B oligomers 
stimulate the release of IL-6 and TNF-α to a similar extent. Only in the case of IL-1β, 
type A oligomers were found to be stronger inducers than type B aggregates. 
 
5.2.3 Differences between type A and type B oligomers in stimulating the 
inflammatory response 
In order to better understand the biological mechanism of the pro-inflammatory 
response triggered by type A and type B oligomers, we performed ELISA tests in 
Figure 5.2. Interleukin profile of microglia cells stimulated by type A and B oligomers. IL-6 (A), 
TNF-α (B) and IL-1β (C) release measured by ELISA assays in culture supernatants of murine N13 
cells treated with 3 µM (A and B) or 4 µM (C) type A and type B oligomers. In every experiment 
LPS at a concentration of 1 µg/ml and culture medium alone were used as positive and negative 
controls, respectively. Non detectable amounts of cytokines were indicated with ND. Error bars 
correspond to standard errors of the means of 6 (A), 5 (B) or 2 (C) independent experiments.  
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conditions in which both types of aggregates do not display significant levels of 
cytotoxicity, as indicated by the MTT results shown in Figure 5.1. Therefore, N13 cells 
were treated with different concentrations of oligomers and the release of IL-6 and 
TNF-α was measured. The results reported in Figure 5.3 show that type A oligomers 
stimulated the release of IL-6 in a dose-dependent manner (Figure 5.3A), whereas such 
a release was found to be less affected by the different concentrations of type B 
oligomers (Figure 5.3A). A similar trend was also revealed in the measurement of TNF-
α levels, where the release of this mediator induced by type A oligomers rose by 
increasing the HypF-N concentration, whereas type B aggregates triggered a secretion 
of TNF-α in a dose-independent manner (Figure 5.3B).  
In addition, type B oligomers were able to stimulate a considerable release of both IL-6 
and TNF-α even when they were added at the low concentration of 0.7 µM. By contrast, 
the same concentration of type A oligomers is not sufficient to induce such a release of 
Figure 5.3. Pro-inflammatory interleukin profile of microglia cells stimulated by type A and B 
oligomers. IL-6 (A) and TNF-α (B) release measured by ELISA assays in culture supernatants of 
murine N13 cells treated with the indicated concentrations of type A (red dots) and B (blue dots) 
oligomers.  
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these mediators. Therefore, it is interesting to notice that at very low concentration of 
oligomeric protein, in which the two types of oligomers do not affect the cellular 
viability to any detectable extent, type B aggregates differ significantly with respect to 
type A oligomers in releasing both IL-6 (p value < 0.001) and TNF-α (p value < 0.05), 
with type B oligomers being stronger inducers of the inflammatory response than type 
A oligomers. 
 
5.2.4 Differences in cell internalisation between type A and B oligomers 
The difference in stimulating the cytokine secretion observed following a treatment with 
type A and B oligomers at the concentration in which they do not alter the cellular 
viability was further investigated. 
As described in section 1.4.1, cytokine release can be triggered following the 
recognition of DAMPs, such as misfolded oligomers, by pattern-recognition receptors 
located on membranes [Glass et al., 2010; Amor et al., 2010; O’Neill, 2004]. 
The different ability of the extracellularly added type A and B oligomers in interacting 
with such receptors may be responsible of their differences in stimulating the cytokine 
secretion. The interaction with the receptors can be related to differences in the affinity 
of the two types of oligomers for the receptors, or to differences in penetrating into the 
cells. Since now, only the second hypothesis has been investigated. 
We posited that the entrance of the oligomers in the cells could be responsible for the 
reduction of the ability to induce cytokine release, whereas the permanence outside the 
cells makes the oligomers able to maintain their stimulus. 
Therefore, microglia N13 cells were incubated for 24 hours in the presence of either 
type A or type B oligomers. The cells were washed accurately, permeabilized and 
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treated with anti-HypF-N primary antibodies and then with Alexa Fluor 633-conjugated 
anti-rabbit secondary antibodies. Other cell samples, after the incubation with of the 
oligomers and the intensive washing step, were treated with the antibodies without 
being permeabilized. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). 
The two sets of samples were then compared through the acquisition of confocal 
microscopy images (Figure 5.4). In the cell samples not subjected to permeabilization, 
the antibodies were prevented from entering and detecting the oligomers inside the 
cells. Therefore, the red fluorescence signal indicating the presence of HypF-N 
oligomers arises from aggregates that are stuck on the membrane. By contrast, in the 
permeabilized samples the red fluorescence derives from both the oligomers stuck on 
membranes and the oligomers that are inside the cells. 
The comparison of the two sets of images obtained after the treatment of the cells with 
type A oligomers revealed that numerous red dots are present in the permeabilized 
samples (Figure 5.4A and magnification in Figure 5.4E), whereas such dots are hardly 
detectable in the samples not permeabilized (Figure 5.4B). This result suggests that 
most of the type A oligomers are inside the cells and very few remain outside on the cell 
surfaces.  
Regarding the cells incubated with type B oligomers, the amounts of oligomers in the 
permeabilized (Figure 5.4C and magnification in Figure 5.4F) and not permeabilized 
(Figure 5.4D) samples are similar, indicating that the net number of oligomers 
internalized into the cells is very low and the majority remains outside. 
Moreover, type B oligomers seem to be more tightly bound to membranes than type A 
oligomers, since it is more difficult to remove them in the washing step, as indicated by 
the higher amount of type B oligomers in the cell samples not permeabilized (Figure 
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5.4D) with respect to the amount of type A aggregates detected in cell samples similarly 
treated (Figure 5.4B).  
No red fluorescence signals were observed in the cells incubated in absence of the 
oligomers (Figure 5.4G) 
 
 
 
Figure 5.4. Representative confocal microscopy images showing the internalization of type A 
and B oligomers in N13 cells. Microglia cells were seeded on glass coverslips and incubated with 
preformed type A (A and B) and B (C and D) oligomers resuspended in the cell culture medium 
at the final concentration of 0.7 µM. After 24 hours treatment, the cells were washed with 
phosphate-buffered saline and fixed. Half of the coverslips were treated with a PBS solution 
containing 3% BSA (w/v) and 0.5% (v/v) triton in order to allow plasma membrane 
permeabilization (A and C); the remaining coverslips were not permeabilized and treated with a 
PBS solution containing 3% BSA only (B and D). The coverslips were incubated with rabbit 
polyclonal anti-HypF-N antibodies and then with Alexa Fluor 633-conjugated anti-rabbit 
secondary antibodies (red). In (E) enlarged detail of (A); in (F) enlarged detail of (D). In (G) 
untreated cells. The nuclei were stained with DAPI (blue). Confocal scanning microscope images 
of the median planes were reported in all cases.  
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Overall, these data suggest that in N13 cells there is a preferential internalization of 
type A oligomers with respect to type B aggregates, which, in addition, seem to be 
prone to adhere to cell membranes. Hence, the results obtained confirm the hypothesis 
according to which type A oligomers are internalized and consequently prevented to 
exert their cytokine release stimulation; whereas type B aggregates remain outside on 
the surface membrane where they can realize their induction. 
 
5.2.5 Hsps protect microglia cells from toxic HypF-N oligomers 
Since Hsp70 and αB-crystallin are able to protect SH-SY5Y and HEK293 cells from the 
damage of type A aggregates, provided the oligomers are incubated in the presence of 
the chaperones before they are added to the cells [Chapter 2], we performed a 
preliminary analysis to verify the ability of the chaperones to prevent the toxic effects 
caused by type A oligomers in N13 microglia cells. The final goal was to reveal the 
potency of Hsps as immune mediators. As a further indication in this regard, it has been 
demonstrated that extracellular Hsp70 can act as an autocrine or paracrine signal 
[Henderson and Pockley, 2010]. 
Hence, type A oligomers were incubated in the absence or in the presence of Hsp70 
or αB-crystallin for 1 hour at 37 °C and then added to N13 cells at the corresponding 
monomer concentration of 3 µM. Viability measurements of untreated cells and of cells 
incubated in the presence of the chaperones alone were also acquired. As a control, cells 
were also treated with 3 µM type B oligomers incubated with or without the two 
chaperones. The cellular viability was assessed by means of the MTT reduction test and 
the results are reported in Figure 5.5. N13 microglial cells, treated with type A 
oligomers pre-incubated with the chaperones, were found to reduce MTT to levels 
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comparable to untreated cells or to cells treated with the chaperones alone or with type 
B oligomers, pre-incubated in isolation or in combination with the chaperones. Hence, 
the ability of Hsp70 and of αB-crystallin to protect SH-SY5Y and HEK293 cells from 
oligomer mediated damage was confirmed with N13 microglia cells. 
 
5.2.6 Hsp70 as an immune mediator  
The role of Hsp70 as an immune mediator in the extracellular space was investigated 
through the evaluation of the activation of the microglial cells in terms of secretion of 
IL-6 and TNF-α, pro-inflammatory cytokines, and IL-10, anti-inflammatory cytokine. 
Firstly, N13 cells were treated by adding different concentrations of Hsp70 to their 
extracellular medium and, after incubation, the culture supernatants were collected. 
Figure 5.6 shows the data obtained from ELISA assays of these samples. Hsp70 was 
Figure 5.5. MTT reduction assay on murine N13 cells treated with Hsp70, αB-crystallin, type A 
oligomers incubated in isolation or in combination with Hsp70 or αB-crystallin and type B 
oligomers incubated with or without Hsp70 or αB-crystallin. Oligomers were added at a 
corresponding monomer concentration of 3 µM in the absence or presence of the indicated 
chaperones; protein:chaperone molar ratio was 5:1. Error bars correspond to standard errors. 
Single, double and triple asterisks refer to p values lower than 0.05, 0.01 and 0.001, respectively 
with respect to the experiment with type A oligomers. 
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found to trigger the release of IL-6 (Figure 5.6A) and TNF-α (Figure 5.6B) in a dose 
dependent manner, in agreement with previous findings [Kakimura et al., 2002]; by 
contrast IL-10 was not detected in the samples, even in those treated with the highest 
concentration of Hsp70 (data not shown). 
For comparison, Figure 5.7 reports, in the same graph, the release of IL-6 (Figure 
5.7A) and TNF-α (Figure 5.7B) stimulated by Hsp70 and type A and B oligomers, all 
added to the cells at the concentration of 0.7 µM. As described in section 5.2.3, at this 
concentration type B oligomers are stronger inducers of both IL-6 and TNF-α than type 
A oligomers. Hsp70 was found to induce a higher and comparable secretion of IL-6 
with respect to type A and type B aggregates, respectively (Figure 5.7A). By contrast, a 
similar and significantly lower amount of TNF-α was detected after the treatment with 
Hsp70, with respect to type A and type B oligomers, respectively (Figure 5.7B). These 
data suggest that different pathways of microglial activation might be used by Hsp70 
and by the aggregates.  
 
 Figure 5.6. Pro-inflammatory interleukin profile of microglia cells stimulated by Hsp70. IL-6 (A) 
and TNF-α (B) release in culture supernatants of murine N13 cells treated with different 
concentrations Hsp70 measured by ELISA assays. Error bars correspond to standard errors.  
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In order to assess if Hsp70 affects the inflammatory response mediated by HypF-N 
oligomers, this chaperone was incubated in isolation or in combination with type A and 
B oligomers at different HypF-N:Hsp70 molar ratios, and the resulting mixtures were 
added to N13 cells. After proper incubation, culture supernatants were recovered and 
analyzed by means of ELISA tests. Since an inflammatory response is observed also in 
the presence of Hsp70 alone, it is necessary to consider the specific contribution of type 
A and B oligomers to the stimulation of IL-6 and TNF-α secretion, as opposed to that of 
Hsp70 itself.  
In Figure 5.8, the amount of cytokine (IL-6 or TNF-α), detected in supernatants of 
cells treated with the oligomers (type A, indicated in red; type B, indicated in blue) pre-
incubated with Hsp70, has been divided by the sum of the amounts of cytokine released 
after the treatment with Hsp70 and HypF-N oligomers. This ratio is indicated as 
Figure 5.7. Comparison between the ability of Hsp70 and type A and B aggregates, all added to N13 
cells at 0.7 µM, in stimulating the secretion of IL-6 (A) and TNF-α (B) measured by ELISA assays. 
Error bars correspond to standard errors. Double and triple asterisks refer to p values lower than 
0.01 and 0.001, respectively with respect to the experiment with Hsp70. 
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cytolig+chap / (cytchap + cytolig) and it allows to point out three scenarios: (i) cytolig+chap / 
(cytchap + cytolig) = 1, in which the amount of cytokine secretion stimulated by the 
mixture Hsp70+oligomers simply corresponds to the sum of the contributes of Hsp70 
and oligomers; (ii) cytolig+chap / (cytchap + cytolig) < 1, in which the mixture 
Hsp70+oligomers has a lower ability in triggering the cytokine release with respect to 
Hsp70 and the oligomers, both added to the cells in isolation; (iii) cytolig+chap / (cytchap + 
cytolig) > 1, in which the mixture Hsp70+oligomers is a stronger inducer of the cytokine 
release with respect to Hsp70 and the oligomers both added on the cells in isolation. 
The HypF-N:Hsp70 molar ratios were 5:1 (Figure 5.8A), 10:1 (Figure 5.8B) and 20:1 
(Figure 5.8C), while HypF-N aggregates were at a corresponding monomer 
concentration of 3 µM in all cases. 
When Hsp70 was incubated with HypF-N oligomers at the HypF-N:Hsp70 molar 
 
Figure 5.8. Effect of Hsp70 and type A and B oligomers in triggering the release of IL-6 or TNF-α. 
The ratio cytolig+chap / (cytchap + cytolig) is repored, where cytolig+chap corresponds to the amount of 
cytokine (IL-6 or TNF-α) detected in supernatants of N13 cells treated with the oligomers (type A, 
red dots; type B, blue dots) pre-incubated with Hsp70; cytchap is the amount of cytokine released 
after the treatment with Hsp70; cytolig represents the amount of cytokine secreted after the 
treatment with HypF-N oligomers. The HypF-N:Hsp70 molar ratios were 5:1 (A), 10:1 (B) and 20:1 
(C). In all cases HypF-N aggregates were at a corresponding monomer concentration of 3 µM. Error 
bars correspond to standard error.  
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ratio of 5:1, the cytolig+chap / (cytchap + cytolig) values were found to be similar or slightly 
lower than 1, indicating that the oligomers, after the incubation with Hsp70, maintain 
unaltered or slightly decrease the ability in triggering the cytokine release (Figure 5.8A). 
By decreasing the HypF-N:Hsp70 molar ratio to 10:1 (Figure 5.8B), the cytolig+chap / 
(cytchap + cytolig) values were generally similar to 1. At the 20:1 HypF-N:Hsp70 molar 
ratio (Figure 5.8C), the cytolig+chap / (cytchap + cytolig) values resulted to be similar to or 
higher than 1. Although this trend suggests an ability of high concentration of Hsp70 to 
lower the cytokine secretion induced by the type A and B oligomers, this anti-
inflammatory effect of Hsp70 is not evident at HypF-N:Hsp70 molar ratio of 10:1 and 
20:1, and the effect is weak even at a molar ratio of 5:1. 
 
5.2.7 αB-crystallin an as immune mediator  
In order to study the role of αB-crystallin as an immune mediator, we estimated its 
ability to activate microglial cells, by means of ELISA measurements of the release of 
IL-6, TNF-α and IL-10. To this purpose, αB-crystallin was incubated in isolation or in 
combination with the two types of HypF-N oligomers and then added to N13 cells. In 
Figure 5.9 four representative experiments are reported. When αB-crystallin was added 
to microglial cells, neither IL-6 (Figure 5.9A,B) nor TNF-α (Figure 5.9C,D) were 
detected in cell culture supernatants, indicating that this protein is not able to activate 
N13 microglial cells. Following the incubation of αB-crystallin with type A and B 
oligomers at a corresponding monomer concentration of 3 µM (Figure 5.9A,C) and 0.7 
µM (Figure 5.9B,D), no significant changes in either IL-6 (Figure 5.9A,B) or TNF-α 
(Figure 5.9C,D) secretion were found with respect to the release stimulated by HypF-N 
aggregates alone. The cytolig+chap / (cytchap + cytolig) values reported in Figure 5.9E,F are  
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Figure 5.9. Effect of αB-crystallin and type A and B oligomers in triggering the release of IL-6 or 
TNF-α. IL-6 (A,B) and TNF-α (C,D) release measured by ELISA assays in culture supernatants of 
murine N13 cells treated with αB-crystallin and 3 µM (A,C) or 0.7 µM (B,D) type A and type B 
oligomers incubated in isolation or in combination. The HypF-N:αB-crystallin molar ratio was 5:1 
in all cases. (E,F) The ratio cytolig+chap / (cytchap + cytolig) is repored, where cytolig+chap corresponds to 
the amount of cytokine (IL-6 or TNF-α) detected in supernatants of N13 cells treated with the 
oligomers (type A, red dots; type B, blue dots) pre-incubated with αB-crystallin; cytchap is the 
amount of cytokine released after the treatment with αB-crystallin; cytolig represents the amount of 
cytokine secreted after the treatment with HypF-N oligomers. HypF-N aggregates were at a 
corresponding monomer concentration of 3 µM (E) or 0.7 µM (F). The HypF-N:αB-crystallin molar 
ratio was 5:1 in all cases. Error bars correspond to standard errors of the means of two 
independent experiments. 
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close to 1 and confirm that HypF-N oligomers, after the incubation with αB-crystallin, 
maintain unaltered their ability to trigger the cytokine release. The cytokine IL-10 was 
not detected (data not shown), indicating that both αB-crystallin and the mixture αB-
crystallin+HypF-N aggregates are not able to induce this anti-inflammatory signal. 
 
5.3 Discussion 
5.3.1 Type A and B oligomers: a useful tool to investigate inflammation in protein 
deposition disease 
The study of the mechanisms of neurodegeneration has led to the evidence that a single 
scientific perspective might not be sufficient to understand the multifactorial nature of 
neuropathologies. The inflammatory process, inevitably associated with 
neurodegeneration, has been recognized to give an important contribution to the onset 
and progression of neuropathologies. For this reason, the activation of microglia has 
been studied following the treatment with type A and type B HypF-N oligomers. 
Type A and B oligomers were found to stimulate the release of pro-inflammatory 
cytokines, in agreement with previous results obtained for disease-related misfolded 
oligomers [Masters and O’Neill, 2011]. Interestingly, when the activity of type A and B 
oligomers was evaluated at a concentration in which neither type is toxic, type B 
oligomers were found to be stronger inducers of the cytokine release. Such a release is 
not coupled to alterations in cellular viability and therefore represents a specific 
oligomer mediated-response. 
An explanation to this phenomenon possibly resides in the differences of 
internalization of the two oligomer types into the cells. Indeed, through the analysis of 
confocal microscopy images and in agreement with previous analysis performed on 
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neuroblastoma cells [Campioni et al., 2010; Zampagni et al., 2011], type B oligomers 
were found to remain outside and stuck on the membranes, where they can produce a 
prolonged stimulation responsible for the stronger cytokine response detected in our 
experiments. By contrast, type A oligomers were found inside the cells and therefore 
not able to act on the membrane receptors. In addition, microglia cells are the resident 
phagocytes of the CNS [Perry and Gordon, 1988]. Hence, the entrance of the oligomers 
into the cells can be an active or a passive mechanism that deserves further 
investigation. 
Most importantly, it is worthwhile to study other aspects for which type A and B 
oligomers can be useful tools, such as differences of affinity for pattern-recognition 
receptors and differences in the ability to induce the transcription of such receptors. 
The similar morphology and diverse fine structure of type A and B oligomers 
[Campioni et al., 2010] could shed light on the structural determinants responsible for 
the immune properties of misfolded oligomers and, importantly, offer the opportunity to 
understand if a persistent inflammatory stimulus can damage the cells on the long 
timescale, to an extent similar to that by which toxic aggregates kill the cells on the 
short timescale. 
 
5.3.2 Inflammation induction in the absence of toxicity and the role of Hsps 
Type B oligomers and type A oligomers neutralized by Hsp70 and αB-crystallin are not 
toxic to N13 microglial cells, confirming previously reported data [Campioni et al., 
2010; Zampagni et al., 2011; Chapter 2], but they were found to be able to trigger the 
inflammatory response. This could be a beneficial mechanism adopted by the cells in 
order to repair the insult given by the presence of exogenous material. Indeed, in the 
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acute phase, inflammation is targeted to the damage resolution and to the protection of 
the tissue from the insult.  
In agreement with this hypothesis, Hsp70 itself has been found to trigger the release 
of IL-6 and TNF-α, as previously reported [Kakimura et al., 2002], suggesting that the 
microglia activation is a protective mechanism. Interestingly, it has been reported that 
the activation of microglia by Hsp70 correlates with an increase in the uptake and 
clearance of Aβ aggregates [Kakimura et al., 2002; Kakimura et al., 2001; Takata et al., 
2003]. 
It would be of much interest to evaluate the oligomer uptake capacity in microglia 
following the stimulation by Hsp70, and if this ability is affected by the different type A 
and B oligomers. Indeed, the results obtained with neuroblastoma cells and reported in 
Chapter 2 indicated that neither Hsp70 nor αB-crystallin were able to promote the 
uptake of the HypF-N oligomers in this cell types (Figure 2.4). In addition, it is 
important to investigate if a detrimental effect occurs when the molecular machinery 
dedicated to the clearance of the extracellular material is overwhelmed and the release 
of inflammatory mediators is sustained for long periods. 
Noteworthy, Hsps seems to have a double role in the context of neurodegenerative 
diseases associated with protein misfolding: the well established studied traditional 
function of molecular chaperones [Hartl et al., 2011] and the function of immune 
regulators [van Noort, 2008; Henderson and Pockley, 2010]. With particular regard to 
misfolded oligomers, Hsps were found to abolish the oligomer toxicity [Chapter 2; Ojha 
et al.,2011] and both Hsp70 and the neutralised type A oligomers+Hsps were found to 
trigger inflammation, indicating the participation of Hsps in different processes as 
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diverse as protein oligomer-induced cell dysfunction and inflammation in 
neurodegeneration. 
Assessing the importance, the contribute and the balance of such processes could 
led to a multiple approach in the treatment of protein deposition diseases, examining 
neurodegeneration from different perspectives. 
 
5.4 Materials and Methods 
5.4.1 LAL assay and preparation of HypF-N oligomers 
The content of endotoxins in HypF-N protein solution samples, purified as described in 
section 2.4.1 (Chapter 2), was determined by toxin sensor Limulus Amebocyte Lysate 
(LAL) assay kit (Genscript, Piscataway, NJ, USA) and resulted to be ~ 0.02 EU/ml. 
Oligomeric aggregates of HypF-N were prepared by incubating the protein for 4 hour at 25 
°C and at a concentration of 48 µM in two different experimental conditions: (i) 50 mM acetate 
buffer, 12% (v/v) TFE, 2 mM DTT, pH 5.5 (condition A) and (ii) 20 mM TFA, 330 mM NaCl, 
pH 1.7, (condition B) [Campioni et al., 2010]. The oligomers were centrifuged at 16100 
rcf for 10 min, resuspended in cell culture media at a corresponding monomer 
concentration ranging from 12 µM to 0.7 µM and used for treatments of the cells. In a 
set of experiments the preformed oligomers, after resuspension in the cell culture media, 
were incubated at a corresponding monomer concentration of 12 µM in isolation or in 
combination with αB-crystallin or Hsp70 for 1 hour at 37 °C under shaking, then diluted 
to a final concentration of 3 µM or 0.7 µM and finally added to cell cultures. In these 
experiments, the molar ratio of HypF-N:αB-crystallin used was 5:1; whereas the molar 
ratios of HypF-N:Hsp70 were 5:1, 10:1 or 20:1, as stated. The molecular chaperones 
αB-crystallin and Hsp70 were obtained as described in section 2.4.2 (Chapter 2). 
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5.4.2 Cell cultures 
Murine N13 microglia cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) F12 supplemented with 10% fetal bovine serum (FBS), 1.0% non-essential 
amino acids, glutamine and antibiotics. The cell culture was maintained in a 5.0% CO2 
humidified atmosphere at 37 °C and grown until 80% confluence for a maximum of 20 
passages. 
 
5.4.3 MTT reduction assay 
The cytotoxic effect of type A and type B oligomers on N13 cell cultures was assessed 
performing the MTT assay by using the Cell Proliferation Kit I (MTT) (Roche, 
Mannheim, Germany). In a set of experiments, type A and type B oligomers and the 
molecular chaperones αB-crystallin or Hsp70 were incubated in isolation or 
combination and then added to cell culture media. Absorbance values of blue formazan 
were determined at 575 nm and cell viability was expressed as percent of MTT 
reduction in treated cells as compared to untreated cells (assumed as 100%).  
 
5.4.4 Cytokine release measurements  
Murine N13 mcroglia cell cultures were stimulated with type A and type B oligomers 
and, in a set of experiments, with type A and type B oligomers and the molecular 
chaperones αB-crystallin or Hsp70 incubated in isolation or combination. LPS at a 
concentration of 1 µg/ml, and culture medium alone were used as positive and negative 
controls, respectively. The stimulation lasted 6 hours and 24 hours for TNF-α and for 
IL-6, IL-1β and IL-10 release measurements, respectively. Culture supernatants were 
harvested and centrifuged at 400 rcf for 5 min and cell-cleared supernatants were 
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recovered and stored at –20 °C before cytokine measurement. IL-6, IL-1β, TNF-α and 
IL-10 levels were assayed through ELISA tests using Mouse IL-6/IL-1β/TNF-α/IL-10 
BD OptEIA ELISA set (BD Biosciences, Madrid, Spain) according to the 
manufacturer’s protocol. 
 
5.4.5 Cell internalisation of HypF-N oligomers 
N13 cells were seeded on glass coverslips and incubated for 24 hours by adding to the 
culture medium type A and type B oligomers at a corresponding monomer 
concentration of 0.7 μM. Cells were also treated with culture medium alone for control. 
The cells were washed with phosphate-buffered saline and fixed in 2% (w/v) buffered 
paraformaldehyde for 15 min at 4 °C. Half of the coverslips were treated for 1 hour at 4 
°C with a PBS solution containing 3% BSA (w/v) and 0.5% (v/v) Triton X-100 in order 
to allow plasma membrane permeabilization; the remaining coverslips were not 
permeabilized and therefore treated with a PBS solution containing 3% BSA only for 1 
hour at 4 °C. The coverslips were incubated over night with 1:1000 diluted rabbit 
polyclonal anti-HypF-N antibodies (Primm srl) and then for 1 hour at room temperature 
in the dark with 1:800 diluted Alexa Fluor 633-conjugated anti-rabbit secondary 
antibodies. The nuclei were stained with 1 µg/ml DAPI for 5 minutes at room 
temperature. Confocal scanning microscope images were acquired using a Leica TCS 
SP5 confocal scanning microscope (Mannheim, Germany). 
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